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SUMMARY
This work involves an investigation into the feasibility of using 
polyamide microcapsules as a basis for the treatment of glaucoma.
The Introduction considers conventional treatment of glaucoma together 
with novel ophthalmic drug delivery systems. Various methods by which 
microcapsules may be prepared are discussed and the preparation of 
polyamide microcapsules is discussed in detail. The properties of 
polyamides are described together with the properties of polyamide 
microcapsules. Consideration is also given to the theoretical release 
from microcapsules.
The Materials and Methods section lists the materials and instrumentation 
used throughout this work and describes the general methods used.
The Experimental section describes the development and preparation of 
nylon 6.10 and polyphthalamide microcapsules. This is followed by 
details of their properties including appearance, size distribution and 
release of encapsulated pilocarpine nitrate. Methods by which the 
preparation conditions were then modified are considered. These 
involve the addition of gelatin to the core, the use of short chain 
crosslinking molecules and the preparation of double walled microcapsules. 
The properties of these modified microcapsules are described. This 
section is followed by details of the structure of the microcapsule walls 
together with measurements of the permeability of polyphthalamide films. 
The final section of the experimental work discusses in vivo studies 
concerning the effect of microencapsulated pilocarpine nitrate on the 
rabbit eye and the dwell time of polyphthalamide microcapsules in the eye.
The final section of this thesis deals with the discussion of the 
experimental results obtained. The main conclusion drawn is that the walls 
of the polyphthalamide microcapsules do not significantly control the 
release of pilocarpine nitrate from the microcapsule core. This may 
arise due to the presence of pores in the microcapsule walls. Attempts 
to modify or reduce the release rate characteristics of the microcapsules 
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The adult human eyeball is a nearly spherical structure of 
approximately one inch diameter. It consists essentially 
of three separate concentric layers that are modified 
anteriorly to admit and dominate the passage of light. The 
outermost of these layers, the sclera, is purely protective; 
the innermost, the retina, is a light-sensitive recorder of 
images; and the intervening uveal layer contains numerous 
blood vessels. The anterior rim of this uveal layer is 
continued forwards to contain the intraocular muscles that 
govern the accommodative and pupillary movements, thus 
forming the ciliary body and the iris. The crystalline lens 
is attached to the ciliary body by means of the suspensory 
ligament or zonule. The cornea is divided into three layers : 
the epithelium, stroma and endothelium, each acting as a 
barrier to drug permeability. The epithelium and endothelium 
are rich in lipids and are more readily traversed by non-polar 
compounds; they are the principal barrier to ions and lipid 
insoluble materials. The stroma,..richer in water content 
is readily penetrated by water-soluble polar compounds, but 
less so by non-polar compounds. The space between the cornea 
and the anterior lens surface is termed the anterior chamber, 
whereas the narrow circular space between the iris, the lens 
and the ciliary body is called the posterior chamber. Both 
anterior and posterior chambers contain aqueous humour, a 
thin watery fluid. The remainder of the eyeball is filled with 
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FIGURE 1.1 THE PRODUCTION AND OUTFLOW OF
AQUEOUS HUMOUR.
The integrity of the shape of the eye is maintained by the 
internal positive pressure of the aqueous humour. This is 
produced by a combined process of secretion and diffusion which 
takes place throughout the blood-aqueous barriers of the eye.
It is probable that most of the aqueous humour is formed by 
secretion and diffusion from the capillaries of the ciliary 
processes. The fluid is secreted into the eye with sufficient 
potential to produce an intraocular pressure of about 100mm Hg. 
However, the pressure usually maintained is in the order of 
15 to 19mm Hg (1), Once formed, the aqueous flows into the 
anterior chamber via the pupil and then, largely under the 
influence of hydrostatic pressure, through the trabecular 
tissue in the angle of the anterior chamber and into the 
circular canal of Schlemm. From the canal it passes by small 
channels into the deep scleral capillary plexuses.
The condition of glaucoma arises as a result of an imbalance 
between the production of aqueous humour and its outflow 
through the canal of Schlemm. The most important 
characteristic of this condition is persistent or repeated 
elevation of intraocular pressure. This raised intraocular 
pressure eventually causes certain ophthalmological changes 
in the affected eye and if it is sufficiently high and persistent 
it may lead to irreversible blindness. The condition, which 
has been estimated to affect approximately 1% of the population 
over the age of 40 (2 - 5) may be divided into three types 
as shown below.
1.1.2 Classification of Glaucoma
1.1.2.1 Primary Glaucoma
This category is further subdivided into two types. The 
difference between the two is physical and refers to the 
angle tended by the cornea and the iris.
a) Closed Angle Glaucoma. Closed angle glaucoma is 
characterised by periodic bouts of raised intraocular pressure. 
The most prominent symptoms are pain and impairment of vision, 
caused by distension of the intra ocular tissues and 
waterlogging of the cornea. This condition is normally 
precipitated in narrow-angled eyes by a swelling or a forward 
displacement of the iris root. As a result of this swelling 
or forward displacement, the root of the iris may come into 
contact with the corneal epithelium. If this zone of contact 
becomes too extensive aqueous cannot escape and a hypertensive 
crisis ensues.
b) Open Angle Glaucoma. Open angle glaucoma is characterised 
clinically by a consistently raised intra ocular pressure, 
cupping of the optic disc and loss of visual field. Unlike 
closed angle glaucoma there is no associated pain. The
exact aetiology of the disease is unknown but it is perhaps 
due to the factors listed below which may lead to an imbalance 
between the production and the outflow of aqueous humour.
1. Abnormal changes in the tissue of the filtration angle 
which gradually impede the passage of the aqueous humour.
2. Failure of action of the cells in the trabecular meshwork.
3. Sclerotic changes in the fine vessels which drain the 
aqueous humour from the canal of Schlemm.
4. An anomaly of the sympathetic or parasympathetic nerve 
complexes of the region.
1.1.2.2 Secondary Glaucoma
Secondary glaucoma arises as a result of a pre-existing 
pathological condition such as intraocular inflammation, 
lens dislocation, lens swelling and uveitis. It may also 
arise as a result of the metabolic upset following a central 
venous thrombosis. The symptoms are usually those of 
primary closed angle glaucoma but pain may be slight.
1.1.2.3 Congenital Glaucoma
This condition is due to the obstruction of the drainage of 
the aqueous humour by some form of congenital anomaly, for 
example malformation of the fibres of the pectinate ligament 
or a persistence of foetal tissue which obstructs the 
filtration angle. The increased intraocular pressure 
causes the infant globe to enlarge and the eyeball thus 
appears prominent. The measured intraocular pressure may 
be only slightly increased since this is largely mitigated 
by the distensibility of the globe. The optic disc is 
usually cupped and these eyes are normally myopic owing to 
the increase in their axial length.
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1.1.3 Treatment of Glaucoma
1.1.3.1 Introduction
Treatment depends upon the type of glaucoma exhibited and 
upon the relative increase in the intraocular pressure of a 
particular patient. In closed angle glaucoma the first 
necessity is to constrict the pupil and draw the iris away 
from the angle of the anterior chamber. To this end 
pilocarpine is used, especially in combination with eserine.
This regime may also be supplemented by systemic acetazolamide. 
The mode of action of the drugs is discussed in Section 1.1.3.2. 
Surgical treatment however is normally indicated in established 
closed angle glauxoma. The classical operation is a 
'glaucoma iridectomy'. In this a wide sector of the iris is 
excised so that, over this area, the drainage angle can no 
longer be obstructed by the iris root.
The treatment of primary open angle glaucoma normally involves 
the use of drugs for example pilocarpine, adrenaline, guanethidine 
and timoptol. Where the intraocular pressure is not relieved 
by such treatment it may be necessary to establish a fistula 
through which the aqueous under tension can filter away.
In secondary glaucoma treatment of the underlying cause is 
called for, but when this is difficult, a reduction of aqueous 
production by acetazolamide is especially helpful. In cases 
of uveitis steroids can be used to diminish the exudate.
In congenital glaucoma only surgical treatment will avail and 
this is most simply effected by division of the pectinate 
ligament.
1.1.3.2 Mode of Action of Drugs used in the Treatment of Glaucoma
a) Parasympathomimetic Agents. The parasympathomimetic 
agents fall into two classes.
1. Cholinergic,for example pilocarpine, carbachol.
(pilocarpine will be discussed in greater detail elsewhere)
2, Anticholinesterases, for example eserine,neostigmine, 
echothiopate.
They are all miotics and have the ability to reduce resistance 
to outflow of intraocular fluids. The site of action of the 
cholinergic drugs is at the parasympathomimetic receptors.
The cholinergic activity of the anticholinesterases is achieved 
indirectly by inhibition of the enzyme acetylcholinesterase, 
thereby allowing increased amounts of acet^choline to act for 
larger periods. The main disadvantage of treatment by miotics 
is they often produce ciliary spasm. The majority of miotics 
have activity of short duration and frequent instillations are 
necessary to control the intraocular pressure.
b) Sympathomimetic Agents. The sympathomimetic agents, for 
example, laevo adrenaline and phenylephrine are mydriatics and have 
the ability to reduce the formation of intraocular. fluids.
Their mode of action is stimulation of the sympathetic nervous 
system.
c) Sympatholytic Agents. These agents fall into two classes, 
adrenergic neurone blocking drugs and 3 receptor blocking drugs.
The former block the release of noradrenaline and also cause 
some depletion of the noradrenaline stores at the adrenergic 
nerves. The principal drug in this class, guanethidine.
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reduces the intra ocular pressure by decreasing the production 
of aqueous humour. The 3 receptor blocking drugs,for example, 
timoptol also decreases the production of aqueous humour 
by blocking the actions of the catecholamines.
d) Diuretic Agents. Carbonic anhydrase inhibitors, that is 
diuretic agents,(for example acetazolamide) have a general 
effect on metabolism resulting in an increase in loss of 
water accompanied by an increase in the excretion of sodium 
and potassium. A result of the diuresis caused is a 
lowering of the intra ocular pressure.
e) Osmotic Agents. The osmotic agents raise the osmolarity 
of the plasma so that the fluid is drawn out of the eye with a 
resultant fall in ocular tension. Their effect is only 
temporary, becoming ineffective as soon as osmotic equilibrium 
is re-established. The drugs used in this type of treatment 
are urea, mannitol and glycerol.
In the case of diagnosed open angle glaucoma miotic treatment 
at the earliest stages in both eyes is essential. For this 
purpose pilocarpine 1 - 2% is the drug of choice (6).
1.1,3.3 Pilocarpine
Pilocarpine is a parasympathomimetic alkaloid.
9
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It has the muscarinic actions of acetylcholine but is 
resistant to the hydrolytic action of the cholinesterases and 
thus has a useful duration of effect. It is stable, penetrates 
the cornea, is well tolerated and rarely toxic. The isomer 
of pilocarpine, isopilocarpine, has little or no therapeutic 
effect.
When instilled into the eye pilocarpine causes pupillary 
constriction, stimulates the ciliary muscle so as to increase 
accommodation and increases the permeability of the trabecular 
meshwork. The mechanism by which this increase in 
permeability occurs is not fully understood but may be due to 
the increase in prominence of cellular bulges in the endothelial 
monolayer of the trabecular wall of the canal of Schlemm. 
Alternatively it may arise as a result of the increase in size 
and frequency of the endothelial pores which occurs on the 
administration of the pilocarpine (7).
In the treatment of primary open angle glaucoma the drug is 
generally given as drops of a solution of the hydrochloride or 
nitrate salt at concentrations ranging from 0.5 to 4% and at 
a frequency of one to four times daily. Since the condition
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is permanent the drops are administered for the remainder 
of the patient's life.
The pilocarpine eye drops suffer from various drawbacks.
These include stinging of the eyes and irritation on instillation 
and blurring of vision. Stinging of the eyes may be due to the 
pilocarpine itself or to preservatives present in the formulation, 
for example benzalkonium chloride. Benzalkonium chloride has 
been reported to disrupt the superficial cells of the corneal 
epithelium and increase the intercellular spaces (8). It also 
hastens corneal drying either by disrupting the oily layer which 
normally spreads over the watery lachrymal film or it may 
encourage dissolution of the conjunctival mucin layer adsorbed 
on the surface of the corneal epithelium (9).
The side effects of the pilocarpine eye drops together with 
the frequency and duration of administration required may be a 
cause of the poor patient compliance observed amongst eye drop 
users (10, 11) and clearly indicate a case for the development 
of acceptable sustained release dosage forms requiring once 
daily administration or less for the treatment of open angle 
glaucoma.
1.1.3.4 Novel Ophthalmic Drug Delivery Systems
In recent years there have been various attempts at controlling 
the release of pilocarpine in the eye and thereby reduce the 
frequency of administration.
11
Many of the early sustained release pilocarpine formulations 
involved the addition of viscolysers to the eye drops.
The rationale behind this was to increase the contact time 
of the drug with the ocular surface and thereby increase 
the amount of drug available for absorption by the cornea.
The theory is apparent from consideration of the kinetics of 
pilocarpine in the eye.
On instillation of a solution of pilocarpine the amount of 
drug available to the eye is determined by three factors.
1. The rate of loss of the drug by drainage and by
non productive absorption,
2. The permeability of the cornea to the drug.
3. The rate of disappearance of the drug from the eyeball.
Makoid and Robinson (12) suggested that rapid elimination 
from the precorneal area together with a rapid decrease in 
the concentration gradient between the tears and the corneal 
surface was responsible for the early peak concentration 
they observed in the aqueous humour, following instillation 
of pilocarpine nitrate drops in the rabbit eye. This rapid 
elimination was probably caused by the tear volume returning 
to its normal resident volume of 7.5yl (13) after instillation 
together with dilution of the drug by the normal tear flow of 
0,66yl/min (14) and also by non productive absorption. It 
may be expected therefore that by decreasing the drainage of 
pilocarpine solutions by increasing solution viscosity, a 
marked therapeutic effect would be observed.
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Chrai and Robinson (15) used methyl cellulose to increase the
viscosity of a solution of pilocarpine nitrate. They showed
that the viscosity of the instilled solution was related to
the rate of solution drainage. They noted that over the
range 1 - 15cps solution viscosity there was a linear relationship
between the first order drainage rate constant and both the
miotic activity and the aqueous humour drug levels attained.
They reported however that there was only a relatively small 
increase in aqueous humour drug level for a large increase in 
solution viscosity. This may be explained by the hypothesis 
of Sieg and Robinson (16). They suggested that the cornea acts 
both as a barrier to pilocarpine penetration and as a reservoir 
for the drug. They postulated a mechanism with a small initial 
absorption rate in the presence of a large dose. Since the 
corneal epithelium is acting as a reservoir, increasing the 
contact time does not increase the epithelial concentration 
above its maximum value because the concentration gradient is 
unfavourable. Increasing the contact time does however 
maintain the epithelial concentration at a maximum value for 
an extended time, thus causing a shift in.the peak time.
This maximum value is fixed by the concentration of the 
applied dose.
Davies and others (17) looked at the effect of polyvinyl alcohol 
as a viscosity raising agent on the degree of miosis and 
intra ocular pressure reduction induced by pilocarpine in the 
human eye. Their results showed that the presence of polyvinyl 
alcohol to give a viscosity of 20 cs markedly increased the 
period of activity of the pilocarpine from about three to 
seven hours.
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Another method which has been used to prolong the effect of 
pilocarpine is by the preparation of pilocarpine alginate 
flakes. These flakes when placed in the rabbit eye gave a 
significantly greater miotic response than that obtained from 
pilocarpine solutions (18). Restoration of normal pupillary 
diameter for the solid state alginate flakes was observed to 
occur between 7 and 8 hours after instillation as compared 
with 4 hours for pilocarpine alginate solution and pilocarpine 
hydrochloride in methyl cellulose solution.
A third method which has been developed to prolong the activity 
of pilocarpine in the eye is the preparation of an aqueous 
emulsion 'Piloplex' (19). In this emulsion the dispersed 
phase consists of a polymeric material to which the active 
ingredient is chemically bound.
An alternative approach to sustaining the release of the 
pilocarpine involves the use of polymeric delivery systems.
Soft contact lenses, for example, prepared from 2 hydroxy ethyl 
methcrylate and soaked in pilocarpine hydrochloride solution 
have been used to deliver pilocarpine to the eye (20).
At all concentrations and soaking durations tested however 
virtually all of the pilocarpine was released from the lenses after 
four hours of wear.
Possibly the most common polymeric ocular device for sustained 
pilocarpine delivery is the Ocusert. The Ocusert system 
consists of a pilocarpine core sandwiched between two 
transparent rate controlling ethylene vinyl acetate copolymer
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membranes. It is slightly larger than a contact lens. When 
it is placed under the upper or lower lid of the eye the 
pilocarpine molecules permeate through the rate limiting 
membranes following zero order release over a period of several 
days. The Ocusert systems however have not proved successful. 
They are not well accepted by patients but even when in place 
may pin hole, releasing the entire pilocarpine content (21).
Other ocular inserts which have been developed include 
cellulose acetate hydrogen phthalate latices containing 
pilocarpine hydrochloride (22) microporous inserts and three 
layer inserts (23).
To date only two patents have been issued describing the use of 
microcapsules specifically for drug delivery to the eye. In 
the first (24) the microcapsules which may be of a variety of 
materials were embedded in a bioerodible matrix for example 
polylactic acid. The drug molecules released from the 
microcapsules diffused into the matrix and then migrated 
through the matrix for administration to the eye. Eventually 
the polylactic acid matrix would erode releasing the microcapsules, 
In the second patent (25), ophthalmic drugs were incorporated 
directly into release rate-controlled polymers which bioerode 
in the eye. For example chloramphenicol was encapsulated 
with polylactic acid and the resultant microspheres were 
dispersed in an aqueous ophthalmic medium. When drops of the 
preparation were placed in the eye the microcapsules embedded 
in the soft tissue lining the eye lids and gradually released 
chloramphenicol over 48 hours.
1.2 Microencapsulation
1.2,1 Introduction
Microcapsules are individual entities in the micron size range 
which are coated with a polymeric or macromolecular layer. 
Microencapsulation may be used to encase small particles of 
liquids, solids or gases with coatings which may be designed 
in such a way as to protect, separate, control core release 
or aid in storage and handling. Although most microcapsules 
range in diameter between 5 and 500 microns it is possible to 
prepare microcapsules with diameter outside these limits.
The first practical use for microencapsulation appeared in 
United States patents issued to Green and Schleider who used a 
coacervation method to encapsulate dyes in the preparation of 
carbonless copy paper (26) (27). In 1964 Miller and Anderson 
(28) were granted a United States patent for the manufacture of 
microcapsules containing "hydrophobic film forming polymeric 
wall materials dispersed in a liquid manufacturing vehicle".
The first reported preparation of microcapsules by interfacial 
polymerisation was in 1966 by Chang and others'(29). These 
workers prepared semipermeable polyamide microcapsules containing 
erythrocyte haemolysate, later publishing information 
concerning the use of this type of microcapsule in an 
extracorporeal shunt system (30).
The use of microcapsules has now spread to the food and 
flavour industries,for example for encapsulating fats, oils 
and flavours to prevent oxidation and volatilisation 
(31) (32). Microcapsules are used in the cosmetic industry
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to encapsulate perfumes (33) and in the agrochemical 
industry to control the release of pesticides, e.g. methyl 
parathion (34). They have also been used to encapsulate 
activated charcoal (35), adhesives (36) and electrophotographic 
materials (37).
1.2.2 Techniques for the Preparation of Microcapsules
A number of techniques have been developed for the preparation 
of microcapsules using a variety of materials. A brief outline 
of the methods is given below. The work has been more 
extensively reviewed elsewhere. (32, 38 - 45).
1.2.2.1 Coacervation
This is the term used to describe the salting out or phase 
separation of lyophilic colloids into liquid droplets.
Simple coacervation involves the addition of a strongly 
hydrophilic substance to a solution of a colloid. The added 
substance causes two phases to be formed. One phase is 
rich in colloidal droplets and the other poor in colloidal 
droplets. The most commonly employed simple coacervation 
procedures utilise gelatin as the wall forming material.
In such a system coacervation is brought about by the 
addition of, for example, sodium sulphate or alcohol which 
causes deposition of the wall material as a continuous 
coating about the dispersed phase. The resultant 
microcapsules are then filtered, washed and hardened with 
formaldehyde before being dried. The principle requirement 
for simple coacervation to occur is the creation of an 
insufficiency of water in a part of the total system and 
therefore depends primarily on the degree of hydration produced.
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Another process which may be used is complex coacervation.
This technique is largely dependent upon the pH of the system 
and occurs as a result of the interaction of oppositely charged 
polyelectrolytes. This interaction results in the formation 
of a complex having such a reduced solubility that phase 
separation occurs. Gelatin, a protein with both carboxyl and 
amino groups, and acacia, a carbohydrate with carboxyl groups, 
are typical polyelectrolytes which can be caused to interact.
A non aqueous solution of the core material is emulsified in 
an aqueous solution of acacia. To this is then added an 
aqueous solution of gelatin at a pH above its isoelectric 
point. On reducing the pH to 4 by the addition of acetic acid 
for example, the gelatin becomes positively charged and interacts 
with the acacia to form a complex. This complex exhibits phase 
separation and is deposited around the oil droplets.
Coacervation may be used for encapsulating lipophilic compounds 
only. Chlorthiazide (46) , sulphamethoxazole (47) and 
thiabendazole (48) are examples of oil soluble drugs which 
have been encapsulated by this technique.
1.2.2.2 Non Aqueous Phase Separation
Non aqueous phase separation is one of the techniques by which 
water soluble substances may be encapsulated. In order to 
effect encapsulation by this technique an emulsion consisting 
of the aqueous dispersed phase containing the material to the 
encapsulated is prepared in an organic continuous phase 
containing the polymeric wall material. A second solvent, 
which is miscible with the first but a non solvent for the
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polymer is then added. Due to the reduced solubility of the 
polymeric wall material in the new solvent system the wall 
material is forced to separate out and forms a film around 
the aqueous droplets. An example of a system which exhibits 
phase separation is an emulsion consisting of a dispersed 
aqueous phase and a continuous oil phase of ethyl cellulose 
dissolved in methyl ethyl ketone. Phase separation is brought 
about by the addition of polybutadiene. Aspirin is probably 
the most common drug which has been encapsulated by this 
technique (49). Another pharmaceutical which has been 
microencapsulated by non-aqueous phase separation methods is 
phenobarbitone sodium (50).
1.2.2.3 Mechanical Methods
A wide variety of mechanical methods have been developed for 
the production of microcapsules.
Air suspension coating: In this process the core materials,
which are fluidised by an upward moving air stream, are sprayed 
with a coating agent dissolved in a solvent. The solution 
coats the fluidised particles and hot air dries the solvent.
Centrifugal extrusion; Centrifugal extrusion involves the 
microencapsulation of liquids using a rotating extrusion head 
containing concentric nozzles. In this process, a jet of core
liquid is surrounded by a sheath of wall solution or melt.
As the jet moves through the air it breaks into droplets of 
core, each coated with the wall solution. Using this process 
it is possible to encapsulate aqueous solutions in waxy wall 
materials.
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Spray drying and spray congealing: Spray drying as a method
of microencapsulation involves the atomisation and spray 
drying of an emulsion in which the core is the discontinuous 
phase and the wall material is a constituent of the continuous 
liquid phase. Spray congealing is the term used to describe 
spray drying when the coat is applied as a melt. Other 
mechanical methods developed for microencapsulation include 
vacuum metallizing, vapour deposition, meltable dispersion 
and electrostatic methods.
1.2.2.4 In Situ Polymerisation
This process involves the direct polymerisation of a single 
monomer on a particle surface. Particles to be encapsulated 
are first dispersed in a liquid vehicle such as toluene and 
an appropriate catalyst is added to create activated sites 
on the particle to be encapsulated. The monomer is then 
bubbled into the slurry and polymerises on the surface of the 
core material. An example of this process is the encapsulation 
of cellulose fibres in polyethylene (51).
1.2.2.5 Interfacial Polymerisation
Microencapsulation by interfacial polymerisation involves the 
formation of an emulsion. One monomer is present in the 
disperse phase and a second monomer is incorporated into the 
continuous phase. When the two monomers come into contact 
at the surface of the emulsion droplets they polymerise, 
forming a polymeric wall. A typical example of microencapsulation 
by interfacial polymerisation is the formation of polyamide 
microcapsules using a diacid chloride as monomerr. The reaction
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depends upon the fact that although acid halides such as 
sebacoyl chloride are virtually insoluble in water diamines, 
such as hexamethylenediamine, have an appreciable partition 
coefficient towards the organic phase. The polymer is 
therefore formed in the organic phase but is deposited almost 
entirely at the interface. The mechanism of the interfacial 
polymerisation reaction is discussed in more detail in 
Section 1.4. Other classes of monomers which can be used 
to form microcapsules by interfacial polymerisation are given 
in Table 1.1.
1.2.2.6 Multiple Walled Microcapsules
An extension of the microencapsulation techniques discussed is 
the preparation of multiple walled microcapsules. Three walled 
microcapsules for example have been prepared by Morris and 
Warburton (52, 53) using acacia and polychloroprene. An aqueous 
solution containing acacia was emulsified in xylene containing 
polychloroprene to form a water in oil emulsion which was then 
re-emulsified in the aqueous phase. The xylene which was 
trapped within the microcapsule walls could be removed after 
bubbling air through the multiple emulsion. This resulted in 
microcapsules with an aqueous core and three concentric layers 
of wall. The preparation of microcapsules with concentric 
walls of epoxy resin, polyurea and polyamide has also been reported 
(54). In this process an aqueous solution of polyamine was 
dispersed in toluene. Solutions of epoxy precondensates 
polyisocyanate and polyacid chloride were then successively 
added to the tolu^A-ephase to cause interfacial polymerisation 








A further extension of microencapsulation is the preparation 
of nanocapsules, microcapsules in the nonometer size range.
The preparation of the nanocapsules is undertaken with 
micellar systems. An aqueous solution of the material to be. 
encapsulated is solubilised in a weakly polar vehicle to yield 
micelles of water in an organic outer phase. An amphiphilic 
monomer is then added to the lipophilic external phase and is 
enriched at the interface to form a mixed micelle. The monomer is 
then polymerised with the aid of suitable procedures for example 
gamma radiation, heat and chemical agents to produce.solidified 
hardened micelles with drug molecules entrapped. Finally, 
the outer lipophilic vehicle is replaced by water.
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TABLE 1.1 CHEMICAL CLASSES OF POLYMERS THAT MAY BE 
PREPARED BY INIERFACIAL POLYCONDENSATION.
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1.3 Release Characteristics of Microcapsules - Theoretical Considerations
The term microcapsule is generally used to describe a hollow sphere 
of polymeric material with encapsulated drug contained in solution 
or suspension within the core. This type of system is termed a 
reservoir device. In the majority of capsule type delivery systems 
the polymers are non-porous and drug traverses the membrane by a , 
process involving solute dissolution in the membrane structure 
followed by solute diffusion along and between polymer segments and 
is finally released into the external medium. Thus the release of 
drug from a capsule type device is a permeation process and in the 
case in which the drug is dissolved in the core the situation is 
analogous to the diffusion of drug through a planar membrane (55). 
From a consideration of Picks law of diffusion which defines the 
flux across a plane surface and may be written as equation 1.1, it 
can be seen that as drug is released from the microcapsules so the 
concentration gradient decreases and therefore the rate of drug 
release decreases.
^  ~ (equation 1.1)
X
where ^  is the rate of drug rèlease 
dt
P is the permeability constant for a given drug
and membrane
A is the surface area of the microcapsule
X is the membrane thickness
Cg and Cĵ  are the concentrations of drug in the
encapsulated and bulk (sink) solutions 
respectively
Equations governing release under changing concentration gradient 
for microcapsules in which the thickness of the microcapsule wall 
is much smaller than the core radius have been proposed by Benita 
and Donbrow (56). Under sink conditions in which the sink solution
24
volume is much larger than the internal volume of the microcapsules 
the equations derived simplify to give equation 1.2.
= Me exp - PAt (equation 1.2)
xV,
where and M© are the mass of drug in the microcapsules 
at time t and time O respectively
is the internal volume of the microcapsule 
In the case in which the drug is dispersed in the microcapsule core,
that is the drug loading is greater than the drug solubility the
microcapsule behaves as a true reservoir device. The drug traverses 
the microcapsule membrane by a diffusion process following 
dissolution in the core vehicle. The undissolved drug therefore 
acts as a constant source of solute available for diffusion. The 
release is again governed by Picks law which has been modified by 
Baker and Lonsdale (S7) to relate to the release from a spherical 
reservoir of radius î, surrounded by a spherical membrane of 
radius r^. (equation 1.3).
^  , 4it DK AC rpfi (equation 1.3)
where D is the drug diffusion coefficient in the membrane
K is the drug partition coefficient in the membrane
AC is the concentration gradient across the membrane
Mathematical expressions defining the cumulative amount of drug
released from unit surface area of a capsular reservoir system
were derived by Chien and Lambert (58). It was proposed that if sink
conditions were maintained throughout and there were no diffusion
effects in the boundary layer, that is release was governed by
diffusion through the polymer, then the rate of drug release was




C D s (equation 1,4)
where is the solubility of the drug in the polymer phase. 
From equation 1.4 it is seen that the release rate is independent 
of time but is a linear function of both the solubility of the 
drug in the polymer and the membrane diffusivity. The release 
from such a device will therefore exhibit zero order kinetics over 
a time period t^ to t^ which is illustrated diagrammatically in 
Figure 1.3.
Figure 1.3





During the initial period t^ to t^ the release rate will not be 
constant. For example, if the system is loaded with drug and used 
immediately some time will be required before a concentration gradient 
is established within the membrane and a lag time effect will be 
observed. Conversely if a device is stored for some amount of 
time before release, the membrane will be saturated with drug and 
the initial release rate will be high. At some time t^ the mass 
of drug per unit volume in the core will approach the solubility 
of the drug. At this point the release characteristics will be
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those exhibited by a solution containing device according to 
equation 1.2.
The term microcapsule is also used to describe a polymer matrix in 
the micron size range containing drug dissolved or dispersed as 
solid throughout. This type of delivery system is known as a matrix 
device. In the case of a delivery system containing drug dissolved 
in the polymer matrix the drug traverses the polymer by diffusion 
and is desorbed. During the release process drug is lost from 
the outer layer of the microcapsule. Therefore as time continues 
the diffusion path increases since the outer layers become depleted 
of drug and the remaining solute must diffuse through these outer 
layers before being released. From a consideration of Ficks 
equation written as equation 1.5 it may be seen that the concentration 
gradient and therefore the flux is time dependent for a matrix type 
device.
= "D dc (equation 1.5)
dx
where Jd is the flux across a plane surface of unit area 
dc~  is the concentration gradient of the solute across 
^ the diffusion path dx
The effects of various parameters on the release rate of matrix
devices of different geometries have been considered by Baker
and Lonsdale (57). For a sphere the rate of release during early
and late time periods was given by equations 1.6 and 1.7 respectively.
dMt_
dt
= 3 ^ 2 ”^  ^ - 3D (equation 1.6)
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^Moo = — “2” exp ^ "2"^  (equation 1.7)
dt  ̂ \  ̂ /
where Moo is the total amount of drug in the polymer
M(j is the amount of drug desorbed at time t
r is the radius of the device
In the case in which the drug is dispersed as a solid in the
polymer matrix the kinetics are altered. The mathematical model
describing dispersed drug release from a polymer by a solution-
diffusion mechanism has been described by Higuchi (59, 60)
and the amount of drug released is given by equation 1.8.
/ I k= A J DCg (2 - Cg)t y (equation 1.8)
where is the solubility of the drug per unit volume 
in the matrix
C(L is the total amount of drug present per unit volume 
In this case the amount of drug released is linear with time to 
the power one half. Therefore the rate of release decreases 
with time. In the situation where the drug is dispersed in the 
polymer but diffuses through channels or pores in the polymer 
rather than by a solution diffusion mechanism it is necessary to modify 
equation 1.8 to take account of the tortuosity and porosity of the 
matrix.
In the case of microcapsules with microporous membranes or those in 
which a partially soluble membrane encloses a drug core the kinetics 
of release are again different. In the case of microporous 
membranes the rate of a solutes permeation through the membrane 
will depend on the pore size and the solutes molecular volume.
In the second type of capsule the dominant factor will be the 
fraction of soluble polymer in the coat. An alternative type of
8
controlled release capsule is one controlled by dissolution.
An example of this is microencapsulated drug in which all the drug 
is in the core and complete erosion of the coat leads to an abrupt 
release of contained drug. In this instance the time taken for 
release of the drug is governed by the dissolution rate constant 
for the polymer and the coating thickness. The release kinetics 
from an erodible solid sphere with solute dispersed throughout 
have been examined by Hopfenberg (61), who has shown that since the 




1.4.1 The Synthesis and Structure of Polyamides
Nylon is the generic name given to a series of polymers known 
as polyamides. The first nylon to be developed commercially 
was the condensation product of hexamethylenediamine and 
adipic acid. It was called Type 6.6 nylon, the name being 
derived from the number of carbon atoms in the parent diamine 
and diacid monomers. Later a different method of making 
polyamides was discovered, namely by condensation of certain 
W-amino acids. Nylons prepared by this method are described 
by a single number which is derived from the number of carbon 
atoms in the parent amino acids. Examples of the synthesis 
of polyamides are given below.
1. Condensation of a Diacid and a Diamine
coo”  **‘nh
n HOOCXCOOH + n H^NYNH^ n
 ̂  ̂ 3
X + yI ICOOH NH^
-► f OCXCONHYNH j- +  2(n-l)H^0n 2
Nylon 6.6 and nylon 6.10 are synthesised by this method;
using hexamethylenediamine and adipic acid or sebacic acid
respectively. There are a large number of other diamines
and diacids which can be used to prepare polyamides by
this route ranging from ethylenediamine and phthalic acid
to BIS (3-aminophenyl)methyl phosphine oxide and
BIS (4 carboxyphenyl)-methyl phosphoric acid (62)"
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2. Self-condensation of an W-Amino Acid
n NH^XCOOH -> {■ NHXCO ^ n + n-1 H^O 
This is the method used to prepare nylon 11 from 
W-amino-undecanoic acid. A suitable catalyst is 
phosphoric acid,




Nylon 6 is prepared from &-caprolactam by this route 
using water as a catalyst. Nylon 12 is also prepared 
by this method from laurilactam.
The general structure of the polyamides is that of alternating 
hydrocarbon and imido groups as typified by nylon 6.6 (Figure 1.4)
Figure 1,4
Schematic Representation of Nylon 6.6
CH ÇH CH NH CH^ CH.V V  V  V  V V
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The polymer matrix is heterogeneous in nature consisting of 
both amorphous and crystalline regions. Within the 
crystalline regions the presence of the polar imido groups 
leads to a strong attraction between the molecules due to 
hydrogen bonding. The way in which these interchain hydrogen 
bonds may form is shown schematically in Figure 1.5.
Figure 1.5
Schematic Representation of Hydrogen Bond Formation between 
Nylon 6 Molecules
C=0
 o = c
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Although the alignment of chains as represented above is only 
strictly found in the crystalline regions where intermolecular 
hydrogen bond formation will be at a maximum, hydrogen bonding 
does occur in the amorphous regions but to a more limited 
extent. The proximity of the amide chains and thus the 
extent of bond formation is influenced by environmental 
factors such as physical stress (63) hydration (64) and
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temperature (65). Chemically, within the polymer matrix, 
there are polar and non polar regions which correspond to 
the local relative abundance of amide groups and methylene 
chains.
1.4.2. Properties of Polyamides
The high degree of intermolecular attraction in the 
crystalline regions of polyamides results in high melting 
points and high solubility parameters. Only solyents 
capable of specific hydrogen bond formation with the polymer 
effect solution of polyamides at room temperature, for 
example, formic acid.
The properties of polyamides are readily altered by varying 
the hydrocarbon chain length or by substitution of groups.
For example, the longer the hydrocarbon chain the lower will 
be the attractive forces between the polymer chains, as a 
result of the reduced number of hydrogen bonding amide groups. 
This results in a lowering of the melting point. Substituting 
an alkyl group for a hydrogen in the hydrocarbon chain also 
lowers the melting point and increases the solubility of the 
polymer. This occurs as a result of the presence of the 
alkyl group which prevents the close approach of the molecules 
thus reducing hydrogen bonding between adjacent chains.
Hydration of the polyamide matrix occurs by specific bond 
formation between water molecules and unassociated amide groups, 
Water penetrates the polymer matrix via the amorphous regions 
but cannot gain access to the relatively denser crystalline
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regions. Three types of water-amide group bond have been 
postulated (66) giving rise to three possible 'types* of water 
being present in polyamides:
1. Tightly bound water in which the molecules from a double 
hydrogen bond between the carboxyl free electron pairs of 
two adjacent amide groups.
2. Loosely bound water where the molecules can bind by 
joining existing hydrogen bonds between the carboxyl 
and amide groups of adjacent amide links.
3. Capillary condensed water which occurs by the self
association of incoming water molecules with existing 
bound water.
1.4.3 Interaction of Solutes with Polyamides
1.4.3.1 Classification of the terms used in Solute-Sorbent Interactions
The various types of solute-sorbent interactions which may occur 
when an adsorbent is placed in a solution of a solute are listed 
below.
a) Adsorption: This term refers to the transfer of solute 
from bulk solution to the interface between the two phases 
of the sorption system.
b) Sorption: is the term applied to the interaction whereby 
the solute penetrates into the bulk of the sorbent by 
crossing the interface between the sorbent and the bulk phase.
c) Persorption describes the process whereby solute molecules 
penetrate a series of pores in the bulk of the sorbent, as 
opposed to sorption which occurs at a molecular level within 
the sorbent.
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d) Permeation is the term used to describe the process in 
which solute molecules cross a sorbent which separates 
a solute solution from a second bulk phase. The 
mechanism of permeation takes place by sorption, 
distribution and diffusion processes.
e) Desorption is the term applied to the process whereby 
the net transfer of solute occurs from the sorbent back 
into solution. It applies to the reverse of adsorption, 
sorption and persorption.
1.4.3.2 Polyamide - Solute Interactions
The interaction between polyamides and weak organic acids and 
bases in the unionised form is generally considered at the 
molecular level to be a sorption process. These interactions 
are typified by linear (C Type) adsorption isotherms (67, 68) 
which are representative of systems where the solute is capable 
of penetrating the sorbent. They may therefore be considered 
as akin to a partition process.
The nature of the interaction between solutes and polyamides 
has been the subject of several reports in the literature.
It has been suggested that these interactions may involve 
ionic attractions. Van der Waals' forces or hydrogen bond 
formation. Ionic forces, for example, are usually involved 
when the ionised form of organic acids or bases are sorbed by 
polyamides (69). The uptake of organic acids such as formic 
acid however involves only forces of the Van der Waals' type 
(70), whereas the interaction between weak organic acids such 
as sorbic acid and polyamides have been reported to involve
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hydrogen bond formation (71). Kapadia and others (72) 
investigated the interaction of a number of 4-hydroxybenzoate 
derivatives with polyamides. They proposed that these solutes 
formed very weak hydrogen bonds with the amide groups in the 
polymer which were then stabilised by Van der Waals* forces.
Later Richardson proposed that the sorption of ethyl-4--aminobenzoate 
by nylons may also be related to the swelling of the matrix by 
water (67).
Consideration of the structure of the nylon matrix, namely 
the presence of amorphous and crystalline regions, hydration of 
the amorphous areas and the presence of polar and non polar 
regions, led Wicks (73) to propose three possible mechanisms 
of binding of solutes in polyamides.
1. A solute, unable to form hydrogen bonds directly with the 
polymer, may associate with the hydrophobic regions present 
by the formation of weak Van der Waals* forces.
2. Solute molecules which are capable of forming weak 
hydrogen bonds with the polymer, but are unable to displace 
bound water from the amide linkages, may form an association 
with this bound water. In this case sorption of the solute 
would depend upon the degree of hydration of the matrix.
3. Direct association of a solute with the polyamide can 
arise in two ways. A solute capable of forming 
moderately strong hydrogen bonds could displace loosely 
and tightly bound water from the amide groups in the 
amorphous regions of the matrix and hydrogen bond directly.
If the solute was not capable of forming sufficiently
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strong hydrogen bonds to break the interchain hydrogen 
bonds in the polymer access to the highly crystalline 
regions would not occur. If, however, the solute was 
able to break the interchain hydrogen bonds and gain 
access to the cryskoulline regions the result would be 
eventual plasticisation and dissolution of the polymer.
1.5 Polyamide Microcapsules
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1.5.1 The Interfacial Polymérisation Reaction in the Formation of 
Polyamides
1.5.1.1 Reaction Mechanisms
Interfacial polymerisation may be defined as a polymerisation 
reaction which takes place at the interface of two or more 
immiscible liquids. For example, at the interface between a 
water layer containing a diamine and an oil layer containing a 
diacid chloride, polycondensation will occur to form a film of 
polyamide with the release of hydrogen chloride.
n Cl C (CHg)^ C Cl + n HgNfCHgly NH^ ^
n
0 O
1 II Cl C (CH ) C
HIN (CH ) NH ; 2 y 2
Cl H





The reaction is believed to take place by an S^2 mechanism 
to form a protonated amide from which a proton is rapidly 
eliminated by the presence of an added base (74, 75). It 
has been shown that reactions between acid chlorides and 
nucleophiles proceed essentially irreversibly (76). Reaction 
rates of polycondensation reactions vary widely from 10^ to 
10^ litre mole”^ sec”^ (77). In the case of piperazine 
reacting with phthaloyl or terephthaloyl chloride the rate 
constant has been reported to be 10^ to 10^ litre mole”^
sec"l (78).
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when a solution of the diacid chloride is brought into contact 
with the aqueous phase containing the diamine high molecular 
weight polymer forms rapidly. It is generally accepted that 
the polymer forms on the organic side of the interface while 
the acid by product accumulates as a salt in the aqueous phase.
Upon phase contact both reactants and solvents tend to become 
partitioned to some extent into the opposite phase and the 
success of the reaction depends upon this (Figure 1.6).
The diamine nearly always has an appreciable potential partition 
toward the organic phase whereas the acid chloride has very 
little solubility in water. Partition equilibria in diffusion 
controlled systems however are never achieved during 
polymerisation as acylation takes place in the organic phase 
as rapidly as diamine is transferred. Were this not so, 
the diamine would have time to penetrate more deeply into the 
acid chloride layer and reaction and polymer precipitation 
would take place more diffusely, as occurs in kinetically 
controlled systems (77),
During interfacial polycondensation the first diamine molecules 
meet a high concentration of acid chloride and are acylated to 
a large extent at both ends. The following diamine molecules 
find a layer of acid chloride terminated oligomers (that is 
polymers with few monomer units) plus diacid chloride and the 






- ' ,, 










FIGURE 1.6 DIAGRAM OF RELATIONSHIP OF REACTANTS IN 
INTERFACIAL POLYMERISATION.
a. — Diamine molecules
<=» Diacid chloride molecules
b. A Amine groups in water phase
B Amine groups at partition ’equilibrium* in 
organic phase 
C Acid chloride groups in organic phase
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The concentration and size of the oligomers increases until 
a layer of high polymer is obtained. High polymer forms 
because of the increasing probability that diamine reacts with 
an oligomer rather than new diacid chloride.
The reaction therefore may be considered to take place in a 
series of incremental layers through which the diamine advances 
from the liquid interface and into the organic phase. As the 
concentration of polymer species increases interchain contacts 
increase until an intact network is formed. Polymerisation 
however does not entirely stop at this stage but is greatly 
decreased in rate. This is because of the lower mobility of 
the polymer chains and the decreased diffusion rate of the 
intermediates. It may also be due to hydrolysis of the acid 
chloride (79) . It has been observed experimentally that as 
the diamine diffuses it carries with it some water into the 
organic phase. This water hydrolyses the reactive acid 
chloride which cannot now react with the diamine and therefore 
may result in inhibition of further growth of the membrane.
R - COCl + H^O -> RCOgH + HCl
During the course of the reaction the ratios of the reactants 
within the layers of the polymer vary. Therefore there may 
exist a gradation of average molecular weights across the 
width of the film which would vary with the original 
concentration of the reactants. It has also been suggested that 
as the membrane thickness increases so the structure of the 
membrane becomes more and more disordered (79). Thus the
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membrane will have two surfaces; a smooth surface near the 
water phase and a rough surface near the organic phase.
The same workers also reported that the polymer chains are 
mainly oriented perpendicular to the interface (79) and 
because of the growth mechanism both surfaces will expose 
different end groups. They also suggested that there was 
a continuous change in the concentration of type of end 
group across the membrane.
To obtain the highest polymer, the balance of transfer rates 
of reactants must be such that equivalents of reactants enter 
the polymerisation zone just within the solution period.
For this reason, the system is sensitive to those factors 
which change the transfer rate of diamine to the organic 
phase as well as to changes in the reaction rate and solvent 
swelling of the polymer.
1.5.1.2 Factors Affecting Polymer Yield
The factors affecting the yield of polymers formed by 
interfacial polycondensation have been proposed by Morgan 
and Kwolek (80, 81) and MacRitchie (82) for nylon 6.10 and by 
Bradbury (83) for polyterephthalamide.
1. Chemical Reaction Rate: The chemical reactions employed
in interfacial polycondensation are often extremely fast 
having rate constants of the order of 10^ to 10^ litre 
mole”^ sec“ .̂ The reaction rates are dependent upon 
the nature of the reactants used (77). The basic 
constraint on the rate however is that it must be faster 
than any important side chain reactions which occur at
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the polymerisation site such as hydrolysis of the acid 
chloride (79) and incorporation of monofunctional monomers. 
The polymerisation must also be complete before the 
polymer is immobilised by precipitation.
2. Precipitation Rate of the Polymer; The precipitation rate 
of the polymer is important in terms of the chemical 
reaction rate in that precipitation must not occur before 
the reaction is complete. It is also important that the 
precipitation rate is such that the polymer should stay
in solution for a sufficient period to attain a high 
degree of polymerisation,
3. Material Purity; A high grade of purity of reactants and 
solvents is a requirement for the preparation of polyamides 
of high molecular weight by interfacial synthesis. The 
presence of monofunctional compounds will result in the 
termination of propagating molecules (84) whereas
polyfunctional compounds will give rise to branching and 
crosslinking. Mono or polyfunctional compounds may be 
formed on storage of reactants as a result of hydrolysis, 
oxidation and so on. Some impurities may be tolerated in 
interfacial polycondensation provided they react more 
slowly than the polymer intermediates. They may also be 
tolerated if they are withheld selectively from the 
polymerisation zone by the aqueous phase. Slow reacting 
impurities however, may accumulate in the polymerisation 
phase and compete successfully with polymer intermediates 
in the formation of final polymer. This would result in a 
lowering of the molecular weight.
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4. Hydrolysis of the Acid Chlorides; Acid chloride hydrolysis 
occurs primarily in the aqueous phase and since most diacid 
chlorides have low solubility in water they are protected 
to a large extent. Of the diacid chlorides, the 
shorter chain aliphatic molecules are the most water 
soluble and are therefore hydrolysed to the greatest 
extent (81) resulting in a depletion of the reactant.
It has also been reported that some water is present
in the organic phase (79) and therefore some hydrolysis
must occur at the interface and in the bulk of the
organic phase. Any hydrolysis products which are
formed will be water soluble and therefore will be held out of
the polymerisation region by the aqueous phase.
5. Stirring Rate; Stirring rate is important in relation to 
the generation of 'interfacial area* (85). The interfacial 
surface area provides the points of contact for the 
reacting molecules. Additionally, the rate of mass 
transfer of material across films adjacent to the interface 
is directly proportional to the interfacial area as well as 
to the concentration gradient. The effect of stirring rate 
on the molecular weight of the polymer produced is variable.
It has been suggested that the effect of stirring is to 
increase the availability of the diamine (81). Therefore, 
in a system in which the diamine concentration in the 
organic phase is below the optimum concentration for the 
relative amount of diacid chloride present, increasing
the stirring speed will increase the molecular weight of 
the polymer formed. Conversely for a system in which
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the concentrations of the monomers in the organic phase 
are at an optimum for polymer formation, increasing the 
stirring speed will decrease the molecular weight of the 
polymer formed. This will occur due to the creation of 
a relative deficiency of diacid chloride molecules in the 
organic phase arising as a result of the increased 
availability of the diamine.
6. Effect of additives and pH: Small amounts of detergents are 
sometimes helpful to stirred polycondensation reactions.
This is due to improved mechanical mixing and contact of 
the reactants which may result in the formation of smaller 
droplets of dispersed phase. Surface active agents may 
also assist the transfer of both diamine and salt across 
the interface.
The presence of salts such as acid acceptors strongly 
affects the polymerisation. Neutral salts, in particular, 
shift the partition of the diamine toward the organic phase. 
This is probably due to a change in the amount of unionised 
diamine, as well as salting out effects. Changes in the 
pH of the aqueous phase will also affect the relative 
amounts of ionised and unionised diamine. Salts in the 
aqueous phase also reduce the solubility of the acid 
chloride in the water thereby reducing any hydrolysis.
The addition of sodium bicarbonate as an acid acceptor (29) 
is detrimental to the polyermisation as it is a weak base. 
When acted upon by an acid it produces carbon dioxide which 
in turn withholds diamine from the reaction resulting in
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lowered yield and molecular weight, Bradbury and others 
(83) looked at the salt effect on the rate of reaction 
between terephthaloyl chloride with piperazine. They 
considered that the observed changes in rate constant 
with varying salts and salt concentrations was due to the 
salting in or salting out of amine from the aqueous phase 
and acid chloride from the organic phase.
7. Phase Volume and Monomer Concentration Ratios: The viscosity
of the polymer obtained varies according to the relative 
amounts of each monomer present in the polymerisation zone
at a given time. This is dependent upon the phase volumes 
and monomer concentrations used. On increasing the 
relative amount of diamine present the diffusion of the 
diamine into the organic phase will increase with the 
result of the formation of a less compact polymer.
Increasing the relative amount of diacid chloride however, 
will increase the concentration of this monomer in the 
polymerisation zone, restricting the thickness of the 
film formed.
8. Choice of Organic Solvent; The choice of organic solvent 
determines the partition coefficient of the diamine.
As the consequence of a change in the organic solvent 
therefore, there will be a shift in the reactant 
concentration ratios in the polymerisation zone. This will 
result in a change in the molecular weight of the polymers 
obtained. Additionally the better the solvent for the 
polymer the higher the molecular weight of the product
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due to the greater time for which the polymer will be in 
solution before precipitation occurs.
9. Method of reactant addition: It has been suggested that
the mixing of the organic and aqueous phases should be as 
rapid as possible (81). If the acid chloride, for example, 
is added slowly the first portion will react with an excess 
of diamine resulting in a lowering of the molecular weight 
of the polymer.
1.5.1.3 The Interfacial Polymerisation Reaction in Microencapsulation 
The factors which influence the interfacial polymerisation 
reaction discussed in Section 1.5.1.2 will also affect the 
formation of microcapsules using this method. For example, 
it has been found that because of the increased water solubility 
of the shorter chain aliphatic diacids and therefore their 
increased hydrolysis, microcapsules cannot satisfactorily be 
prepared from diacid chlorides where the chain consists of 
less than eight carbon atoms (86). It is also probable that 
the properties of the microcapsules and the microcapsule 
membranes will be affected by all those factors influencing 
the partition of the diamine into the organic phase. This has 
been found to be true, for example, in the case of the presence 
and nature of any emulsifier (87, 88), solvent composition (87), 
pH of the aqueous phase (88) and the nature of the diamine 
(87, 89). The effect of each of these conditions on the 
microcapsules formed is discussed in Section 1.5.3.
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In particular, the choice of any core material to be 
encapsulated is important as it may interfere with the 
polymerisation reaction. This may occur not only by 
affecting the partition of the diamine but also by reacting 
with either of the monomers. J^iline, for example, has a 
high affinity for the organic phase and when included as a 
core material hinders the interfacial reaction by reacting 
with the acid chloride and terminating propagation of the 
chains (54). Some quarternary ammonium compounds have also 
been found to interfere with the polymerisation reaction 
preventing the formation of microcapsules (90).
1.5.2 The Preparation of Polyamide Microcapsules by Interfacial 
Polycondensation
1.5.2.1 Original Method
The preparation of nylon 6.10 microcapsules containing erythrocyte 
haemolysate was first described by Chang and others in 1966 (29). 
Details of this method are given below and are shown schematically 
in Figure 1.7.
Stage I. To 1.5ml of haemolysate in a 100ml beaker was added 
an equal volume of 0.4M hexamethylenediamine in 0.45M carbonate- 
bicarbonate buffer at pH9.8. The buffer was present as an acid 
acceptor to neutralise the hydrogen chloride formed during the 
polymerisation reaction. The beaker was surrounded by ice.
This may have been to counteract the heat formed during the 
polymerisation possibly denaturing the protein. It may also 
have had the effect of slowing any hydrolysis of the diacid 
chloride (91). The buffered haemolysate was then immediately 
emulsified for 1 minute with 15ml of a "mixed solvent"
(chloroform:: cyclohexane 1:4 containing 1% v/v Span 85).
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O.OIM sebacoyl chloride in 
chloroform: cyclohexane 1:4 
containing 155 Span 8 5. (15ml)
Chloroform:cyclohexane 1:4 




containing 1% Span 8 5.(15ml)
Emulsify for 
1 minute*








Disperse microcapsules in 
25ml Tween 20 solution 
(555 in water).
Stir.
After 30 seconds add 50ml 
water and stir.
Centrifuge.
Resuspend microcapsules in 
25ml 0.9% sodium chloride 
solution.
FIGURE 1.7 SCHEMATIC REPRESENTATION OF NYLON 6.10 MICROCAPSULE 
PREPARATION ACCORDING TO THE METHOD OF CHANG AND 
OTHERS (291.
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Chang and co-workers noted that although many other solvent 
phases could be used, that particular combination satisfied 
the following requirements.
(1) The liquid should be one which does not readily denature 
proteins, as protein was the core material, e.g. 
cyclohexane,carbon tetrachloride and chloroform.
(2) It is desirable to have a liquid with specific gravity 
fairly close to unity as with denser liquids the formed 
microcapsules would tend to rise to the surface and consequently 
be less easily separated by centrifugation. With liquids
of lower specific gravity the microcapsules would sediment 
rapidly and become harder to redisperse.
(3) The partition coefficient of the organic liquid for the 
diamine determines the properties of the membrane (80). 
Chloroform which has a high affinity for diamine produces 
strong but coarse and thick membranes whereas cyclohexane 
produces smooth and very thin but weak ones. The two 
solvents combined in the stated proportion resulted in an 
organic phase with a satisfactory specific gravity which 
also allowed the production of thin but satisfactorily 
strong membranes.
No indication was given as to the selection of surface active 
agent. Span 85 was presumably used as it produced a stable 
water in oil emulsion using the above disperse and continuous 
phases. Emulsification was effected using a magnetic stirrer 
and 4cm stirring bar. The concentration of surfactant and 
stirring speed were possibly selected so as to produce microcapsules 
of the desired size.
stage II. Without stopping the stirring, 15ml of sebacoyl 
chloride solution was added and stirring continued for 3 minutes. 
The sebacoyl chloride solution was prepared immediately before use
by adding 0.1ml of pure sebacoyl chloride to 25ml of the 
mixed solvent to give a concentration of 0.018M. It was 
necessary to prepare this solution immediately before use in 
order to decrease the possibility of hydrolysis of the acid 
chloride. The stirring time was also important. If the 
reaction time is too brief a leaky macroporous membrane is 
formed whereas prolonged contact of diamine with diacid 
chloride yields a thick membrane with an excess of low 
molecular weight polymer on the organic liquid side.
Removal of the microcapsules from the reaction mixture was 
therefore carried out rapidly.
Stage III. At the end of the reaction time 30ml of the 
'mixed solvent' was added to the stirred suspension. The 
addition of the solvent may have had the effect of quenching 
the reaction by diluting the system. The suspension was then 
centrifuged at 350g for 15 seconds and the supernatant discarded; 
possibly at high spin speeds the microcapsules are likely to 
rupture. The microcapsules were then dispersed in 25ml of 
50% v/v aqueous Tween 20 solution. Tween 20 was used as it 
is capable of forming a stable oil in water emulsion and it 
assists in separation of the organic phase associated with the 
microcapsules. Chang and othérs (29) noted that the 
concentration of the surfactant was important as at lower 
concentrations the microcapsules were not completely separated 
from the organic phase. Dispersal of the microcapsules was
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achieved first by gentle stirring with a glass rod and then 
using a magnetic stirrer. 50ml of water was added and the 
suspension stirred for 30 seconds, centrifuged and the 
supernatant discarded. The microcapsules were then quickly 
resuspended in 25ml 0.9% sodium chloride solution. Chang and 
others (29) noted that the microcapsules at this point may have 
been crenated due to their exposure to hypertonic Tween 20 
solution but that they regained their sphericity in the saline 
if the period of contact with the strong Tween 20 medium had 
been kept as short as possible.
Photographs of microcapsules prepared by this method show that 
they had the appearance of hollow spheres with clear interiors 
(29). Their size ranged between 20^m and 80^m diameter 
depending on the Span 85 concentration and the stirring speed 
used. It was estimated that the membrane thickness of the 
80ym diameter microcapsules was approximately 0.2ym. It was 
also noted that the microcapsules were flexible and under 
hydrostatic pressure a lOOym diameter microcapsule would pass 
through a capillary half that diameter.
1.5.2.2 Modifications to the Original Method
The above method developed by Chang and his colleagues (29) 
has been modified by a number of workers to produce microcapsules 
containing different core materials or with different physical 
properties. Parameters which have been modified include the 
following :
1. Solvent System. The majority of microcapsule preparations 
in the literature utilise chloroform and cyclohexane in
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various ratios as the solvent system, Shiba and others 
(92) Koishi and others (37) and Jenkins and Florence (93) 
all used an organic phase consisting of cyclohexane and 
chloroform in the ratio of 1 to 3. Aisina and co-workers 
(94) prepared polyamide microcapsules using an organic 
phase also consisting of cyclohexane and chloroform but 
in the ratio of 1 to 5. The polyterephthaloyl microcapsules 
prepared by Ishizaka and others (95) were formulated using 
chloroform to cyclohexane ratios ranging from 1 to 2, to 
1 to 6. Degennaro and colleagues (96) however in the 
preparation of nylon 6.10 microcapsules used carbon 
tetrachloride as the organic phase.
2. Surface Active Agent. Span 85 is the most often used 
surfactant in polyamide microcapsule preparation. The 
original concentration used by Chang and co-workers (29) 
to prepare microcapsules of 80ym diameter was 1% v/v.
It was noted however, that in order to prepare smaller 
microcapsules of approximately 5ym diameter using an 
homogeniser it was necessary to increase the concentration 
of Span 85 to 15% v/v to prevent aggregation of the 
microcapsules. Other workers have used Span 85 
concentrations ranging from 2% v/v to 20% v/v 
(87, 89, 97, 98). Although in the majority of reports 
no reason is given for the selection of surfactant 
concentration, it may have been to prepare microcapsules 
of a given size. Luzzi and others (99) used Brij 52 at 
a concentration of 1% v/v as the surfactant in the 
preparation of polyamide microcapsules and Jenkins and 
Florence (93) used 10% Arlacel A. Again no reason for
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the choice of surfactant was given but presumably both 
surfactants resulted in the formation of a stable water 
in oil emulsion.
3. Monomers. A number of diamines and diacid chlorides have 
been used in the preparation of polyamide microcapsules. 
Takamura and others (100) for example, prepared microcapsules 
from various combinations of the following diamines and 
diacid chlorides: phenylenediamine, piperazine,
2,5 dimethyl piperazine, 1,6 hexamethylenediamine with 
sebacoyl chloride or phthaloyl dichloride. Koishi 
and colleagues (87) used phthaloyl chloride in combination 
with either 1,6 hexamethylenediamine or piperazine.
Ishizaka and co-workers (95) prepared microcapsules using 
piperazine and terephthaloyl chloride.
4. Phase Volume and Monomer Concentration Ratios. The 
relative concentrations of diaqid chloride and diamine 
vary widely between authors. Ishizaka and colleagues (95) 
for example reacted 0.2M piperazine in 0.225 M sodium 
carbonate with 0.04M terephthaloyl chloride, and 0.4M 1,6 
hexamethylenediamine with 0.08M sebacoyl chloride.
Luzzi and co-workers (99) used 0.58M 1,6 hexamethylene­
diamine with 6.7 X lO'^M sebacoyl chloride and Koishi and 
others (101) 0.4M piperazine or 1,6 hexamethylene-diamine 
with 0.04M phthaloyl chloride.
The phase volumes also vary considerably from author to 
author. In the preparation of microcapsules by Aisina and 
others (94) the volume of the internal aqueous phase was 
1.5ml and that of the external organic phase.was 15ml.
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Luzzi and co-workers (99) however used an internal phase 
volume of 50ml and an external phase volume of 330ml,
5. Inclusion of Additives. In the original method of
microcapsule preparation Chang and others (29) encapsulated 
haemoglobin. It has been suggested that the encapsulated 
haemoglobin may have the effect of maintaining the internal 
pressure of the microcapsules and may also directly 
crosslink the linear strands of the nylon polymer, 
thereby strengthening the membrane (94, 102). Other 
workers therefore, who have encapsulated haemolysate 
and other enzymes containing reactive amine groups may 
have inadvertently included a crosslinking agent in their 
formulation. A crosslinking agent which has been 
deliberately included in the preparation of microcapsules 
to strengthen the membrane and act as a capsule 'filler' 
is polyethyleneimine (94, 103). Polyethyleneimine
was selected by Aisina and co-workers (94) as it was not 
washed out of the capsules, it contained reactive amino 
groups and was therefore capable of crosslinking and 
because it was not hydrolysed by the proteolytic enzymes 
which were encapsulated. Vandegaer and Wayne (104) 
suggested the use of the bifunctional monomers trimesoyl 
trichloride and 1,3,5 benzenetriamine.trihydrochloride for 
crosslinking the linear strands forming the polyamide 
microcapsule membranes. They reported that the extent 
of the crosslinkage governed the strength, rigidity and 
porosity of the capsule membrane. Degennaro (96) used 
diethylenetriamine and triethylenetetramine as crosslinking 
agents in the preparation of nylon 6.10 microcapsules.
The crosslinking agents were included in order to slow 
the release of sodium pentobarbital from the microcapsules. 
Other microcapsule 'fillers' which have been used include 
bovine serum albumin and polyvinylpyf'Olidone (105),
The bovine serum albumin possesses reactive amino groups 
and is therefore capable of crosslinking. Polyvinyl 
pyrrolidone was also used by Takamura and co-workers (100) 
to increase the viscosity of the aqueous phase in order to 
alter the permeability of the microcapsules to electrolytes. 
Luzzi and others (99) used 2% methyl cellulose solution 
for this purpose. Jenkins and Florence (93) included 
polyethylene glycol 400 (PEG 400) in their formulation.
By adjusting the relative amounts of PEG 400 and buffer 
solution they were able to obtain an aqueous phase 
containing the drug to be encapsulated, pericyazine 
embonate, either in solution or in suspension form.
However, the microcapsules prepared by these workers 
had a continuous structure and did not possess a thin 
polymer membrane surrounding a liquid core (106). In 
an attempt to improve the method for the microencapsulation 
of pharmaceuticals by polyamides McGinity (107) included 
formalised gelatin in the core of the microcapsules to 
slow the release of drug. Microcapsules were prepared 
containing gelatin in the aqueous solution and after 
preparation the gelatin was hardened by adding 
formaldehyde to the organic phase. This had a slight 
effect on delaying the release of sodium sulphathiazole 
from the microcapsules. McGinity and others (90) also 
prepared nylon microcapsules containing calcium sulphate
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and calcium alginate. Calcium sulphate microcapsules 
were prepared by adding calcium sulphate hemihydrate to 
the aqueous phase. In the case of the calcium alginate 
microcapsules sodium alginate was included in the initial 
aqueous phase and after capsule formation saturated calcium 
chloride solution was added to the reaction mixtures.
A number of drugs were successfully encapsulated using this 
technique such as morphine sulphate and diphenhydramine 
hydrochloride. No information on their properties however 
was given.
44' diamino stilbene 22 ' disulphonic acid (DASSA) was 
included in the preparation of polyphthalamide microcapsules 
by Koishi and others (101) so that negative charges were 
incorporated on the surface of the microcapsules thereby 
preventing aggregation.
6. Emulsion Formation. The method of emulsion formation and 
stirring time also differs between authors. Shigeri and 
others (89) and Koishi and others (87) both report the 
use of a "Chemistirrer" stirring at 620 rpm with an 
émulsification time of 5 minutes. Degennaro (108) 
used a "Brookfield Counter Rotating Stirrer" for 15 seconds 
to form the emulsion. Emulsion formation was effected by 
Luzzi and colleagues (99) using a "Waring blender" for 
30 seconds at "low speed". Depending on the droplet 
size required Jenkins and Florence (93) formed the 
emulsion either by stirring, by using a hand homogeniser 
or by using an ultrasonic homogeniser. They also prepared 
microcapsules by a method based on Nawab and Mason's
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method of emulsion formation (109). Using this method 
the buffered aqueous diamine solution was dispersed as fine 
droplets by an electrical potential and sprayed directly 
into a stirred organic solvent containing the dichloride. 
This method has the advantage that the diffusing diamine 
is not removed from the proposed polymerisation site 
prior to the addition of the diacid chloride, as occurs 
with conventional stirred systems.
7. Temperature. In the majority of reports of microcapsule 
preparation in the literature the reaction has been 
carried out surrounded by ice (87, 92). Microcapsules 
have also been prepared at -10°C and 30°C (89).
8. Microcapsule Recovery. A wide variety of techniques for the 
transference of microcapsules to an aqueous phase have been 
reported in the literature. Many of these techniques are 
closely related to the original method described by Chang 
and others (29) and involve washing the microcapsules with 
various concentrations and volumes of Tween 20 solution, 
centrifuging at different speeds and resuspending in 
either sodium chloride solution or Tween 20 solution
(87, 89, 92, 97). The Tween is used to prevent the g
microcapsules aggregating.
The
polysorbate molecules adsorb onto the polyamide molecules 
thereby making the membrane hydrophilic. Mori and 
colleagues (110) collected microcapsules either by 
filtration or centrifugation. They were then washed with 
ethanol to remove any residual organic reagents which 
might be adhering to the membrane and finally washed
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with water to remove the ethanol. This has the 
advantage of avoiding the use of surface active agents 
which may be difficult to remove. The microcapsules 
are also not subjected to a hypertonic medium causing 
crenation, Luzzi and others (99) recovered their 
microcapsules by either a spray drying process or by 
flash evaporation. In the case of the spray drying 
process the microcapsule slurry formed after removal 
from the organic phase was diluted with chloroform 
and spray dried. The internal temperature of the 
drier was maintained at 125°C. The collected powder 
was placed in a vacuum oven at 35^C for 10-12 hours 
to remove residual solvent and moisture. In the flash 
evaporation process the wet slurry was placed in a flash 
evaporator at 35°C for 24 hours, Degennaro (108) also 
reported the use of spray drying and flash evaporation 
for the recovery of formed microcapsules.
9. Modifications to the Microcapsule Wall Structure. Lim 
and MOSS (111) reported a "two step room temperature 
interfacial polycondensation process". Microcapsules 
were initially prepared by a method similar to that of 
the original (29) using various diamines with either 
sebacoyl or terephthaloyl chloride. The surfactant was 
Span 85 and the organic phase consisted of 1 part chloroform 
and 4 parts cyclohexane. Three to four minutes after the 
addition of the diacid chloride the reaction was stopped 
by separating the microcapsules from the continuous phase 
using centrifugation. The separated microcapsules were 
then resuspended in a volume of pure cyclohexane equal
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to the volume of the mixed solvent used in the first 
reaction. Another portion of the diacid chloride was 
added and the second reaction was allowed to continue 
for 3 minutes. Separation and transfer of microcapsules 
from organic to aqueous phase were accomplished by washing 
with 50% Tween 20 solution followed by saline. In the 
first reaction the diamine had a reasonably high affinity 
for the organic phase and therefore a relatively thick 
polymer network was produced around the aqueous droplets.
By removing the formed microcapsules from the reaction 
mixture and immersing them in cyclohexane the affinity 
of the diamine for the organic phase was decreased. 
Therefore on addition of further diacid chloride 
polymerisation with any unreacted diamine will take place 
within the voids of the already formed network.
The converse situation has also been reported (112).
In this case after recovering the microcapsules from the 
reaction mixture they were resuspended in a solvent for 
which the diamine had a higher affinity before the addition 
of a further volume of diacid chloride. Thus during the 
second stage of the process additional quantities of the 
diamine were drawn through the initially formed membranes. 
On the addition of the diacid chloride the two monomers 
polyermise on the organic side of the original 
membrane producing thicker walls. In both cases the 
authors have suggested these methods may be used to control 
the upper limit of permeability of the microcapsules.
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Another variation of the original method has been to prepare 
microcapsules where the wall consists of a copolymer.
For example, an organic liquid pesticide has been 
encapsulated in a polyamide-polyurea skin (104). The 
organic phase contained the pesticide, sebacoyl chloride 
and polymethylene polyphenylisocyanate and the external 
aqueous phase consisted of polyethylene glycol, piperazine, 
water and sodium hydroxide. In another example of a 
polyurea polyamide skin the aqueous phase contained 
ethylenediamine and diethylenetriamine and the organic 
phase contained toluene 2,4-diisocyanate and trimesoyl 
trichloride (104).
Another modification involves the preparation of 
microcapsules with multiple walls (105). Concentric 
multi-wall capsules in which each wall is separated by a 
layer of liquid were prepared as follows. Large droplets 
1-lOmm of a diacid chloride solution in 'mineral spirits' 
were introduced into a second solution containing 
diethylenetriamine in water. The suspension was allowed 
to stand for 2 minutes during which time a polymer shell 
formed around each drop. The capsules were carefully 
removed allowed to drain and immersed in a diacid chloride 
solution. A second interfacial film of the same polymer 
formed around the original capsule but was separated from 
the original shell by a thin layer of aqueous triamine 
solution. These double walled capsules were carefully 
removed, drained and re-immersed in the aqueous triamine 
solution to form a third film of polymer separated from
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the second film by a thin layer of 'mineral spirits' 
solvent. Alternate dipping was continued until six 
distinct concentric shells each separated alternately 
by aqueous and solvent layers were formed about the 
original drop.
10. Preparation of Oil containing Microcapsules. Oil containing 
microcapsules have also been prepared by interfacial 
polycondensation of a diacid and a diamine. For example 
the pesticides ethyl and methyl parathion have been 
encapsulated by this process (34, 113). In this case it 
is necessary to form an oil in water emulsion with the 
diacid chloride dissolved in the disperse phase. The 
reaction will again occur on the organic side of the 
interface and the microcapsule membranes will 'grow' 
inwards. In the encapsulation of oil yellow dye (114) 
a solution of the dye in 0-dichlorobenzene was prepared 
containing sebacoyl chloride and polyethylene glycol.
This solution was emulsified in aqueous polyvinyl alcohol 
solution using a magnetic stirrer. On addition of one or 
more diamines to the aqueous phase a polyamide membrane 
was formed encapsulating the dye. The reaction was 
stopped after 30 minutes of agitation. The microcapsules 
were washed with water and fractionated.
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1.5.3 Properties of Polyamide Microcapsules
1.5.3.1 Microcapsules Appearance
In all cases reported microcapsules formed were invariably 
spherical (29, 92, 93) although Chang and co-workers (29) 
noted that the smallest size range microcapsules in their 
study also contained a proportion of discoid or cup shape forms. 
Emulsion droplets which are normally spherical distort under 
shear (115) and this is possibly the reason for the appearance 
of these microcapsules. The appearance of the microcapsules 
prepared by Chang and others (29) also suggests that they are 
hollow. This is in contrast to the microcapsules prepared by 
Jenkins and Florence which have been shown by scanning electron 
microscopy to be of a solid nature (106). The structure of 
microcapsules prepared by other workers is difficult to assess 
due to the preparative technique used.
1.5.3.2 Microcapsule Size and Size Distribution
From consideration of the method of preparation of polyamide 
microcapsules it may be expected that the microcapsule size 
will be determined primarily by the size of the emulsion droplets 
formed during the microcapsule preparation. The size of the 
microcapsules formed therefore will be affected by those 
factors influencing emulsion formation for example, method 
of émulsification, stirring speed and surfactant concentration.
In the preparation of haemoglobin loaded nylon 6.10 microcapsules 
Chang and co-workers (29) noted the relationship between 
microcapsule diameter, stirring speed and surfactant concentration, 
Increasing the stirring speed resulted in microcapsules of a more
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uniform size. This was also the effect observed on increasing 
the emulsifier concentration from 1% to 5% v/v. Further 
increasing the concentration of emulsifier had little effect. 
These workers also noted that microcapsules of a mean 
diameter of less than 20ym could not be prepared using a 
conventional stirring method. Smaller microcapsules however 
could be formed using a "Virtis 45" homogeniser. The role of 
the haemoglobin in forming the microcapsules in this study is 
unknown and therefore analysing the results is difficult.
To overcome this problem Koishi and others (87) prepared water 
containing polyphthalamide microcapsules under various 
conditions and determined their size distribution curves.
The size of the microcapsules was again found to be strongly 
affected by the concentration of the emulsifier and the degree 
of mechanical agitation, as were the size distributions. 
Increasing the stirring speed and the Span 85 concentration 
both resulted in a reduction in microcapsule diameter.
The size distribution curves became narrower with an increase 
in emulsifier concentration up to 5% v/v but above this 
concentration no appreciable change in their shape was 
observed. A marked change in the shape of the size 
distribution curve was also noted when the stirring speed was 
raised in the absence of surface active agent, the distributions 
again becoming much narrower. The effect of stirring almost 
disappeared however in the presence of Span 85 at a 
concentration of 5% v/v. Microcapsules were prepared using an 
organic phase consisting of chloroform: cyclohexane either
1:3 or 1:4. There was no difference observed between the
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size distributions of the microcapsules prepared using the two 
different compositions. These effects of stirring rate and 
emulsifier concentration were observed by Mori and co-workers 
(110) in the preparation of polyamide microcapsules.
Ogawa and colleagues (88) examined the effect of pH of the 
aqueous phase on the formation of polyamide microcapsules. 
Although no data was given it was stated that microcapsules 
were generally larger if they were prepared at low pH than if 
prepared at high pH. This is possibly due to the effect of 
pH on the partition coefficient of the diamine (88). In the 
case of piperazine,decreasing the pH of the aqueous phase from 
approximately 12 to 9.5 resulted in an increase in the partition 
coefficient of the diamine for the aqueous phase. It also 
resulted in a decrease in the percentage of reacted piperazine. 
Thus it is possible that at low pH microcapsules with weak 
membranes coalesce upon breakage of the membrane to form 
larger microcapsules.
Varying the chemical structure of the intermediates has been 
shown by Shigeri and others (89) to influence the size 
distribution of microcapsules. Microcapsules were prepared 
from 1,6 hexamethylenediamine with sebacoyl chloride (A) and 
piperazine with phthaloyl chloride (B). The size 
distribution curve was narrower for type B microcapsules 
than type A and the mean diameters for type A and type B 
microcapsules were 5.90ym and 3.37ym respectively. As all 
the conditions for microcapsule preparation were the same the 
difference in the size distribution should, the authors
suggested, arise from the different polymerisation 
characteristics for each combination of monomers. Shiba 
and co-workers (92) prepared polyamide microcapsules containing 
bovine serum albumin using different combinations of the 
following monomers; 1,6 hexamethylenediamine or piperazine 
with sebacoyl chloride or p phthaloyl chloride. They 
observed that there was little difference in the size 
distribution curves of microcapsules prepared using different 
monomers.
Shigeri and others (89) also examined the effect of
temperature during microcapsule preparation, the effect of
monomer concentration and the effect of monofunctional monomer 
on microcapsule size. It was found that an increase in 
temperature from -10°C to 30°C brought about a decrease in 
microcapsule size. The authors reported that since the 
effect of temperature on the size of the emulsion droplets 
was negligible the effect of temperature on microcapsule size 
must result from a change in the polymerisation characteristics 
of the monomers. An increase in the microcapsule size was
observed as the monomer concentration decreased. Also in the
presence of benzoyl chloride, a monofunctional acid chloride 
the microcapsule size was again seen to decrease. These 
findings were explained by correlating microcapsule size 
with the intrinsic viscosity of the polymer membrane in each 
case. This indicated to the authors that the membrane 
strength played an important role in determining microcapsule 
size. A method for the formation of large microcapsules 
which resulted in a broadening of the size distribution was
also postulated. It was proposed that at an early stage of the 
polycondensation reaction primary emulsion particles, with 
membranes of insufficient strength and coverage to prevent 
them from uniting, coalesce. This results in the formation 
of large secondary particles. The membrane on the secondary 
particle may then thicken to prevent further coalescence provided 
the polymerisation reaction is still continuing. If the 
polymerisation rate is too high coalescence will not occur 
initially.
This hypothesis seems to account for the process of formation 
of double microcapsules as observed by Shiba and others (92). 
Their explanation for this observation was that since the ratio 
of surface area to volume is larger for small liquid droplets 
than for large ones then the transfer of diamine from the 
aqueous phase to the organic phase is greater for the former 
than for the latter. Accumulation of the diamine at the 
interface should facilitate the formation of the polymer 
membrane. The small microcapsules having relatively thick 
membranes will be able, on collision, to penetrate the 
larger ones having very thin membranes. As the polymerisation 
is still occuring the membranes of the larger microcapsules 
will reform. It was also suggested that the formation of 
double microcapsules was closely related to the partition 
coefficient of the diamine. Indeed the double microcapsules 
were not found to form until the partition coefficient of the 
diamine reached a fairly high value.
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1.5.3.3 Membrane Thickness
Few observations of membrane thickness have been reported for 
polyamide microcapsules prepared by interfacial polymerisation. 
Those thicknesses reported vary widely. On the basis of 
electron microscope studies Chang and co-workers (29) estimated 
the membrane thickness of nylon 6.10 microcapsules containing 
haemoglobin and of diameter 80^m, to be about 0.2pm. Lim and 
Moss (111) estimated the membrane thicknesses of capsules 
prepared by their method to vary between 0.07 and 0.09pm.
Takamura and others (100) and Ishizaka and others (95) used 
the following mathematical formula to calculate the thickness 
of their membranes.
-  îLr
Ax ~ d.A (equation 1.9)
W is the theoretical weight of microcapsule membranes in 
unit volume of dispersion assuming the complete reaction 
of diamine and acid chloride.
r is the experimentally determined percent reacted diamine.
d is the density of the microcapsules membrane.
A is the total surface area of microcapsules in unit 
volume of dispersion.
Nylon 6.10 microcapsules were estimated to have a membrane
thickness of 0.0224pm whereas the thickness of polyphthalamide
microcapsules was 0.0133pm (100). No estimation of microcapsule
diameter was given. It was shown by Ishizaka and others (95)
that as the content of cyclohexane in the organic phase used
in the capsule preparation increased, so the thickness of
the membrane increased. The authors suggested this was
because on decreasing the concentration of chloroform in the
organic phase the partition coefficient of the diamine decreased.
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As a result, less acid chloride reacted in the bulk of the 
continuous phase and the monomer was consumed in larger amounts 
at the interface resulting in a thicker membrane. They also 
suggested that the purity of the monomers had an effect on 
membrane thickness. Two batches of microcapsules which had 
been prepared were found to have a ten fold difference in 
the thickness of the membranes. The only difference between 
the two preparations was that in the preparation of microcapsule 
with the thicker membranes terephthaloyl chloride of a higher 
purity had been used.
1.5.3.4 Mechanical Properties
The flexibility of polyamide microcapsules was first noted by 
Chang and others (29). These workers observed that 100pm 
diameter haemoglobin loaded polyamide microcapsules folded when 
forced under hydrostatic pressure to flow slowly through a 
narrow portion of tapered glass tube. After passing through 
the tube the capsules gradually returned to their normal shape. 
In 1968 this work was extended by Jay and Edwards (116) who 
used a cell elastometer to measure the mechanical properties of 
nylon 6.10 microcapsules containing erythrocyte haemolysate.
They showed that the nylon membrane had negligible resistance 
to bending but a very high resistance to stretching. Any 
stretch in the nylon was found to be almost irreversible.
They estimated that the diameter of the smallest pipette 
through which a spherical microcapsule could pass without 
irreversible change was no smaller than 90% of the microcapsule
diameter. The pressure required to do this was in the order
5 -2of 10 dynes cm
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These findings however have been questioned (117) since it is 
highly probable that haemoglobin molecules in the aqueous phase 
are chemically incorporated into the microcapsule membranes.
Thus the workers did not measure the tension of membranes 
composed of nylon 6.10 alone.
The strength of microcapsule membranes has been noted by a 
number of authors. Shiba and co-workers (92) prepared 
microcapsules from a selection of diacid chlorides and 
diamines. They reported that the microcapsules prepared 
varied in mechanical resistance to centrifuging.
Piperazine- phthaloyl chloride capsules had the greatest 
resistance. In the case of 1,6 hexamethylenediamine 
-phthaloyl dichloride microcapsules the strength of the 
membrane was affected by the concentration of bovine serum 
albumin incorporated into the aqueous phase. 1,6 hexamethylene­
diamine -phthaloyl chloride microcapsules prepared in the 
absence of bovine serum albumin were mostly destroyed by 
centrifugation leaving only very small capsules. However, 
many large microcapsules could survive even after 
centrifugation when prepared in the presence of bovine serum 
albumin. This is probably due to incorporation of the 
protein into the microcapsule membrane thereby strengthening 
it.
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The presence of strongly ionisable groups present in the 
membranes also affects the membrane strength as shown by 
Koishi and others (101). Sulphonated polyphthalamide 
microcapsules were prepared by including 4,4' diaminostilbene- 
2,2' disulphonic acid in the aqueous phase during microencapsulation, 
It was noted that the sulphonated polyphthalamide microcapsules 
were generally more resistant to centrifugation than the 
unsulphonated ones.
Migawaki and others (118) noted the mechanical strength of 
microcapsules prepared containing ovalbumin, haemoglobin and 
casein. They calculated that the weight fraction residues of 
the three amino acids lysine, arginine and histidine in 
ovalbumin, haemoglobin and casein were 23.3, 22.5 and 12.1% w/w 
respectively. This order corresponded to the order of the 
observed mechanical strength of the microcapsules. That is, 
the greater the percentage of amino acids present, the stronger 
the microcapsule membranes. This also suggests therefore that 
the proteins present in the aqueous phase are likely to 
participate in the polymerisation reaction.
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1,5.3.5 Permeability
The permeability characteristics of nylon 6.10 haemolysate- 
containing microcapsules were measured by Chang and Poznansky (119) 
using a 'rapid mixing and sampling technique'. The microcapsules 
were of mean diameter 210.9ym and were equilibrated with 
3 X 10”^M sodium chloride before use. The test solutes were 
urea, creatinine, creatine, uric acid, glucose, sucrose, acetyl 
salicylic acid and tritriated water. The test solutions 
consisted of 0.5 m moles 1  ̂of the test solute containing the 
corresponding carbon 14 isotope dissolved in a 3 x 10”^M sodium 
chloride solution, except in the case of the tritiated water.
Equal volumes of the microcapsule suspension and test solutions 
were mixed. A sampling syringe was set to aspirate 
microcapsule-free aliquots at 1, 2, 4, 8, 16, 32 and 64 seconds.
The aliquots were assayed for the radioactivity remaining.
From the data obtained the permeability constants were 
calculated. These are shown in Table 1.2.







(P X 10~4cm sec"l)
Urea 4.3 2.01
Creatinine 17.5 0.61




Acetylsalicylic acid 39.0 0.32
Tritiated Water <1.0 -
The permeabilities, of polÿhexanediamine terephthaloyl chloride) 
microcapsules reported by Lim and Moss (111) were of the same 
order as those reported by Chang and Poznansky (119). The 
solutes used included glycerol (molecular weight 92), glucose 
(molecular weight 180) and sucrose (molecular weight 342).
The permeabilities of these solutes expressed as half 
equilibration times were 1.75, 4.9 and 10.6 seconds 
respectively.
Takamura and others (98, 100) used changes in electrical
conductance to determine the permeability of polyphthalamide
microcapsule membranes to electrolytes. The microcapsule
dispersion was added to an electrolye solution in a conductance
cell and the conductance monitored immediately after mixing.
In all cases studied the distribution equilibrium of electrolyte
between the inside and the outside of the m'icrocapsules was
established almost within 2 hours. The permeability constants
were calculated using the equation P = C ^ V  _ , .. ^f m . S (equation 1.10)
2.303 C^A
where and are the initial and final electrolyte 
concentrations
V and A are the total volume and surface area of 
the microcapsules
S is the slope of the plot log [ (C^-Cf )/(Cj_.-Ct) ] against 
time. is the concentration at time t.
The values of the permeability constants were found to be of
the order of 10~®cm sec~^ and independent of temperature.
This apparent low permeation rate was attributed to the
formation of a stable diffusion layer of the electrolytes
in the interior of the microcapsules. The membrane material
was shown to have an effect on permeability and the apparent
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coefficients of sodium chloride and sodium sulphate were 
reported for a variety of polyamide membranes. The diffusion 
coefficients were greater for polyamides with polymethylene 
chains than with aromatic rings. This is probably due to the 
difference in polarity and degree of hydrogen bonding of the 
polymer chains formed by the two types of monomer. The effect 
of increasing the viscosity of the aqueous phase by the addition 
of polyvinylpyrrolidone was to decrease the permeability of the 
sodium chloride and sodium sulphate. This was interpreted as 
indicating that the diffusion of the electrolyes in the interior 
of the microcapsules was rate determining in the permeation process,
The permeability coefficients for sodium, potassium and 
rubidium hydroxides in polyphthalamide and nylon 6.10 
microcapsules were measured by Ishizaka and others (95).
The coefficients were estimated by determining the change in 
the hydroxyl ion concentration of the medium with time by means 
of a pH meter. Reported permeability coefficients for sodium 
hydroxide, potassium hydroxide and rubidium hydroxide were 
1.82 X 10“^^, 4.91 X lO'll and 1.46 x 10"^^ cm sec"l respectively. 
It was shown that on increasing the proportion of cyclohexane in 
the organic phase used in the preparation of the microcapsules, 
the membrane thickness increased and there was a corresponding 
decrease in the permeability. The permeability was also 
affected by the nature of the polymeric membranes, the 
permeability coefficient in polyphthalamide membranes 
being 30 to 350 times higher than in nylon 6.10. This is not 
in agreement with the findings of Takamura and colleagues 
(100) described above. A possible reason for this
is the different conditions used in the capsule
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preparation which alters the interaction between the solvent 
and the polymer. The authors suggested it was likely that 
ion permeation depended strongly on the interaction between 
water and the ions when they passed through the pores in the 
polymer membrane. In order to examine the water structure 
in and around the polymer membrane a differential scanning 
calorimeter was used. It was observed that on the addition 
of increasing concentrations of urea, which is believed to 
promote water structure formation, the potassium hydroxide 
permeability coefficient first increased and then decreased.
The initial increase was interpreted as being due to the 
predominant effect of the increase in water structure which 
occurs on the addition of urea. The decrease was interpreted 
as being due to the decreasing cation potential gradient which 
also occurred on the addition of urea and became the 
predominant feature at high urea concentrations. From these 
findings it was concluded that the ion permeation was related 
to the water structure in and around the microcapsule membrane.
Miyawaki and co-workers (118) used an ammonium chloride tracer 
to determine the permeability of polyamide microcapsules.
The microcapsules were placed into an ammonium chloride solution 
and allowed to equilibrate. The suspension was allowed to 
sediment and the supernatant removed. To the capsule layer 
was added a known amount of buffer and the release of ammonium 
chloride from the capsules to the external solution was 
measured using an ammonium electrode. The permeabilities were 
determined for microcapsules prepared containing aqueous 
solutions of ovalbumin at pH7.0 and 4.6, haemoglobin at pH7.0
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and casein at pH7.0. The permeability coefficients were
0.608. 1.53, 2.65 and 2.46 x 10”^cm min”  ̂ respectively. The 
fact that the presence of these proteins influenced the 
permeability coefficient confirmed the finding of Shiba and 
others (120) that the protein participated in the copolymerisation 
reaction. The authors noted the discrepancy between their
data and that of the previous workers and suggested this could 
be due to the following:
1. The method by which the data was obtained.
2. The point on the full release profile at which measurement 
was commenced.
3. The mean diameters of the microcapsules in each case.
According to Kondo and Koishi (121) the quantity of water 
bound to the capsule membranes increases in a very small capsule. 
From the work of Ishizaka and others (95) this will clearly 
influence the permeability and therefore permeability will be 
affected by size.
The rate of release of sulphathiazole sodium from nylon 
microcapsules and formalin treated nylon microcapsules 
containing gelatin was investigated by McGinity (107).
The release characteristics of the two types of microcapsule 
were studied in O.IN HCl and O.IM acetate buffer pH 5.6.
The dissolution apparatus consisted of a round bottom flask 
into which was placed a stirring blade. The stirrer was 
rotated at 100 rpm and the release of drug was measured
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spectrophotoraetrically. The release of the drug into dilute 
acid from the nylon and the formalin treated nylon gelatin 
microcapsules was delayed. There was however little 
difference between the two formulae 25-35% being released in the 
first 2 minutes in both cases and 99% release occuring between 
approximately 30 and 60 minutes. A greater retardant effect 
was seen when examining the release into pH 5.6 acetate buffer 
50% release occuring after approximately 40 minutes. Again 
however there was little difference between the two formulae.
The difference between the data for the two release media 
possibly indicates that the presence of the acid was adversely 
affecting the membrane structure. However, the effect of the 
presence of O.IN HCl on the release of sodium pentobarbital 
measured by Luzzi and co-workers (99) was to decrease the release 
rate when compared with the release into water. The effect 
of the acid may therefore be purely a pH effect. The release 
of the sodium pentobarbital from polyamide microcapsules was 
measured by a similar method to that of McGinity (107) but the 
suspensions were stirred at only 6 rpm. Microcapsules prepared 
by a flash evaporation process had much faster release rates than 
those which had been spray dried. This may have been due 
to the breakage of a portion of flash evaporated microcapsules 
during processing. These broken microcapsules would release 
their contents immediately resulting in an increase in the 
observed release rate. In both cases however 50% of the drug 
content was released within 15 to 30 minutes. Luzzi and 
co-workers also reported on the release from tabletted 
microcapsules. As expected the release was dependent upon 
tablet hardness. It was also dependent upon the release 
medium used.
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Much smaller release rates were reported by Florence and 
Jenkins (122) for polyamide microcapsules containing 
pericyazine embonate and trifluoperazine embonate. The time 
taken for release of 50% trifluoperazine embonate was in the 
order of 4 hours. The discrepncy between this data and 
release rates measured by other workers may arise as a result 
of the apparent continuous structure of the microcapsules 
prepared by these authors (106).
The effect of change in the polymerisation reaction condition 
as the release from microcapsules was studied by Degennaro (108) 
and Naik (123). The latter encapsulated amaranth and used this 
to determine the effect on the release profile of the nature 
of the monomers, the nature of the surfactant and the 
concentration of the acid chloride. The time taken for 50% 
amaranth release varied in all cases between only 20 and 30 minutes. 
Phenylpropanolamine hydrochloride was also encapsulated and it 
was shown that the rate of release of the drug decreased with 
an increase in the concentration of polymer forming materials.
This is probably to be expected, as an increase in the amount of 
monomers present will increase the thickness of the wall formed.
The rate of release of phenylpropanolamine hydrochloride also 
decreased with an increase in the concentration of hydroxypropyl 
cellulose encapsulated along with the drug. This was 
probably due to the increased viscosity of the core which would 
arise on the encapsulation of increasing amounts of the 
cellulose. This increased viscosity would decrease the 
diffusion of the drug to the microcapsule wall.
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Degennaro (108) used sodium pentobarbital as the core material 
and found that its release from polyamide microcapsules was 
affected by the choice of organic solvent, émulsification time, 
stirring speed, the relative ratios of aqueous and organic 
phases, the presence of crosslinking agents and the size of 
the microcapsules. It was found for example that an 
émulsification time of 5 seconds yielded microcapsules having 
a somewhat faster release rate than those produced using a 
15 second émulsification period. A faster release rate was 
also obtained from those microcapsules which had been prepared 
using a si ower rate of stirring. Alteration of the ratio of 
aqueous to organic phase produced microcapsules having different 
release rates. Those microcapsules prepared using an aqueous 
phase of 200ml and an organic phase of 500ml produced microcapsules 
having a faster release rate than when an aqueous phase of 100ml 
was used. It was also reported that there was an optimum ratio 
of diamine to acid chloride for the preparation of nylon 6.10 
microcapsules. This was found to be 0.41 moles of diamine 
to 1 mole of acid chloride. The progressive addition of 
the crosslinking agents diethylenetriamine and 
triethylenetetramine produced microcapsules having increased 
rates of release. The increase followed no discernible 
pattern. It was suggested the presence of the crosslinking 
agents resulted in microcapsules with membranes of increased 
porosity, which therefore resulted in the increased release 
rate observed. The effect of microcapsule size on the release 
rate was also investigated. It was found that the smaller 
microcapsules had a faster release rate than the larger ones.
This was in agreement of the findings of Kondo of Koishi (121) 
and Ishizaka and others (95). In this report typical time
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intervals taken for 50% release of the core material varied 
between only 5 and 10 minutes.
1.5.4 Polyamide Microcapsules in Pharmacy and Medicine
The first suggested use for polyamide microcapsules was as 
artificial red blood cells (29). Encapsulation of haemolysate 
resulted in the preparation of microcapsules containing 
haemoglobin which maintained some enzymatic activity and the 
ability to combine with oxygen. These microcapsules however 
were unsatifactory as a model for red blood cells as they were 
too large in size and too rigid.
A further suggested use for these microcapsules is as 
artificial cells in an extracorporeal shunt system, or for 
use as an artificial kidney (119, 124, 125). In haemodialysis
one of the toxins to be removed from the blood is urea. The
urea does not readily adsorb onto the activated carbon which is 
the adsorbent normally used in haemodialysis. If urease is 
encapsulated with a polyamide shell it has been found that the 
urea readily permeates the microcapsule wall and is broken down 
into ammonia and carbon dioxide. These degradation products 
are readily adsorbed by the carbon. The advantage of using 
encapsulated enzyme is that it acts without coming into direct 
contact with protein and formed elements of the blood and 
therefore does not provoke an immunological reaction. The 
large surface area which can be generated using
microencapsulation is also advantageous as it decreases the total 
volume necessary for haemodialysis. In order to decrease the
possibility of a thrombosis caused by interaction between the
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blood and the microcapsules in an extracorporeal shunt system. 
Chang and co-workers (126) reported on the preparation of non- 
thrombogenic microcapsules. These nylon microcapsules were 
prepared with heparin complexed membranes.
Other enzymes which have been encapsulated using this technique 
include catalase and L asparaginase. Encapsulated catalase 
in the form of a paste was applied topically to acatalasaemic 
mice to remove hydrogen peroxide in oral lesions (127). Two 
advantages were observed. First, the enzymes acted 
efficiently on the hydrogen peroxide without being absorbed and 
without producing any immunologic or hyposensitive reactions. 
Secondly, the microcapsule paste remained at the site of action 
longer than the catalase solutions. Encapsulated catalase 
has also been injected into acatalasaemic mice for the enzyme 
replacement in acatalasaemia (128). L asparaginase, an 
enzyme which suppresses the growth of certain tumours, was 
also microencapsulated by Chang (129). Parenteral injections 
of encapsulated L-asparaginase and free L-asparaginase were 
administered to mice with tumours. The comparative results 
showed that the microencapsulated form was more effective 
than the free solution in suppressing the growth of the 
induced lymphosarcoma. The reason for this was thought to 
be the increased duration for which the microencapsulated 
enzyme remained in the peritoneum.
Reports in the literature of drugs which have been 
microencapsulated using the interfacial polymerisation 
technique are few. Such drugs include pen tobarbital (99)
sulphathiazole sodium (107) and pericyazine (106). The 
reason for encapsulating those drugs cited above was to 
control the release of the active ingredient from the 
microcapsule core. The release of these microencapsulated 
drugs is discussed in Section 1.5.3.5.




Pilocarpine nitrate was used as obtained from MacFarlan Smith 
Ltd., Edinburgh. The purity of the pilocarpine nitrate was 
assessed by TLC and by melting point determination as discussed 
in Section 2,4.1.1.
Prednisolone sodium phosphate (Becpharm Ltd.) was also used 
without further purification.
Ethyl-4-aminobenzoate (BDH Chemicals Ltd.) was recrystallised 
from 50% ethanol before use.
Tritiated pilocarpine was obtained from New England Nuclear and 
from the same source as a gift from Smith and Nephew Ltd.
2.1.2 Reagents used in Microcapsule Preparation
Sebacoyl chloride (BDH Chemicals Ltd.) was re-distilled under
vacuum at 0.2mm Hg and 106°C before use.
Cl C O (CHg)^ COCl
The following monomers were used without further purification: 
phthaloyl chloride (BDH Chemicals Ltd.)
QQQl
1, 3, 5 benzene tricarboxylic acid 
chloride (Aldrich Chemical Company)






diethylenetriamine (Aldrich Chemical Company) H^NCH^CH^NHCH^CH^NH^
Gelatin was obtained from BDH Chemicals Ltd.
Bovine Serum Albumin and polyethyleneimine (molecular weight 
range 50,000 to 60,000) were obtained from Sigma Chemical Company.
Cyclohexane and chloroform (BDH Chemicals Ltd.) were AnalaR grade.
Span 85 (sorbitan trioleate) and Tween 20 (polyoxyethylene 20 
sorbitan monolaurate) were obtained from Atlas Chemical Company.
2.1.3 Chemicals used for preparing Liquid Scintillation Cocktail 
Xylene obtained from BDH Chemicals Ltd. was Scintillation Grade.
PPO (2,5 diphenyloxazole), dimethyl POPOP (l,4-bis[2 (4-methyl-5- 
phenyloxazolyl)] benzene) andiTriton X114 (octyl phenoxy 
polyethoxyethanol) were obtained from Sigma Chemical Company.
2.1.4 Miscellaneous Materials
Albumin fluorescin isothiocyanate and fluorescin isothiocyanate 
dextran were obtained from Sigma Chemical Company.
99MThe kit for labelling human albumin with Tc was obtained
99Mfrom International CIS France. Tc was supplied by Queens
Medical Centre, Nottingham. The albumin was labelled by
99Minjecting a known volume of Tc sodium pentechnetate solution 
of known activity into a vial containing lOmg human albumin.
The vial was shaken, allowed to stand for 20 minutes and used 
immediately.
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Non oriented nylon 6 film was Carran grade 77c.
N-l-naphthyl ethylenediamine dihydrochloride was obtained from 
BDH Chemicals Ltd.




Liquid Scintillation Counting System. Liquid Scintillation Counting 
was carried out using an LKB Rakbeta 1215 liquid scintillation counter 
(Wallac Oy Finland). Samples to be assayed were dispensed into 
5ml capacity polyethylene mini vials (LKB) contained within 22ml 
capacity glass vials (LKB). Sample volumes were measured using 
a replicating pipette (Oxford Ltd.) with delivery volumes of 
0.2, 0,5 and 1.0ml fitted with plastic disposable tips.
HPLC System. The HPLC system consisted of a Constametric IIG pump 
(Laboratory Data Control, Staffs.) connected to a Pye-Unicam Type 
LC3UV variable wavelength detector and Tekman TE 200 flat bed chart 
recorder. 10cm stainless steel columns (0.5mm I.D.) were packed
with Hypersil 5 C (Shandon Southern) or Partisil 10 S AX (Whatman).JLo
Samples were injected onto the column using a Rheodyne 20]il loop valve.
Size Analysis. Size analysis was undertaken using a Coulter Counter 
model ZB (Coulter Electronics Ltd.) and a Particle Size Micrometer 
and Analyser Type 526 (Fleming Instruments Ltd.).
Microscopy. A Carl Zeiss Jena microscope with camera attachment 
was used for microscopy work and for photographing prepared slides. 
Electron microscopy studies were undertaken using a JEOL 100 CX 
Transmission Electron Microscope with ASID Attachment (scanning) 
and Energy Dispersible X-Ray Detector (JEOL UK Ltd. London)
(EDAX Illinois) as appropriate.
pH Meter. Measurement of pH was carried out using a Pye Unicam 
model 291 pH meter in conjunction with a Pye Unicam Ingold 401 glass 
silver-silver chloride combined électrode. Scale range 0 - 14 pH units
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Spectrophotometer. Absorbance measurements were determined using 
a Unicam SP 500 UV and visible spectrophotometer. Range 190-700nm.
Waterbath. A Grant shaking water immersion bath type SS 30 was
used. This was set at 32°C ± 0.1° throughout.
Balance. An Oertling model R20 single pan analytical balance was 
used for weights in excess of O.lg. Below O.lg a Stanton 
Instruments Unimatic HCL 5D single pan analytical balance was used.
Rotary Evaporator, The rotary evaporator used was a Biichi 
Rotavapor-R.
Centrifuge. An MSE bench centrifuge was used throughout.
Overhead Stirrer Motor. The overhead stirrer motor was a Citenco 
type DTS 7333. The stirring speed was varied by means of a Variac 
rheostat type VSHM connected to the motor. A stroboscopic light 
was used to determine the speed of stirring.
Gamma Camera. The gamma camera used was a Maxi Camera 11 obtained 
from The International General Electrics Company of New York, It 
was fitted with a pinhole collimator and spacer.
Vernier Microscope. The vernier microscope was obtained from
The Precision Tool and Instrument Company, Surrey.
Melting Point Apparatus. The melting point apparatus was supplied 
by Gallenkamp Ltd,
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TLC Plates. TLC plates were pre-coated and obtained from 
Anachem Ltd. The adsorbent was silica gel G of 250]im thickness.
Animal Model. The animal model used throughout this work was male
New Zealand White rabbits of approximate body weight 3.0 Kg.
Analytical Glassware. Analytical glassware was Grade A.
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2.3 General Methods 
pH Measurement
Solutions under test and standard buffers were equilibrated to 
25°C ± 0.1°C prior to pH measurement or pH meter standardisation, 
pH meters were calibrated before use with two standard buffers 
borax (pH 9.180 at 25°C) and phosphate (pH 7.413 at 25°C). 
Standard buffers were prepared according to the method of Perrin 
and Dempsey (130). When not in use the buffers were stored in 
stoppered flasks in a refrigerator and discarded every four weeks
Temperature Measurement
Throughout this study all temperature measurements were made with 
reference to a calibrated mercury in glass thermometer graduated at 
intervals of O.l^C.
Spectrophotometric Determination
1cm path length quartz cuvettes were used throughout this work.
The solvent systems used for preparing the solutions to be 




2.4.1.1 Purity of pilocarpine nitrate
It has been reported that pilocarpine hydrolyses to form 
pilocarpic acid or epimerises to form isopilocarpine. The 
pilocarpic acid and isopilocarpine may then degrade to form 
isopilocarpic acid (131) as shown below.











Two methods were used to detect the presence of degradation 
products in the pilocarpine nitrate used in this study, namely 
melting point determination and thin layer chromatography (TLC).
Melting Point Determination. Purified pilocarpine nitrate was 
obtained by recrystallisation of the drug from ethanol. After 
recrystallisation the pilocarpine nitrate was dried under vacuum 
over phosphorous pentoxide at room temperature until constant 
weight was achieved. The melting points of both the original
00
material and the recrystallised material ranged between
170°C and 170.5°C.
TLC Method. lOjjl samples of a 3.69 x 10~^M aqueous solution 
of pilocarpine nitrate were spotted onto silica gel GF plates 
of 250pm thickness. The running solvent was equivolume 
methanol and chloroform (132) and the spots were visualised 
with iodine vapour. Standard solutions of purified pilocarpine 
nitrate recrystallised from ethanol, degraded pilocarpine 
nitrate and isopilocarpine base were spotted on the same plate. 
The Rf values are given in Table 2.1. The degraded pilocarpine 
nitrate was obtained by heating with O.IM sodium hydroxide at 
90°C for 1 hour.
The pilocarpine nitrate showed no degradation detectable by TLC 
throughout the study and was therefore used without further 
purification.
Table 2.1 R f  Values for TLC of Pilocarpine Nitrate and its 
Degradation Products
Compound R^ determination 1 determination 2
Pilocarpine nitrate 0.70 0.70
Pilocarpine nitrate
(purified) 0.68 0.70
Isopilocarpine base 0.71 0.71
Degraded pilocarpine nitrate 
(assumed to be pilocarpic 
acid) 0.22 0.23
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2.4.1.2 Assay of Pilocarpine Nitrate by Liquid Scintillation Counting 
Introduction
3 14A beta-emitting isotope such as tritium ( H) or carbon 14 ( C)
decays with the emission of a detectable, negative, beta
particle which carries a quantum of energy within a range
characteristic of a given isotope. In the environment of a
liquid scintillator the kinetic energy of these nuclear
particles is converted into light photons which may then be
counted. The liquid scintillator is composed of a solvent,
a number of fluors and several additives. The function of
the solvent molecules is to convert the kinetic energy of the
nuclear emissions into molecular excitation energy and to
transfer this energy to a fluor molecule. The fluor molecule
re-emits the energy as light photons which in a scintillation
counter are converted to electrical pulses. The amplitude
of each pulse is directly proportional to the energy of the
initiating beta particle and the number of pulses is directly
related to the number of decay events.
Interference or competition with the orderly progression of
energy transfer from the nuclear particle to the fluor reduces
the fluorescence and thereby the detected pulses. This phenomenon 
is known as quenching and may occur due to the presence of 
additives or to the specimen itself. If each sample is not
quenched to the same degree, for example, as a result of the
presence of impurities, it is necessary to determine the degree 
of quenching and correct for it. One method of doing this is 
by External Standards Ratio. In this method a gamma emitting 
isotope is positioned adjacent to the sample vial. The gamma
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radiation induces Compton electrons and hence scintillation in 
the sample by their interaction with the solvent molecules.
This results in the instrument 'seeing' a pulse height spectrum 
representative of the external standard source. This Compton 
spectrum will be affected by quenching materials in a similar 
way to the spectrum produced from the samplers beta emitting 
source. Hence, by calibrating with quench standards of known 
disintegrations per minute (dpm), observing the measured counts 
per minute (cpm) and noting the calculated external standard 
ratio numbers, correlation curves of counting efficiency and 
external standard ratio can be obtained, where efficiency is 
the ratio of cpm to dpm. The disintegrations per minute of 
any unknown sample may then be calculated from the observed counts 
per minute and the efficiency.
Pilocarpine Nitrate Assay
Unless otherwise stated pilocarpine nitrate was assayed using 
a liquid scintillation counting technique. A known activity 
of tritiated pilocarpine was incorporated into the stock 
solution of pilocarpine nitrate of known concentration used for 
each experiment. The activity of the tritium in subsequent 
dilutions of this stock solution was then determined by the 
following method:
Five 200]jl samples were removed from each solution to be 
assayed using a replicating pipette. Each sample was placed 
into a 5ml capacity mini vial and 4.5ml of scintillation 
cocktail added and shaken. The scintillation cocktail, which 







Samples were counted employing the appropriate quench curve to 
determine the disintegrations per minute. Each sample was 
counted for 10,000 counts or 10 minutes whichever was the 
shorter, with an external standard time of 30 seconds.
Background count was subtracted from the mean of the five 
measured disintegrations per minute before any calculations were 
made. The value of background count was generally found to be 
60 dpm ± 5 dpm. The highest and lowest background counts 
observed were approximately 80 dpm and 40 dpm respectively.
Reproducibility of Sampling
To assess the reproducibility of sampling a volume of 200yl 
using a replicating pipette repeated measurements of the weight 
of nominal 200yl samples of distilled water were made.
Table 2.2 gives the delivery weights for two sets of ten samples. 
From the data in Table 2.2 it was considered that the accuracy 
and precision of delivery of 200yl by the replicating pipettes 
was satisfactory.
Quench Curve Construction
Quench curves were constructed using the external standards 
ratio method for each of the following solvent systems. These 
solvent systems were sampled and assayed for tritiated 





































TABLE 2.2 MEAN DELIVERY WEIGHTS OF A NOMINAL 200ul
VOLUME DELIVERED BY A REPLICATING PIPETTE.
Chloroform
Chloroform: cyclohexane 1:5 containing 1% v/v Span 85
Acetone
Phosphate buffer pH 7,4
5% v/v aqueous Tween 20 solution
Into each of six mini vials was placed a capsule of known 
activity (LKB cat. n° 1210 - 120 dpm = 101,100 [0.09yCi] 
corrected for decay) and 4.5ml scintillation cocktail.
To each sample 200yl distilled water was added. Vial 1 was 
capped. To vials 2, 3, 4, 5 and 6 was added 5, 10, 20, 40 
and lOOyl chloroform respectively. The samples were loaded 
into the LKB 1215 liquid scintillation counter which had been 
programmed to count and automatically construct a quench curve 
which is shown in Figure 1 ^ , The process was repeated for the 
four remaining solvent systems using volumes 0, 20, 40, 100 
and 200yl. All quench curves were found to lie on the same 
line as that for chloroform and this curve was therefore 
stored in the instrument's memory so that disintegrations 
per minute for all subsequent samples were calculated 
automatically (Figure 2.2).
Purity of Tritiated Pilocarpine
The purity of tritiated pilocarpine was determined by two 
methods.
i) The TLC method outlined in Section 2.4.1.1 was used
to assess the degradation of the tritiated pilocarpine. 
lOyl samples of a 3.69 x 10“^M aqueous solution of 
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FIGURE 2.2 QUENCH CURVE FOR TRITlQvl DETERMINED BY 
LKB 1215 LIQUID SCINTILLATION COUNTER.
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were spotted onto silica gel TLC plates. The unlabelled 
material was present as a carrier for the labelled drug. 
After elution the TLC plates were scraped at 1cm intervals 
and each scraping placed in a 5ml capacity mini vial 
together with 200yl distilled water and 4.5ml scintillation 
cocktail. These were then assayed for tritium. The 
results are shown in Figure 2,3 as a histogram. The 
tritiated pilocarpine showed no degradation products, 
there being only one region of activity found on the TLC 
plate. This corresponded to the value obtained for 
unlabelled pilocarpine nitrate when visualised by Iodine 
vapour (see Section 2.4.1,1) on a TLC plate which was 
eluted at the same time as that used for determination of 
tritiated pilocarpine nitrate purity,
ii) It is well known that tritiated compounds may exchange 
the tritium label with water. In order to assess the 
degree of exchange of tritium with water for pilocarpine 
stock solutions, 200yl of tritiated pilocarpine solution 
was pipetted into each of ten mini vials. To five of 
these was immediately added 4.5ml scintillation cocktail. 
The remaining five were evaporated to dryness before 
adding 200yl distilled water and 4.5ml scintillation 
cocktail. The ten vials were assayed for tritium.
Table 2.3 gives the percent of tritium remaining attached 
to the pilocarpine molecule. It is apparent that there 
was a rapid exchange of tritium with water. Approximately 
5% exchange occurred within 3 days and consequently stock 
solutions were evaporated to dryness and reconstituted 





DISTANCE FROM ORIGIN (cm)
FIGURE 2.3 DISTRIBUTION OF TRITIATED PILOCARPINE
ON TLC PLATE AFTER ELUTION.
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1 day 94.3 5.7
3 days 94.7 5.3
6 days 93.6 6.4
13 days 90.6 9.4
4 weeks 85.1 14.9
Reproducibility of Liquid Scintillation Counting 
The reproducibility of the liquid scintillation counting 
technique was determined by preparing stock solutions of 
pilocarpine nitrate containing a known activity of tritiated 
pilocarpine. Five 200yl samples were removed from each solution 
for counting. Table 2.4 shows the disintegrations per minute 
obtained at three different levels of count. The coefficients 
of variation obtained were in all cases approximately ± 1,5%.
In assessing the reproducibility of delivery of 200]il sample 
volumes, the coefficient of variation was found to be 
approximately ± 1.4% (Table 2,2) and therefore the 
inaccuracies involved in the liquid scintillation counting 
assay possibly arise from sampling error. The values 
obtained for the reproducibility of the liquid scintillation 
counting technique were considered satisfactory.
Calibration Curve for Pilocarpine Nitrate
In order to demonstrate that there was a linear relationship 
between relative count and relative concentration for a given 







































71321.6 1077.1 + 1.5%
TABLE 2.4 REPRODUCIBILITY OF LIQUID SCINTILLATION 
COUNTING.
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known drug concentration containing tritiated pilocarpine was 
prepared. Successive dilutions from this stock solution 
were made and the resulting solutions assayed for tritium.
The results are given in Figure 2.4. Values for the slope 
and intercept of the calibration curve were calculated using 
least squares regression analysis (Appendix 1) and are given 
in Table 2.5. Reproducing each initial activity exactly was 
not possible and therefore only one set of representative data 
is given. The data show a high correlation coefficient and the 
intercept passes through zero within one standard deviation.
It is apparent therefore that the activity of the tritiated 
pilocarpine is directly proportional to the concentration of 
pilocarpine nitrate present. This was therefore considered 
a satisfactory method for determining pilocarpine nitrate 
concentration provided that the activity of a standard solution 
of known pilocarpine nitrate concentration is assayed for each 
set of experiments. Subsequent data within that experiment 
may then be related to this single point reference standard.
Incorporation of Tritiated Pilocarpine - Effect on Concentration 
Under all circumstances in which pilocarpine nitrate was assayed 
by a liquid scintillation counting technique tritiated 
pilocarpine was added to a solution of unlabelled drug of 
previously determined concentration. This addition therefore 
altered the concentration and an example of the calculation for 







FIGURE 2.4 CALIBRATION CURVE FOR THE LIQUID 
SCINTILLATION COUNTING ASSAY OF
PILOCARPINE NITRATE.
1 0 2
Slope 7.124167 X 10^
Intercept -1.276021
Correlation Coefficient 0.9990467
Standard Deviation of Slope 1.556553 X 10^
Standard Deviation of Intercept 1.336769 X 10^
TABLE 2.5 STATISTICAL DATA FOR THE CALIBRATION
CURVE FOR THE LIQUID SCINTILLATION COUNTING 
ASSAY OF PILOCARPINE NITRATE.
1 0 4
-1Specific activity of tritiated pilocarpine lO.OCi mmol
Typical total activity of 10ml of initial ,5stock solution 5 x 10 dpm
l]jCi = 3.7 X 10'̂  disintegrations per second = 2.22 x 10”^ dpm
Therefore 5 x 10^ dpm = 5 x 10^ x 10  ̂^Ci = 0.23]iCi
-10 2.22 0.23)iCi = 0.23 X 10 moles tritiated pilocarpine
Typical concentration of unlabelled pilocarpine nitrate 
in stock solution = 1,85 x 10“2m
Therefore total mass of unlabelled pilocarpine in 10ml =
1.85 X 10"4 moles
It may be seen from the above calculation that the mass of 
labelled pilocarpine added is negligible relative to the total 
mass of unlabelled pilocarpine nitrate present. Similar 
calculations for subsequent assays were therefore not carried out.
2.4.1.3 Assay of Pilocarpine Nitrate by High Pressure Liquid Chromatography 
The method used for the assay of pilocarpine nitrate by HPLC 
was based on a method described by Noordam and others (131).
Conditions
Column Hypersil 5 C__ 10cm x 0.5cm IDlo
(approximately 5,000 plates)
Mobile Phase Double distilled water: methanol 97:3
containing potassium dihydrogen orthophosphate 
5% w/v pH adjusted to 2.5 with orthophosphoric acid
-1Flow rate 2.5ml min
Wavelength for detection 215nm
Injection volume 20^1
±0 6
Verification of HPLC System
To ensure separation of pilocarpine and its degradation
products was achieved using the above HPLC system, 20yl of a
solution containing pilocarpine nitrate, isopilocarpine and
degraded solutions of the above was injected onto the column.
Retention times are given in Table 2.6 and a typical
chromatogram is shown in Figure 2.5. Pilocarpine and
_2isopilocarpine were degraded by heating a 3.69 x 10 M 
solution in O.IM sodium hydroxide at 90°C for 1 hour.
Table 2.6 Retention Times for Pilocarpine Nitrate and its 
Degradation Products Conditions as p 90
Compound Retention Time (minutes)
Isopilocarpine 5.93
Pilocarpine nitrate 6.73
Degraded pilocarpine nitrate 
(assumed to be pilocarpic acid) 7.77
Degraded isopilocarpine 
(assumed to be isopilocarpic acid) 8.53
From Figure 2.5 it may be seen that under the conditions stated 
separation of pilocarpine nitrate and its degradation products 
was not complete. Separation however, was not improved by 
altering the composition of the mobile phase such as changing 
the water methanol ratio, altering the amount of potassium 
dihydrogen orthophosphate present or adjusting the pH. Since 
the proportion of degradation products in the pilocarpine nitrate 
assayed was expected to be small it was unlikely that these 
would interfere with the assay values obtained despite incomplete 
separation of the peaks. To ensure this hypothesis was correct
a. Isopilocarpine
b. Pilocarpine nitrate








FIGURE 2.5 HPLC TRACE OF A MIXTURE OF PILOCARPINE NITRATE, 
ISOPILOCARPINE AND DEGRADED SAMPLES OF THE
IWO COMPOUNDS.
1 0 7
the calibration curve for the pilocarpine nitrate assay was 
determined in the presence of isopilocarpine (see below).
Calibration Curve for Pilocarpine Nitrate 
To determine if there was a linear reltionship between the 
concentration of pilocarpine nitrate and the equivalent peak 
heights obtained using the above HPLC system it was necessary 
to construct a calibration curve plot. A series of aqueous 
solutions of known concentrations of pilocarpine nitrate and 
isopilocarpine were prepared such that the total concentration 
of the two isomers was 9 x lO^^M. 20^1 of each solution 
was injected onto the column and the peak heights obtained 
corresponding to pilocarpine nitrate measured.
Figure 2.6 shows there is a linear relationship between 
pilocarpine nitrate concentration and peak height and the 
presence of the isopilocarpine had no apparent effect on the 
assay. The data were submitted to a computerised least 
squares regression analysis and the values of the slope and 
intercept together with their associated standard deviations are 
given in Table 2.7. Although the intercept is not zero the 
curve passes through the origin within one standard deviation.
On the basis of these findings it was considered that 
measurement of concentration by determination of peak height 
in this case was satisfactory.
As column performance may vary with use, the slope of the 
calibration curve cannot always be used with confidence to 





PILOCARPINE NITRATE CONCENTRATION (xlO^M)
FIGURE 2.6 CALIBRATION CURVE FOR THE HPLC ASSAY 
OF PILOCARPINE NITRATE.
I u
Slope 1.133137 X 10^
Intercept -0.7539099
Correlation Coefficient 0.9982942
Standard Deviation of Slope 3.826069 X 10^
Standard Deviation of Intercept 2.373931
TABLE 2.7 STATISTICAL DATA FOR THE CALIBRATION
CURVE FOR THE H.P.L.C. ASSAY OF PILOCARPINE
NITRATE.
X I 0
practice therefore, duplicate standard solutions of a known 
pilocarpine nitrate concentration were injected to 'bracket* 
injections of the test sample. In this way the concentration 
of pilocarpine nitrate in the test solution could be calculated 
with reference to the standard solution.
2.4.2 Assay of Prednisolone Sodium Phosphate by HPLC
The method used for the assay of prednisolone sodium phosphate 
was based on a method described by Stroud and others (133).
Conditions
Column Partisil 10 SAX 10cm x 0.5cm ID
Mobile Phase 10% y/v methanol in 0.02 molar
Mcllvaines citrate - phosphate buffer 
pH 5.2
—1Flow Rate 1.5ml min
Wavelength of detection 254 nm 
Injection volume 20^1
A typical chromatogram is shown in Figure 2.7.
Calibration Curve for Prednisolone Sodium Phosphate 
A calibration curve for the assay of prednisolone sodium 
phosphate by HPLC was determined in order to verify a linear 
relationship between peak height and prednisolone sodium phosphate 
concentration. A series of aqueous solutions of known 
concentrations of the drug were prepared. 20pX of each 
solution was injected onto the column and the heights of the 
peaks obtained measured. Calibration data are given in 










FIGURE 2.7 HPLC TRACE OF DUPLICATE INJECTIONS






PREDNISOLONE SODIUM PHOSPHATE 
CONCENTRATION (xlO^I)
FIGURE 2.8 CALIBRATION CURVE FOR THE HPLC ASSAY
OF PREDNISOLONE SODIUM PHOSPHATE.
Slope 6.085509 X 10^
Intercept -5.673298
Correlation Coefficient 0.9941774
Standard Deviation of Slope 3.2997940 x 10^
Standard Deviation of Intercept 4.719850
TABLE 2.8 STATISTICAL DATA FOR THE CALIBRATION 
CURVE FOR THE H.P.L.C. ASSAY OF
PREDNISOLONE SODIUM PHOSPHATE.
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a linear relationship between peak height and prednisolone 
sodium phosphate concentration over the range studied.
The line does not however pass through the origin although 
the value of the intercept is within two standard deviations 
of the origin. As discussed in the HPLC assay of pilocarpine 
nitrate, the calibration curve was not used to determine 
solution concentration. In practice, duplicate standard 
solutions of known prednisolone sodium phosphate concentration 
were injected to 'bracket' injections of the test samples 
an&the test samples assayed with reference to the standard 
solutions.
2.4.3 Colorimetric Assay of Ethyl-4-aminobenzoate
Ethyl-4-amincbenzoate was assayed using a modified Bratton- 
Marshall reaction (134). To 3ml aliquots of etKyl-4- 
aminobenzoate solutions over the concentration range 2 to 10 
X 10 was added 3ml O.IM HCl and 1ml 0.1% w/v sodium nitrite 
solution. After shaking for 5 minutes 1ml 2% w/v ammonium 
sulphamate solution was added and the solutions shaken for a 
further 2 minutes. 1ml 0.1% w/v N-1 naphthylethylenediamine 
solution was then added. The volume was adjusted to 25ml 
with distilled water and the colour allowed to develop, in the 
dark, for at least 15 minutes. The absorbance of each solution 
at the wavelength of maximum absorbance was then determined against 
a blank prepared as above but omitting the ethyl-4-aminobenzoate.
The wavelength of maximum absorbance was reported by
Bray (134) and in this study found to be 554nm.
Calibration Curve for Ethyl-4-aminobenzoate
In order to demonstrate that there was a linear relationship
between ethyl-4-aminobenzoate concentration and absorbance
a calibration curve was constructed. Solutions of ethyl-4-
aminobenzoate of known concentrations over the range 2 to 10 
-5X 10 M were prepared and assayed for ethyl-4-aminobenzoate. 
Calibration data are given in Figure 2.9 and Table 2,9.
In both determinations the intercepts are within one standard 
deviation of the origin and the calibration curves show high 
linear correlation coefficients. The values of the two slopes 
obtained were compared using a t-test (Appendix 2). The two 
values are not significantly different at the 95% level of 
significance. The colorimetric assay was therefore considered 
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TABLE 2.9 STATISTICAL DATA FOR THE CALIBRATION 




3.1 Preparation of Nylon 6.10 Microcapsules
3.1.1 Development of Method
Initial attempts to prepare nylon 6.10 microcapsules were 
based on the method of Chang and others (29) which is described 
in Section 1.5.2.1 and is shown schematically in Figure 1.7.
The compositions of the solutions were the same as those reported 
by Chang and others except that no haemolysate preparation 
was used. Solutions were cooled to 4^C by immersing in ice for 
approximately 1 hour prior to use. Emulsion formation, which 
was carried out in a 100ml glass beaker, was effected using a 
magnetic stirrer for the time stated in Section 1.5.2.1 and 
following addition of the sebacoyl chloride solution polymerisation 
was allowed to continue for 3 minutes. 'Microcapsules' were 
harvested by centrifugation, washing in Tween 20 solution and 
resuspended in sodium chloride solution. Microscopic 
examination of the final suspension in saline revealed the 
presence of small solid particles believed to be nylon 6.10 
polymer. Also present were a large number of emulsion droplets 
thought to have arisen from the transfer of organic solvents to
the aqueous medium during the harvesting procedure. As 
discussed in Section 1.5.1^there are many factors which may 
influence both nylon 6.10 polymerisation and microcapsule 
formation. These include such factors as emulsion formation 
and stability, composition of the organic phase, ratio of 
monomers present and so on. A number of modifications to 
the method outlined above were therefore carried out to achieve 
satisfactory preparation of nylon 6.10 microcapsules. These 
investigations are briefly described in Section 3.1.1.1.
Throughout the development procedure sebacoyl chloride solutions
1 i i}
were prepared immediately prior to use and the entire volume 
added rapidly to the formed emulsion,
3.1.1.1 Modifications to Initial Method
A. Method of Harvesting: Microcapsules prepared by interfacial
polymerisation techniques are thin walled (27) and it was 
thought possible that centrifugation may have caused the 
formed microcapsules to disintegrate. Also, the 50%
Tween 20 solution used by Chang: and others to disperse 
the microcapsules in an aqueous medium may, even on dilution, 
have been too viscous to achieve satisfactory separation of 
the microcapsules by centrifugation. Using the method of 
preparation described in Section 3.1.1 the following methods 
of harvesting were investigated;
i) after quenching, the contents of the beaker were passed 
through phase separating paper, 
ii) a 50% v/v solution of a non-ionic surfactant.
Pluronic L64 was used instead of Tween 20 solution,
iii) the 'microcapsule' suspension was centrifuged, washed 
with ethanol or acetone, centrifuged again and then 
transferred to 0.9% w/v sodium chloride solution, 
iv) procedure (iii) above was used except that after 
washing in ethanol or acetone the suspension was 
dispersed in 50% v/v,Tween 20 solution which was then 
diluted with water, centrifuged and the 'microcapsules' 
transferred to 0.9% sodium chloride solution,
v) cyclohexane was used to quench the reaction and the
microcapsules harvested by either the initial method, 
method (iii) or method (iv).
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vi) the contents of the beaker were rotary evaporated 
for 1 hour at 30°C to form a slurry which was then 
dispersed in ethanol, centrifuged and redispersed 
in sodium chloride solution.
In all cases no microcapsules were observed. The 
suspensions obtained consisted of small, solid particles 
together with emulsion droplets. Method (iv), however, 
resulted in little transfer of organic solvents into the 
final aqueous dispersion medium and was therefore adopted 
as the method of harvesting for further development work.
B. Emulsion Formation; One of the factors which varied between 
different reported methods of polyamide microcapsule 
preparation was the method used to form the emulsion 
(Section 1.5.2.2). The procedure outlined in Section 3.1.1, 
except for the modified harvesting method,was therefore 
investigated using different methods of emulsion formation. 
Samples were removed for microscopical examination at two 
stages (a) from the organic phase prior to the addition 
of the sebacoyl chloride and (b) from the final suspension 
in saline. The methods of forming the emulsion studied 
were ;
i) an ultrasonic probe (Rapidis 300 Ultrasonics Ltd.)
was used to form the emulsion which was then transferred 
to the glass beaker,
ii) A Silverson stirrer fitted with an homogeniser attachment 
(Silverson Machines Ltd.) was used at various speed 
settings to prepare the emulsion before transferring to 
the glass beaker.
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iii) a Silverson stirrer fitted with an homogeniser
attachment was used throughout the preparation,
iv) an overhead Citenco stirrer motor fitted with a
three bladed plastic paddle at various speed settings 
over the range 200 to 2,000 rpm was used throughout the 
preparation.
In all cases, samples removed at stage (a) were found to 
be stable emulsions with droplet size of less than 200]im, 
However, again no microcapsules were formed. The use of 
a glass beaker was found to be inconvenient for many of 
these methods of emulsion formation. Therefore, for 
subsequent investigations a 100ml capacity round-bottom 
flask was used together with a Citenco overhead stirrer 
fitted with a paddle.
C. Composition of Reactant Solutions; In the original method
Chang and others (29) selected an organic phase of chloroform: 
cyclohexane 1;4 as its density was approximately the same 
as that reported for the microcapsules. This was believed 
to minimise damage and allow separation of the microcapsule 
by centrifugation. The composition of the reactant solutions 
however has been altered by a number of workers (Section 
1.5.2.2) and has still resulted in the formation of 
microcapsules. Various combinations of surfactant, 
monomer concentrations and organic phase compositions 
were therefore investigated over the range outlined in 
Table 3.1. None of these resulted in the formation 
of microcapsules however.
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Reaction Conditions: Other factors which may influence
polymerisation and therefore microcapsule formation are the 
temperature of the reaction system, the internal phase 
volume of the emulsion and the duration of the reaction 
prior to quenching. The effect of these reaction 
conditions on microcapsule formation was examined
Table 3.1 Parameters varied in the Investigation of
the Effect of Composition of Reactant Solutions 
on Nylon 6.10 Microcapsule Formation
Variable Range
Chloroform:cyclohexane ratio 
by volume 1:3 1:4 1:5
Surfactant Span 85 
concentration : Arlacel A
0 1 
1
5 10% v/v 
10% v/v
Sebacoyl Chloride 
concentration 0.009 0.018 0.037M
1,6 hexamethylenediamine 
concentration 0.2 0.4 0.8M
using different combinations of organic phase solvent ratio, 
surfactant concentration and monomer concentration as outlined 
in Table 3.1. For each reaction time of 1, 3 and 10 minutes 
the experiment was carried out surrounded by ice and at room 
temperature. The émulsification time was also varied 
between 30 seconds and 3 minutes. In addition the relative 
phase volumes were changed as described in Table 3.2. No 
microcapsules were observed to be formed, in any of the 
above cases.
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E, Presence of Additives: As discussed in Section 1.5.2,2
several workers have included additives in the internal 
aqueous phase of the microcapsules such as polyethylene 
glycol 400 (PEG 400) (93), polyethyleneimine (94) and
bovine serum albumin (105).
Table 3.2 Phase Volume Ratios Investigated in the 
Preparation of Nylon 6.10 Microcapsules
1 2 3
Volume of internal
aqueous phase 5ml 1.5ml 2.5ml
Volume of organic 
phase prior to addition 
of sebacoyl chloride 
solution 25ml 7.5ml 25ml
Volume of sebacoyl
chloride solution 25ml 7.5ml 25ml
The procedures used previously for preparing microcapsules 
were therefore investigated with the inclusion of these 
additives. The conditions used and the amount of 
additives present are described in Table 3.3. The reaction 
was quenched by pouring the suspension produced after the 
addition of the sebacoyl chloride solution into chloroform; 
cyclohexane 1:3 and harvesting was achieved by washing in 
acetone followed by Tween 20 solution. 'Microcapsules' 
formed were resuspended in saline.
In the presence of 10% w/v polyethyleneimine, structures 
resembling microcapsules were observed in the final aqueous 
medium. Their size was approximately 200ym. However,
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the microcapsules were not spherical but had the appearance 
of collapsed hollow 'sacks'.
Table 3.3 Summary of Conditions used to Investigate the
Method of Preparation of Nylon 6.10 Microcapsules 












Organic Phase Composition 25ml of chloroform: 
cyclohexane 1:3 by volume 
containing 10% v/v Span 85
Sebacoyl Chloride Solution 
Composition
25ml of 0.019M sebacoyl 





Reaction Time 3 minutes
Temperature approximately 4°C
Capsular structures were not observed in the presence of 
bovine serum albumin or PEG 400. It was therefore 
apparent that satisfactory microcapsules might be prepared 
in the presence of a crosslinking agent, polyethyleneimine, 
and the use of this crosslinking agent was further investigated.
3.1.1.2 Modifications to the Preparation of Microcapsules using 
Polyethyleneimine, a Crosslinking Agent
It has been reported that particles of less than approximately 
20ym cannot be felt when instilled in the eye (135). Therefore, 
in order to produce a suspension of microcapsules suitable for
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ophthalmic administration it was necessary to develop a method 
for producing smaller microcapsules. This was based on the
method developed in Section 3.1.1.1. Microcapsule size was
assessed using a light microscope fitted with a calibrated 
eye piece micrometer. Using the conditions set out in 
Table 3.3 for the successful preparation of polyethyleneimine 
containing microcapsules as a basis for further modifications, 
the parameters shown in Table 3.4 were investigated. Initially 
the method of emulsion formation was examined. Microcapsules 
were not formed if a magnetic stirrer, Silverson stirrer with 
homogeniser attachment or ultrasonic probe were used instead 
of the overhead stirrer. Increasing the speed of stirring 
of the overhead stirrer and changing the reaction vessel from 
a round bottom flask to a cylindrical centrifuge tube both 
decreased the microcapsule size and improved their appearance. 
Using the overhead stirrer in combination with the centrifuge 
tube and stirring at 2,000 rpm the compositions of the aqueous 
and organic phases were then examined. Various combinations 
of monomer concentration, polyethyleneimine concentration,
Span 85 concentration and so on were investigated as described 
in Table 3.4. Finally, using several of these combinations 
the reaction conditions and method of harvesting were examined 
(Table 3.4). Well formed microcapsules of 20 to 30ym diameter 
were produced using 5% w/v polyethyleneimine solution, 0.019M 
sebacoyl chloride, 0.4M 1,6 hexamethylenediamine solution and 
a chloroform; cyclohexane ratio of 1:3 by volume containing 
1% v/v Span 85. The emulsion was formed using an overhead 
motor with paddle stirrer rotating at 2,000 rpm and the reaction 
vessel was a 100ml capacity centrifuge tube surrounded by ice.
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Speed of overhead stirrer - 500 - 2,000 rpm
Reaction vessel used in ) 
combination with overhead stirrer )
- round bottom flask
- 100ml centrifuge tube





Sebacoyl chloride concentration 
Chloroform: cyclohexane ratio 
Span 85 concentration
1, 5, 10% w/v
0.2, 0.4, 0.8M 
0.009, 0.019, 0.03M 
1:3 1:4 1:5 
1.0 5.0 10.0% v/v






Room temperature 4°C 
1, 3, 5 minutes 
1, 3, 5, 10 minutes 
Chloroform: cylochexane 1:3, 1:4 
or 1:5 or 100% cyclohexane 
Centrifugation from organic phase 
and dispersion in Tween 20 
solution or, wash in acetone 
before dispersion in Tween 20 
solution.
The émulsification and reaction times were 1 minute and 3 minutes 
respectively and cyclohexane was used to quench the reaction. 
Harvesting was facilitated if acetone was used to transfer the 
microcapsules to the aqueous Tween 20 solution. No microcapsules 
were formed if the polyethyleneimine was omitted but above 
1% w/v the polyethyleneimine concentration had no detectable 
effect on microcapsule appearance. Altering the concentration 
of the monomers and the chloroform: cyclohexane ratio also had
127
no obvious effect on microcapsule appearance. Furthermore, 
no effect on appearance was observed on altering the reaction 
temperature or reaction and émulsification times. Recovery 
of the microcapsules from the organic phase was aided if the 
quenching solution was cyclohexane alone and the microcapsules 
showed no differences from those quenched using the appropriate 
external organic phase. Increasing the Span 85 concentration 
from 1% to 10% had no significant effect on microcapsule size 
whilst stirring at 2,000 rpm.
Attempts to further reduce the size of the microcapsules by 
increasing the stirring speed above 2,000 rpm were unsuccessful 
as this resulted in aggregation of the microcapsules. In order 
to prevent or minimise this cohesion the following conditions 
were altered.
1. The relative volumes of the internal and external phases 
were altered as shown in Table 3.5.
2. The Span 85 concentration was increased from 1% v/v to 
15% v/v to increase the stability of the emulsion and 
decrease coalescence.
3. Benzidine disulphonic acid 6,5% w/v was included in the 
preparation by dissolution in the aqueous phase. This 
is believed to give rise to negative charges on the 
surface of the microcapsules which aid dispersion (101).
4. The reaction time was decreased from 3 minutes to 2 minutes 






0.5ml aniline was added to the quenching solution to 
rapidly stop polymerisation.
The volume of sebacoyl chloride added was reduced to 
give a concentration of 0.005M.
The chloroform:cyclohexane ratio was decreased to 1:19 
to reduce the solubility of the diamine in the external 
organic phase.
The concentration of 1,6 hexamethylenediamine was decreased 
to 0.IM to reduce the total amount of nylon formed.
All attempts however to prevent aggregation of the smaller 
microcapsules were unsuccessful.
Table 3.5 Volumes of Internal and External Phases Investigated in the
Preparation of Nylon 6.10 Microcapsules containing Polyethyleneimine
1 2 3 4
Volume of internal phase 5ml 3ml 2. 5ml 1.5ml
Volume of external phase 
prior to addition of 
sebacoyl chloride solution 25ml 15ml 25ml 30ml
Volume of sebacoyl chloride
solution 25ml 30ml 25ml 30ml
'Scale-Up* of Microcapsule Preparation
Further processes developed for microcapsule preparation were 
based on the method described in Section 3.1.1.2. A major 
modification to this method was the increase in weight and 
volume of reactants used. This was carried out in order to 
increase the yield of microcapsules obtained. To accommodate 
the increased volume of reactant solutions it was necessary to 
further change the reaction vessel from a 100ml capacity
129
centrifuge tube to a 250ml conical flask. It was observed 
throughout the development procedure that microcapsule 
appearance improved for a given system if the sebacoyl 
chloride had been recently redistilled. For this reason 
the diacid chloride was redistilled approximately every four 
weeks and stored under nitrogen. It was also found that 
microcapsule suspensions could successfully be stored in water 
in place of saline.
As a result of the investigations described above it was apparent 
that to produce microcapsules with diameters of approximately 
20-30ym several factors had to be taken into account. These 
included the nature of the mechanical stirrer, the type of 
reaction vessel, the use of a crosslinking agent, polyethyleneimine 
and the stirring speed. The method finally selected for 
microcapsule preparation is described in detail in Section 3.1.2.
3.1.2 Method of Preparation of Nylon 6.10 Microcapsules
The following solutions were prepared and cooled to 4^C before use;
Solution 1 Equivolume 0.9M carbonate-bicarbonate buffer pH 9.8 and 
20% w/v aqueous polyethyleneimine solution
Solution 2 0.4M 1,6 hexamethylenediamine in distilled water
Solution 3 Chloroform:cyclohexane 1 part to 5 parts by volume
containing 1% v/v Span 85
Solution 4 0.015M sebacoyl chloride in chloroform:cyclohexane
1 part to 5 parts by volume containing 1% v/v Span 85
3.75ml 'Solution 1' and 3.75ml 'Solution 2' were pipetted into a 
250ml conical flask surrounded by ice and stirred at 2,000 rpm 
using an overhead paddle stirrer connected to a Citenco motor. 
Whilst stirring, 75ml 'Solution 3' was added and stirred for 1
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minute after which time 75ml 'Solution 4' (prepared 20 seconds 
before use) was added and stirred for 3 minutes. The suspension 
was then poured into 100ml cyclohexane, centrifuged at 2,500 rpm 
for 30 seconds and the supernatant removed. The microcapsules 
were washed using 500ml cylcohexane, centrifuged as above and 
washed with 50ml acetone. After centrifuging again the 
slurry was dispersed in 15ml 50% aqueous Tween 20 solution 
and stirred for 30 seconds. This was then diluted to
150ml with distilled water. Microcapsules were removed from
the Tween 20 solution by centrifugation again at 2,500 rpm and 
were resuspended in water. Alternatively the microcapsules 
were removed from the cyclohexane wash by centrifugation, 
washed in 50ml acetone and resuspended in water.
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3.2 Preparation of Polyphthalamide Microcapsules
The method for the preparation of polyphthalamide microcapsules was 
based on that developed for nylon 6.10 microcapsules except that 
the monomers used were piperazine and phthaloyl chloride. It was 
observed, however, that by increasing the concentration of diacid 
chloride used from 0.015M to 0.044M the yield of microcapsules was 
considerably improved (see Section 3.3.3), This was not the case 
with the nylon 6.10 microcapsules. Increasing the sebacoyl 
chloride concentration to 0.044M resulted only in the formation 
of microcapsules surrounded by what appeared to be loosely attached 
low molecular weight polymer. The method used for the preparation 
of the increased yield of polyphthalamide microcapsules is given 
below.
The following solutions were prepared and cooled to 4^C before use. 
Solutions 1 and 3 were as given for nylon 6.10 microcapsule preparation,
Solution 2 0.4M piperazine in distilled water.
Solution 4 0.044M phthaloyl chloride in chloroform:
cyclohexane 1 part to 5 parts by volume containing 
1% v/v Span 85.
The method of preparation was as for nylon 6.10 microcapsules 
described in Section 3.1.2. The method of transference to an 
aqueous phase was also the same.
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3.3 Characteristics of Nylon 6.10 and Polyphthalamide Microcapsules
Samples of both nylon 6.10 and polyphthalamide microcapsules were 
prepared using the methods given in Sections 3.1.2 and 3.2 
respectively and assessed for their appearance, size distribution, 
yield and the distribution of pilocarpine nitrate during preparation.
3.3.1 Appearance
The appearance of microcapsules was investigated using an 
Amplival Carl Zeiss microscope with camera attachment.
Aqueous microcapsule suspensions were appropriately diluted 
with water and mounted in a haemocytometer; Figure 3.1 shows 
the appearance of nylon 6.10 microcapsules. The microcapsules 
are spherical with clear interiors and have thin walls relative 
to their diameter. A large range of sizes is present and some 
capsules have collapsed which is possibly due to crenation.
In contrast, the polyphthalamide microcapsules shown in 
Figure 3.2 are more irregular in shape and have what appear to 
be small particles of polymer associated with them. Again, 
however, the microcapsules are seen to have thin walls relative 
to their diameter and a large size range is present.
Scanning electron micrographs of these microcapsules were 
taken using a JEOL 35C scanning electron microscope. 
Microcapsules were prepared for electron microscopy by two 
methods.
1. Freeze Fracture: Aqueous microcapsule suspensions were
rapidly frozen in Freon 22 which had previously been 
cooled by liquid nitrogen. The microcapsules were then 





FIGURE 3.1 NYLON 6.10 MICROCA P S U L E S  DISPERSED IN 
W A T E R .
î 34




FIGURE 3.2 POLYPHTHALAMIDE M I C R O C A P S U L E S  D I S PERSED 
IN WATER.
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the frozen microcapsules were fractured by placing them 
between two sheets of velim and striking with a hammer. 
Following freeze drying for 12 hours the samples were 
mounted and gold coated using an argon sputter coater.
2. Critical Point Drying : The sample, suspended in acetone
was placed in a critical point drying chamber and the 
acetone replaced by liquid carbon dioxide. The chamber 
was then pressurised to above 1200 psi and after removal 
of the acetone heated to 40°C. After cooling, the 
microcapsules were mounted onto stubs and gold coated 
as above.
Figures 3.3a and 3.3b show respectively the appearance of a 
freeze fractured nylon 6.10 microcapsule and a general field of 
view of nylon 6.10 microcapsules from which the above micrograph 
was taken. The individual microcapsule is seen to be hollow 
and to have thin walls. The thickness of the microcapsule 
wall is estimated to be less than O.Syra. The total field of 
view (Figure 3.3b) shows two microcapsules which have been 
successfully fractured, the remainder appear to be intact.
From the micrograph it appears that the smaller microcapsules 
in the sample have remained spherical whilst the larger ones 
have collapsed. Figure 3.4a shows the appearance of a freeze 
fractured polyphthalamide microcapsule. It is again seen to 
be hollow and to have thin walls but it is of irregular shape. 
The field of view shown in Figure 3.4b is of polyphthalamide 
microcapsules prepared by the critical point drying technique. 
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SCANNING ELECTRON MICROGRAPHS OF
POLYPHTHAL/\M IDE M ICROCAPSULES .
a Prepared by freeze fracture method 
b Prepared by critical point drying method
between these and the collapsed microcapsules shown in 
Figure 3.3b may be due to the different polymeric wall material 
used but it is believed to be due to the preparative technique 
as freeze fractured polyphthalamide microcapsules have also 
been found to be collapsed. For this reason the critical 
point drying method was used for all subsequent samples to 
illustrate the structure of whole microcapsules. A number of 
the microcapsules in Figure 3.3b may again be seen to be of 
irregular shape.
3.3.2 Size Distribution
Size analysis was carried out using a Coulter Counter model Zb 
fitted with a Universal Coincidence Corrector. A 140ym orifice 
tube and 0.5ml volume samples were used throughout the counting. 
Matching switch and gain control settings were 20K and 5 
respectively. Microcapsule suspensions were diluted to below 
14,580 particles per 0.5ml using Isoton (Coulter Electronics Ltd., 
Luton) and counting carried out whilst stirring. All counts 
were taken in quadruplicate. Prior to its use background counts 
were also performed on the electrolyte used for the dilution. 
Solutions with total particle counts above approximately 100 per ml 
over the range 5 to 60^m were discarded. Calibration of the 
Coulter Counter was undertaken using a monodisperse suspension 
of pollen (Coulter Electronics Ltd.) with a nominal particle 
diameter of 13.53|jm using the 'Half-Count Technique' (136).
In order to assess the suitability of using this method to 
determine the size distribution of microcapsules, the number 
size distribution of a given batch of polyphthalamide
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microcapsules was determined using the Coulter Counter and 
the Fleming Particle Size Analyser. The latter is a 
microscopical method of size determination in which the images 
are sheared such that in a given direction the new image and 
the original image are just touching. The distance of the 
shear is therefore the diameter of the particle in the given 
direction and this distance is monitored and recorded for each 
particle. The frequency size distribution of polyphthalamide 
microcapsules determined by the two methods is shown in Figure 3.5, 
Comparison of (a) and (b) reveal differences in the size 
distribution. For example a large number of small particles 
6-7.5pm were detected by the Coulter Counter but not by the 
Fleming Size Analyser. These differences may arise due to 
the diffuse images of the microcapsules obtained using the 
size analyser making accurate measurement of particle diameter 
difficult. They may also arise due to the. basis of the 
measurement technique; that is the Coulter Counter assumes 
the particles are spherical in calculating the diameter of 
each particle. This is not the case (Figure 3.2). The 
cumulative frequency percent oversize curves calculated from 
the number size distributions are shown in Figure 3.6. It 
may be seen that the shapes of the curves are similar.
However, the median frequency diameters were estimated to 
be approximately 15-16pm determined by Coulter Counter and 
20pm determined by Fleming Size Analyser. The relatively 
small value obtained using the Coulter Counter is probably 
due to the significantly large number of small particles 
present in the sample measured. This results in a 'skew' 















FIGURE 3.5 FREQUENCY SIZE DISTRIBUTION OF POLYPHTHALAMIDE 
MICROCAPSULES DETERMINED BY a) COULTER 
COUNTER AND b) FLEMING PARTICLE SIZE ANALYSER.
100-
^Coulter Counter





a. Median diameter determined by Coulter Counter 
15-16pi •
b. Median diameter determined by Fleming Particle 
Size Analyser 19-20pi.
FIGURE 3.6 SIZE DISTRIBUTION OF POLYPHTHALAMIDE 
MICROCAPSULES DETERMINED BY COULTER
COUNTER AND FLEMING PARTICLE SIZE ANALYSER*
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in both cases the microcapsules are in the same size range 
with similar size distributions. As a result of this it was 
decided to use the Coulter Counter in subsequent 
determinations of size distribution due to its ease of 
operation.
Four batches of both nylon 6.10 and polyphthalamide 
microcapsules were prepared and their size distributions 
determined using the Coulter Counter. The data are given in 
Table 3.6 and are shown plotted as cumulative volume percent 
oversize curves in Figure 3.7. The diameters of the microcapsules 
range between approximately 5pm and 60pm and the median volume 
diameters for nylon 6.10 and polyphthalamide microcapsules taken 
from four batches are 16.5pm and 26.0pm respectively. The data 
obtained from all four batches are in close agreement for both v 
types of microcapsule.
3.3.3 Microcapsule Yield
Microcapsule yield was assessed by determining the concentration 
of microcapsules present in a given weight of slurry obtained 
after rotary evaporation; where concentration is defined as the 
volume of microcapsules present in a given weight of slurry 
or suspension. For example 50% v/w refers to a total capsular 
volume of 0.5ml present in Ig of slurry.
Following centrifugation in cyclohexane, microcapsules were 
washed in 50ml acetone, centrifuged, rotary evaporated for 
30 minutes at 30°C and the mass of slurry obtained weighed.
A known weight of this slurry was then dispersed in 200ml
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Cumulative Volume Percent Oversize
Microcapsule Nylon 6.10 Polyphthalamide
D iame ter 
(pm) 1 2 3 4 1 2 3 4
59.98 1.8 1.8 0.5 0.6 1.2 1.1 1.6 5.2
47,61 3.6 4.6 1.3 2.0 6.0 4.1 5.3 11.6
37.38 5.2 7.8 2.3 3.5 16.1 12.5 14.1 24.5
29.99 10.9 9.7 3.7 6.3 40.0 31.1 28.8 44.1
23.80 25.9 13.0 7.1 11.9 64.5 61.7 48.6 65.3
18.89 42.0 22.2 28.1 36.8 81 9 81.6 70.6 81.6
14.99 62.5 44.2 77.8 87.3 90.7 91.4 85.8 91.0
11.90 88.0 78.1 96.4 98.0 96.3 96.0 94.1 95.8
9.45 97.9 98.5 99.2 99.4 98.5 98.4 97.8 98.2
7.50 99.5 99.7 99.7 99.8 99.5 99.5 99.3 99.4




17,5 14.0 17.0 17.5 27.0 26.0 23.0 28.0
TABLE 3*6 BATCH TO BATCH VARIATION IN SIZE DISTRIBUTION 
OF NYLON 6.10 AND POLYPHTHALAMIDE 
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FIGURE 3.7 SIZE DISTRIBUTION OF TYPICAL BATCHES 
OF NYLON 6.10 AND POLYPHTHALAMIDE 
MICROCAPSULES.
Determined by Coulter Counter
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Isoton to give a suitable number of microcapsules for 
measurement and the total capsular volume of this sample was 
determined by Coulter Counter analysis. Total capsular 
volume was calculated by the following method:
If the microcapsule diameters fall in the range a-k (ym) and 
the Coulter Counter size range settings are a-b, b-c, c-d... 
j-k (ym) , then considering the size range a-b, with the number 
of particles with diameters in that size range equal to 
and taking the mean of the size range as the geometric mean
dab = i/a X b (equation 3,1)
the volume of each microcapsule = ^/Stt  ̂ (equation 3,2)
then the total volume of microcapsules in the size range
= X (equation 3.3)
By summing (V , x N , ) + (V. x N. ) + ...... + (V., x N., )ab ab be be ]k ]k
the total capsular volume in the sample is calculated.
Knowing the sample weight and the total capsular volume the 
concentration of microcapsules in that sample may be expressed 
as % v/w. If the total slurry weight from which the sample was 
removed is known then the total capsule volume in the slurry 
may be calculated. An assessment of the reproducibility of 
this technique is given in Section 3.4. An example of the 
calculation of capsule concentration is given for one batch 
of polyphthalamide microcapsules in Table 3.7. Table 3.8 
shows the data obtained for two typical batches of nylon 6.10 
microcapsules and four typical batches of polyphthalamide 
microcapsules. It is evident from Table 3.8 that the yield 






























V X N (pm3)
59.98 - 75.58 67.33 159817.5 2 319635
47.61 - 59.97 53.43 79881.6 12 958580
37.78 - 47.60 42.41 39930.2 71 2835047
29.99 - 37.77 33.66 19961.1 310 6187931
23.80 - 29.98 26.71 9979.6 1021 10189133
18.89 - 23.79 21.20 4988.1 1326 6614267
14.99 - 18.88 16.82 2492.9 1301 3243257
11.90 - 14.98 13.35 1246.2 1237 1541546
9.45 - 11.89 10.60 623.6 1294 806963
7.50 - 9.44 8.41 311.9 1210 377428
5.95 - 7.49 6.68 155.8 1029 160292
Total volume of microcapsules 
in 0,5ml sample of Isoton
Total volume of microcapsules 
in 200ml Isoton
Weight of microcapsule slurry 
dispersed in 200ml Isoton
Therefore, volume of microcapsules 
in Ig of slurry
Therefore, microcapsule concentration
3.323 X lO^pm^







TABLE 3.7 CALCULATION OF CONCENTRATION OF POLYPHTHALAMIDE 


























6.6 91.0 109.6 111.2 







0.23ml 0.34ml 4.67ml 5.51ml 5.8 5m1 3.57ml
TABLE 3.8 YIELD OF NYLON 6.10 AND POLY PH THALAMIDE
MICROCAPSULES.
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Batch Number 1 2
Weight of microcapsules 
after removal from the 
cyclohexane wash.
5.408g 8.833g
Weight of microcapsules 
after rotary evaporation. 1 .858g 4.138g
Concentration of 
microcapsules in slurry 
after rotary evaporation. 27.25%Vw
7.7%v/^
Estimated total capsular 
volume. 0.506ml 0.319ml
TABLE 3.9 YIELD OF POLYPHTHALAMIDE MICROCAPSULES 
PREPARED USING 0.015M PHTHALOYL 
CHLORIDE.
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that of nylon 6.10 microcapsules following rotary evaporation. 
Polyphthalamide microcapsules prepared using a diacid chloride 
concentration the same as that used for nylon 6.10 microcapsule 
preparation, that is 0.015M, have a similar yield to that 
reported for nylon 6.10 microcapsules (see Table 3.9).
3.3.4 Preparation of Microcapsules in the Presence of Pilocarpine Nitrate
1. Distribution of Pilocarpine Nitrate during Preparation of 
Microcapsules
Nylon 6.10 and polyphthalamide microcapsules were prepared 
with pilocarpine nitrate dissolved in the initial aqueous phase 
for which pilocarpine nitrate concentrations are expressed 
as the molar concentration of drug present in the initial 
aqueous phase. Microcapsules were prepared with the 
aqueous phase containing 1.85 x 10“^M pilocarpine nitrate.
After washing in cyclohexane the microcapsules were washed 
with 50ml acetone and then dispersed in 150ml of aqueous 5% v/v 
Tween 20 solution. In order to determine the distribution 
of the drug during the preparation of the microcapsules, 
an appropriate volume of stock tritiated pilocarpine solution 
in water was added to the initial aqueous phase (equivalent 
to approximately 5 x 10^ dpm). Samples of the continuous organic 
phase formed after quenching, the cyclohexane wash, acetone wash 
and Tween 20 solution were taken and assayed for pilocarpine 
nitrate. From a knowledge of the volume of each of these 
solutions the amount of drug present was calculated and the 
data are given in Table 3.10. The presence of polyethyleneimine 
and/or piperazine lowered the count obtained when assaying 
the initial aqueous phase. Consequently, in order to 
determine the total activity included in the system the stock
150
labelled pilocarpine solution was diluted by the same factor 
as that used to prepare the solution containing 
polyethyleneimine or piperazine and this assayed for 
tritiated pilocarpine.
The distribution of the pilocarpine nitrate was also 
determined in the absence of polymerisation in order to 
ascertain if the amount of drug found in the organic phase 
was a function of a partition process between the two phases. 
Solutions were prepared as for polyphthalamide microcapsule 
formation containing 1.85 x 10"^M pilocarpine nitrate in the 
aqueous phase but omitting the phthaloyl chloride and 
piperazine. 3.75ml 'Solution 1' and 3.75ml 'Solution 2' 
without piperazine were pipetted into a 250ml conical flask 
surrounded by ice and stirred at 2,000 rpm. Whilst stirring, 
75ml 'Solution 3' was added and stirred for 1 minute after 
which time 75ml 'Solution 4' without phthaloyl chloride was 
added and stirred for 3 minutes. The emulsion was poured 
into 100ml cyclohexane and centrifuged to separate the 
aqueous and organic phases. Five 200yl samples were 
removed from each of the initial aqueous phase, the external 
organic phase and internal aqueous phase and assayed for 
pilocarpine. The distribution of the pilocarpine nitrate 
under these conditions is given in Table 3.12,.
The data in Tables 3.10 and 3.11 show that during the 
preparation of both types of microcapsule approximately 
50% of the total pilocarpine nitrate recovered was lost 
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cyclohexane wash and the remainder to the acetone and 
Tween 20 washes. In the absence of polymerisation 
(Table 3.12) approximately 50% of the total pilocarpine 
nitrate recovered was again found in the continuous 
organic phase suggesting this loss was purely a function 
of the partition process. From the data in Tables 3.10 
and 3.11 it may be expected that if microcapsules were 
harvested from the cyclohexane wash, that is if the acetone 
wash and Tween 20 solution were omitted, then the formed 
microcapsules would contain half the total amount of 
pilocarpine nitrate included in the system. For this 
reason, all subsequent preparations of microcapsules were 
harvested from the cyclohexane wash.
2. The Effect of Pilocarpine Nitrate Concentration on the 
Preparation of Polyphthalamide Microcapsules
For polyphthalamide microcapsules, the effect of
concentration on the loss of pilocarpine nitrate to the
organic phase during microcapsule preparation was
investigated. Polyphthalamide microcapsules were
prepared containing initial pilocarpine nitrate
concentrations of 1.85, 3.70, 7.38, 14.76, 18.45 and
29.52 X 10”^M. The microcapsules were harvested from
the cyclohexane wash. After preparation, the organic
phase and cyclohexane wash were assayed for pilocarpine
nitrate and the appearance of the microcapsules examined
after rotary evaporation at 30°C for 30 minutes followed
by redispersion in water. The data are given in Table 3.13
and it can be seen that the microcapsules could not be
formed in the presence of 18.5 x 10 ^M pilocarpine nitrate
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or above. The distribution of the drug in the organic 
phase was found to be the same for microcapsules 
containing pilocarpine nitrate at all the lower 
concentrations. That is approximately 50% of the total 




Initial Concentration of 
Pilocarpine Nitrate (M x 10 )
1.85 3.69 7.38 14.76 18.45 29.52
Yes Yes Yes Ye s No No
Appearance of 
microcapsules. Discre te Splleres Aggre
-gates




organic phase. 0. 538 0.586 0.472 0.535
2. Cyclohexane 
wash. 0.002 - 0.001 -
TABLE 3.13 EFFECT OF PILOCARPINE NITRATE CONCENTRATION 
ON THE FORMATION OF POLYPHTHALAMIDE
MICROCAPSULES AND THE DISTRIBUTION OF THE
PILOCARPINE NITRATE IN THE PREPARATION.
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3.4 Freeze Drying of Polyphthalamide Microcapsules
In an attempt to produce batches of microcapsules of a more uniform 
nature from which reproducible samples could be removed, microcapsule 
suspensions were freeze dried. The freeze drier consisted of a 
large glass vessel at the base of which a flask could be connected.
A cold finger protruded into the flask and a vacuum was drawn from 
the side. Acetone and dry ice mixtures were placed in the cold 
finger. The sample to be freeze dried was placed in a round bottom 
flask and frozen by immersing in liquid nitrogen. The flask was 
attached to the freeze drier and drying continued for a period of 
approximately 5 hours until the sample reached room temperature.
Freeze drying of polyphthalamide microcapsules resulted in the 
formation of a fine white free-flowing powder. On addition of 
acetone to a sample of freeze dried material the microcapsules 
remained collapsed. On dispersion in water however, they 
reconstituted well and had a similar appearance to those which had 
not been freeze dried (Figure 3.8). The scanning electron 
micrograph in Figure 3.9a also shows the microcapsule has 
reconstituted and is hollow. The thickness of the wall is 
estimated to be approximately 0.8yra. The micrograph in Figure 3.9b 
however suggests that some of the microcapsules have not fully 
reconstituted as these have remained collapsed.
The effect of freeze drying on the size distribution of polyphthalamide 
microcapsules is shown in Figure 3.10 which gives the size distribution 
of 2 batches of polyphthalamide microcapsules before and after freeze 
drying. The curves for the samples of freeze dried and non freeze 






FIGURE 3.8 FREEZE DRIED POLYPHTHALAMIDE MICROCAPSULES 












SCANNING ELECTRON MICROGRAPHS OF FREEZE 
DRIED POLYPHTHALAMIDE MICROCAPSULES.
a. Prepared by freeze fracture method
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FIGURE 3.10 THE EFFECT OF FREEZE DRYING AND 




The yield of microcapsules obtained following freeze drying was also 
determined using the Coulter Counter. In order to assess the 
reproducibility of this method for determining the concentration of 
freeze dried microcapsules, five samples of known weight were taken 
from a given batch of freeze dried polyphthalamide microcapsules and 
their 'concentrations'determined as given in Section 3.3.3 following 
reconstitution in a known volume of Isoton. The percent volume 
in weight determined for each sample is given in Table 3.14,
The 'concentration' values are in good agreement and have a 
coefficient of variation of ± 2.7%. Data for the yield of 
microcapsules following freeze drying of five different batches of 
polyphthalamide microcapsules are given in Table 3.15. The 
concentration of microcapsules in the freeze dried powder, 
determined by Coulter Counter as in Section 3.3.3 was found to 
range between approximately 200 and 300% v/w for four batches.
The reproducibility of this method of determining capsule 
concentration suggests that the large variation in concentration 
is due to a difference in the microcapsule batches and does not 
arise as a result of the method of measurement used.
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3 4.99 199.6 5.276 ± 2.7%
4 5.81 195.9
5 7.29 188.2
TABLE 3.14 REPRODUCIBILITY OF THE DETERMINATION OF
MICROCAPSULE CONCENTRATION BY COULTER
COUNTER.
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Batch 1 2 3 4
Weight of microcapsules 
after removal from 
cyclohexane wash
9 .208g 9.385g 8.935g 9.131g
Weight of microcapsules 
after rotary 
evaporation.
5.026g 5.030g 5.264g 4.422g
Weight of microcapsules 







TABLE 3.15 EFFECT OF FREEZE DRYING ON THE YIELD OF
POLYPHTHALAMIDE MICROCAPSULES.
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3.5 Release from Polyphthalamide Microcapsules
3.5.1 Release of Pilocarpine Nitrate from Polyphthalamide Microcapsules
3.5.1.1 General Method
The release of pilocarpine nitrate from polyphthalamide 
microcapsules was determined by the following method. A known 
weight of microcapsule slurry or freeze dried powder containing 
the drug was accurately weighed into a 50ml conical flask fitted 
with a glass stopper. To this was added 50ml isotonic phosphate 
buffer equilibrated to 32°C. The flask was then shaken in a
waterbath at 70 cycles per minute and 32°C, ensuring that the
level of water in the bath was above that of the suspension in 
the flask. Approximately 1.5ml samples of the solution were 
removed at timed intervals through a 3ym Millipore filter 
connected to a syringe. The samples were weighed after 
removal and assayed for pilocarpine nitrate. In a separate 
experiment to assess the uptake of pilocarpine nitrate onto 
Millipore filters, five samples were removed from a stock 
solution of pilocarpine nitrate also containing labelled 
pilocarpine. Each was filtered through a clean Millipore 
filter. No significant difference in activity before and 
after passing through the filter was observed. Throughout 
the determination of release the volumes of solution taken 
for sampling (that is 1.5ml) were significant relative to the 
original volume of solution present. It was therefore 
necessary to correct for the amount of pilocarpine nitrate 
removed in each sample in calculating the total mass released.
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3.5.1.2 Determination of Release of Pilocarpine Nitrate
The release of pilocarpine nitrate was determined from four 
different types of polyphthalamide microcapsule preparation.
The techniques used are given below.
Method 1
Microcapsules were prepared containing a known concentration of 
pilocarpine nitrate together with an aliquot of tritiated 
pilocarpine stock solution in the aqueous phase. After 
washing in cyclohexane the microcapsule slurry was rotary 
evaporated for 30 minutes at 30°C. Approximately 5.0g of the 
slurry was accurately weighed into a 50ml conical flask and the 
release measured according to the general method (see Section
3.5.1.1).
Method 2
This technique involved freeze drying polyphthalamide 
microcapsules prepared in the absence of pilocarpine nitrate, 
which were then resuspended in pilocarpine nitrate solution 
containing tritiated pilocarpine. The release from these 
reconstituted microcapsules now containing the drug was 
determined by the addition of a further volume of buffer 
solution. Polyphthalamide microcapsules containing 
electrolyte solution were prepared as in Section 3.2 and frozen 
in liquid nitrogen. After freeze drying for 5 hours 
approximately 1.5g of the dried material,accurately weighed,was 
immersed in 5ml of a solution of pilocarpine nitrate and 
tritiated pilocarpine in pH7.4.isotonic phosphate buffer to 
give a thick suspension. The suspension was allowed to
166
equilibrate at 32°C for 12 hours. A volume of pH7.4 isotonic 
buffer at 32°C sufficient to give 50ml was then added and the 
release determined as given in the general method (see Section
3.5.1.1).
In order to ensure that the pilocarpine nitrate penetrated 
the freeze dried capsule wall on resuspension, 
it was necessary to determine the interaction of pilocarpine 
nitrate with the intact microcapsules and with the polyphthalamide 
wall material. After preparation, polyphthalamide microcapsules 
were washed with cyclohexane, rotary evaporated and dispersed 
in water before freeze drying for 5 hours. Approximately G.7g 
freeze dried capsules accurately weighed, was placed in a flask 
to which was added 5ml 1.47 x 10 pilocarpine nitrate in 
pH 7.4 isotonic phosphate buffer containing tritiated pilocarpine. 
Five 20yl samples were removed through a Millipore filter and 
assayed for pilocarpine nitrate. For the wall material, 
polyphthalamide microcapsules were prepared as in Section 3.2 
and after washing with cyclohexane the slurry was rotary 
evaporated and dispersed in water. The suspension was 
ultrasonicated for 1 hour, centrifuged and the microcapsule 
walls freeze dried. Measurement of the uptake of pilocarpine 
nitrate was as for the freeze dried intact microcapsules.
The uptake of pilocarpine nitrate by whole and broken 
microcapsules is given in Table 3.16 and the data show that the 
uptake of pilocarpine nitrate per gram of freeze dried material 
was not significantly different for the polyphthalamide 
microcapsules and the broken walls. It is probable therefore 
that the pilocarpine nitrate penetrates the microcapsule wall and 


















(g) (M X 104) (M X 104) (M g “ ^  X  104)
Intact
Microcapsules.
A 0.7335 1.478 1.264 1.580
B 0.6814 1.478 1.261 1.591
Polyphthalamide 
Wall Material.
A 0.6656 1.470 1.287 1.378
B 0.7292 1.472 1.270 1.387
TABLE 3.16 UPTAKE OF PILOCARPINE NITRATE BY FREEZE DRIED




Polyphthalamide microcapsules were prepared containing pilocarpine 
nitrate and an aliquot of tritiated pilocarpine solution in the 
aqueous phase. After washing in cyclohexane the slurry was 
frozen in liquid nitrogen and freeze dried for 5 hours.
Approximately l.Og of the freeze dried powder was accurately 
weighed into a 50ml conical flask and the release measured 
according to the general method (see Section 3.5.1.1).
Method 4
The measurement of release by 'Method 4' was similar to that 
described for 'Method 3'. Microcapsules containing pilocarpine 
nitrate were washed in cyclohexane and frozen in liquid nitrogen.
They were then freeze dried but for a period of only 30 minutes 
which resulted in a slurry rather than a powder. Approximately 
4.0g of the slurry was accurately weighed into a 50ml conical 
flask and the release measured as given in Section 3.5.1.1,
In this instance the samples were assayed by HPLC. For the purpose 
of washing the loop valve injector of the HPLC system and the syringe
used for injection onto the column it was necessary to remove 
3.0ml volume samples and therefore fewer samples were taken.
In calculating the mass released it was again necessary to 




The release of pilocarpine nitrate from polyphthalamidjç, 
microcapsules determined by the four methods described above 
is shown in Figures 3.11 to 3.14. Figure 3.11 and the data 
given in Tables 3.17 and 3.18 show the effect of concentration 
on the release of pilocarpine nitrate over the concentration 
range 1.85 x 10 to 14.78 x 10"*^M determined by 'Method 1' 
and indicate that the rate of release of pilocarpine nitrate 
is dependent upon initial drug concentration. It is apparent 
that more than 90% of the total pilocarpine nitrate content 
recovered from the microcapsule phase of initial concentrations 
approximately 1.85 x 10~^M and 3.61 x 10"”̂ M was released in
20 to 30 minutes. However, although the microcapsules
-2 -2 containing 7.36 x 10 M and 14.78 x 10 M pilocarpine nitrate
lost approximately 50% of the total drug content recovered in
the first minute the remainder was lost considerably more slowly.
Figure 3.11 also shows that there was a 10 to 20% variation in the
total mass of pilocarpine nitrate released between replicate
determinations for a given initial drug concentration. This
arises due to the following factors:
1. during microcapsule preparation the amount of drug lost 
to the organic phase is variable (see Section 3.3.4) 
and therefore the microcapsule phase does not contain a 
constant mass of pilocarpine nitrate.
2. the weight of microcapsules formed is not constant and
therefore the final total weight of drug per gram of 
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FIGURE 3.11 THE EFFECT OF CONCENTRATION ON THE RELEASE 
OF PILOCARPINE NITRATE FROM POLYPHTHALAMIDE 
MICROCAPSULES INTO pH 7.4 BUFFER AT 32°C AS 
DETERMINED USING *METHOD 1* SECTION 3.5.1.2.
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TABLE 3.17 THE EFFECT OF CONCENTRATION ON THE RELEASE 
OF PILOCARPINE NITRATE FROM POLYPHTHALAMIDE 
MICROCAPSULES INTO pH 7.4 BUFFER AT 32QÇ 
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TABLE 3.18 THE EFFECT OF CONCENTRATION ON THE RELEASE 
OF PILOCARPINE NITRATE FRCM POLYPHTHALAMIDE 
MICRQCAPSULES INTO pH 7.4 BUFFER AT SR^C 
DETERMINED USING 'METHOD 1'.
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3. for a given weight of microcapsule slurry formed the
microcapsule 'concentration' in the slurry is changeable 
(see Section 3.3,3) and therefore in sampling a given 
weight of slurry a variable weight of microcapsules and 
hence an inconstant weight of drug is taken.
The absolute values of release rate in terms of moles of drug 
released per gram of microcapsule slurry at given time intervals 
cannot be compared for two different methods of determination 
due to the difference in the physical nature of the microcapsule 
slurry or powder sampled and the relative microcapsule 
concentrations. The release rates in terms of moles of drug 
released per batch of microcapsules also cannot be compared 
due to variable unknown microcapsule losses during drying for 
example. For this reason, together with the changeable mass 
of drug encapsulated for a given initial drug concentration, 
release rates are discussed in terms of percent total pilocarpine 
nitrate released in 120 minutes. To ensure equilibrium had been 
reached within 120 minutes some determinations were continued for 
24 hours. Alternatively, data for the fraction of initial 
pilocarpine nitrate content recovered in the external organic 
phase, the cyclohexane wash and the release medium are included in 
Tables 3.17 and 3.18 to show that within the accuracy of the 
experiment 100% of the total mass included was recovered.
Figure 3.12 and Table 3.19 show the release of pilocarpine 
nitrate from polyphthalamide microcapsules determined by 
'Method 2'. Again there is some variation in the profiles 
for replicate determinations of the same initial pilocarpine 
nitrate content. In this instance the variation is due only
174
6.0
Initial Pilocarpine Nitrate 
Concentration
• l;85 X 10“^l
O 1.86 X 10“%I
O 50
Initial Pilocarpine Nitrate 
Concentration
♦  13.89 X  10”^M





FIGURE 3.12 THE RELEASE OF PILOCARPINE NITRATE FRCM 
POLYPHTHALAMIDE MICROCAPSULES INTO pH 7.4 
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TABLE 3.19 THE RELEASE OF PILOCARPINE NITRATE FROM 
POLYPHTHALAMIDE MICROCAPSULES INTO pH 7.4 
BUFFER AT 32°C DETERMINED USING'METHOD 2' .
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to a difference in the mass of freeze dried microcapsules 
sampled. The release of the drug was again extremely rapid 
and the rate of release was dependent upon initial pilocarpine 
nitrate concentration. At both initial concentrations 
investigated, however, approximately 99% of the total mass of 
drug released was lost within the first five minutes.
The release of pilocarpine nitrate from polyphthalamide
microcapsules as determined by 'Method 3 * is given in Figure 3.13
and Table 3.20 which again show pilocarpine nitrate release to be
rapid. Approximately 50% of the pilocarpine nitrate recovered
from the microcapsules was released during the first minute
although the remainder was lost more slowly from the
microcapsules containing the higher initial starting
concentration of the drug. For example, the microcapsules
_2prepared containing approximately 1.85 x 10 M pilocarpine 
nitrate lost 90% of the total amount of drug released within 
the first five minutes. In the case of the microcapsules 
prepared containing approximately 14.7 x 10 pilocarpine 
nitrate a similar percentage was not released until after 
approximately 20 minutes. It is apparent from Figure 3.13 
that there is a large difference in the total mass of 
pilocarpine nitrate released per gram of the two batches of 
microcapsules prepared containing approximately 1.85 x 10"^M 
pilocarpine nitrate. This is believed to be due to the large 
variation in microcapsule concentration observed for freeze 
dried material (see Section 3.4). That is, in sampling Ig of 
freeze dried powder the number of microcapsules present varies 
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FIGURE 3.13 THE RELEASE OF PILOCARPINE NITRATE FROM
POLYPHTHALAMIDE MICROCAPSULES INTO pH 7.4 
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TABLE 3.20 THE RELEASE OF PILOCARPINE NITRATE FROM 
POLYPHTHALAMIDE MICRQCAPSULES INTO pH 7.4 




Initial Pilocarpine Nitrate 
Concentration





FIGURE 3.14 THE RELEASE OF PILOCARPINE NITRATE FRCM 
POLYPHTHALAMIDE MICRQCAPSULES INTO pH 7.4 
BUFFER AT 32^0 DETERMINED BY ’M E T H O D  4 ’ .
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Initial Pilocarpine 
Nitrate Concentration. 1.91 X lO-^M 1.86 X 10-4v)
Mass of Pilocarpine 
Nitrate in Initial 
Aqueous Phase.
1.429 X  10-4 
moles
1.395 X 10*4 
moles
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1 1.525 92.4 1.425 92.8
5 1.591 94.8 1.458 95.0
30 1.671 99.6 1.538 100.3
120 1.678 100.0 1.534 100.0
M a s s  of Pilocarpine 
Nitrate Released 
Expressed as Fraction 
of Total Mas s  
Included.
0.540 0.555
TABLE 3.21 THE RELEASE OF PILOCARPINE NITRATE FROM 
POLYPHTHALAMIDE MICROCAPSULES INTO pH 7.4 
BUFFER A T  32°C DETERMINED USING ’M E T H O D  4* .
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The release of pilocarpine nitrate determined by 'Method 4' 
is given in Figure 3.14 and Table 3.21 from which it may be 
seen that the drug was again released rapidly. Within the 
first minute 90% of the total pilocarpine nitrate recovered 
from the microcapsule phase was released. This method was 
used to determine the release from microcapsules containing 
1.85 X 10 pilocarpine nitrate only.
3.5.2 Degradation of Pilocarpine Nitrate During Microcapsule 
Preparation and Release
To determine the extent of pilocarpine nitrate degradation 
during microcapsule preparation and subsequent release, the 
release medium sampled in 'Method 4' above was analysed by 
HPLC. The conditions were as for pilocarpine nitrate assay 
by HPLC except that the sensitivity was increased to 0.04 aufs. 
The chromatogram obtained is shown in Figure 3.15. No peaks 
corresponding to isopilocarpine, pilocarpic acid or isopilocarpic 
acid were observed, although the shoulder on the pilocarpine 
nitrate peak may suggest the presence of trace amounts of 
pilocarpic acid. The peaks present corresponding to 2 minutes 
6 seconds and 4 minutes 45 seconds are believed to be impurities 
present in the microcapsule system such as unreacted monomers.
3.5.3 Release of Prednisolone Sodium Phosphate from Polyphthalamide 
Microcapsules
-2Polyphthalamide microcapsules were prepared containing 1.86 x 10 M 
prednisolone sodium phosphate by dissolving the drug in the 
internal aqueous phase prior to encapsulation. After washing in 
cyclohexane the microcapsule slurry was frozen in liquid 








FIGURE 3.15 HPLC TRACE SHOWING IMPURITIES PRES E N T  IN 
SOLUTION AFTER THE RELEASE OF PILOCARPINE
NITRATE FROM POLYPHTHALAMIDE MICROCAPSULES
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release of prednisolone sodium phosphate was determined using 
'Method 4' as given in Section 3.5.1.2 for pilocarpine nitrate. 
Figure 3.16 shows a plot of the moles of prednisolone sodium 
phosphate released per gram of microcapsule slurry against time 
from which it may be seen that the release of the prednisolone 
sodium phosphate was rapid. Approximately 60% of the drug 
content released in 120 minutes was lost in the first minute, 
and 90% within the first 15 minutes. Data for the release 
profilé âré given in Table 3.22.
1 8 4
1.4.
Initial Prednisolone Sodium 
Phosphate Concentration
e 1.86 X 10-
1.76 IQ-^M
é  oM  (0
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FIGURE 3.16 THE RELEASE OF PREDNISOLONE SODIUM 
PHOSPHATE FROM POLYPHTHALAMIDE 
MICROCAPSULES INTO pH 7.4 BUFFER AT 





1.86 X 10- 1.76 X 10-^1
Mass of Prednisolone 
Sodium Phosphate in 
Initial Aqueous 
Phase•
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-4 1.323 X 10 
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Fraction of Total 
Mass Included.
0.589 0.635
TABLE 3.22 THE RELEASE OF PREDNISOLONE SODIUM PHOSPHATE 
FROM POLYPHTHALAMIDE MICRQCAPSULES INTO pH 7..4 
BUFFER AT 32°C DETERMINED USING ‘METHOD 4» .
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3.6 Polyphthalamide Microcapsules - Modifications to Core and Wall. 
Preparation and Characteristics
Polyphthalamide microcapsules were prepared with a modified core
or modified walls by methods based on that outlined in Section 3.2.
For each type of microcapsule with the exception of the albumin
containing microcapsules the following characteristics were
investigated. The appearance of microcapsules was examined
microscopically following freezing of microcapsule suspensions in
liquid nitrogen and freeze drying for 30 minutes before resuspending
in water and mounting in a haemocytometer. The size distribution of
microcapsule suspensions prepared as above was determined using a
Coulter Counter and the release of pilocarpine nitrate was measured
using 'Method 4'. For this,microcapsules were prepared containing
_2approximately 1.9 x 10 M pilocarpine nitrate in the aqueous phase 
together with tritiated pilocarpine. The assay technique used 
was liquid scintillation counting.
3.6.1 Polyphthalamide Microcapsules containing Gelatin and 
Crosslinked Gelatin
Preparation: Polyphthalamide microcapsules containing gelatin
were prepared as given for polyphthalamide microcapsules in 
Section 3.2 with the following exceptions: 'Solution 2'
consisted of 17% w/v gelatin in distilled water, polyethyleneimine 
was not included in the formulation, the buffer concentration in 
'Solution 1' was 0.4 5M and the Span 85 concentration was 0.53% v/v, 
'Solution 2' was also warmed to reduce its viscosity so that 
it could be mixed with an equal volume of 'Solution 1'.
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Polyphthalamide microcapsules containing crosslinked gelatin 
were prepared as above. After the addition of 75ml of 
'Solution 4' stirring was continued for 1 hour and the flask 
placed in ice. 5ml formaldehyde solution (38% v/v) was added 
and the stirring continued at a reduced speed for 12 hours.
The suspension was centrifuged, the supernatant discarded and 
the microcapsules washed with 50ml cyclohexane.
Properties : Figure 3.17 shows a photograph of polyphthalamide
microcapsules containing gelatin. In contrast to simple 
polyphthalamide microcapsules the interiors are not clear and 
the microcapsules are larger. Crosslinked gelatin containing 
microcapsules had a similar appearance. The size distributions 
of two batches of gelatin containing microcapsules are given in 
Figure 3.18 and the median volume diameters of the two batches 
are approximately 32^m and 34pm. Figure 3.19 and Table 3.23 
show the release of pilocarpine nitrate from polyphthalamide 
microcapsules containing gelatin and crosslinked gelatin.
It is apparent that the time taken for 90% of the total 
pilocarpine nitrate recovered to be released from the microcapsules 
was approximately 1 minute and 3 minutes for crosslinked gelatin 
and gelatin containing microcapsules respectively.
3.6.2 Polyphthalamide Microcapsules containing Bovine Serum Albumin 
Preparation: Polyphthalamide microcapsules containing bovine
serum albumin were prepared as given for polyphthalamide 
microcapsules (see Section 3.2) with the following exceptions.
The concentration of polyethyleneimine in 'Solution 1' was 10% w/v, 
'Solution 2' consisted of 5% w/v bovine serum albumin in distilled 





FIGURE 3.17 POLYPHTHALAMIDE MICROCAPSULES CONTAINING 
GELATIN DISPERSED IN WATER.
1 8 9













a. Batch 1, median volume diameter 32pm
b. Batch 2, median volume diameter 34pm






Initial Pilocarpine Nitrate 
Concen tration
# Gelatin 1.92 x 10~^1
A Crosslinked gelatin





FIGURE 3.19 THE RELEASE OF PILOCARPINE NITRATE FROM 
POLYPHTHALAMIDE MICROCAPSULES CONTAINING 
GELATIN AND CROSSLINKED GELATIN INTO pH





Nitrate Concentration 1.92 X 10-2m 1.88 X io-%t
Mass of Pilocarpine 
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(minutes) ^ 0.879 81.9 0.909 93.1
3 0.978 91.1 0.989 101.3
5 0.940 87.6 1.009 103.4
10 1.013 94.4 0.989 101.3
20 1.038 96.7 0.987 101.1
30 1.049 97.8 1.000 102.5
60 1.074 100.1 0.988 101.2
90 1.029 95.9 - -
120 1.073 100.0 0.976 100.0
Mass of Pilocarpine 
Nitrate Released 
Expressed as Fraction 
of Total Mass 
Included.
0.373 0.471
TABLE 3.23 THE RELEASE OF PILOCARPINE NITRATE FROM 
POLYPHTHALAMIDE MICROCAPSULES CONTAINING 
GELATIN AND CROSSLINKED GELATIN INTO pH 
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FIGURE 3.20 THE RELEASE OF PILOCARPINE NITRATE FRCM 
POLYPHTHALAMIDE MICROCAPSULES CONTAINING 
BOVINE SERUM ALBUMIN INTO pH 7.4 BUFFER 
A T  320C.
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Initial Pilocarpine 
Nitrate Concentration. 1.90 X 1 0 " %
M a s s  of Pilocarpine 
Nitrate in Initial 
Aqueous Phase.
1.427 X lO-^moles















Total M a s s  
Released in 120 











M a s s  of Pilocarpine 
Nitrate Released 
Expressed as Fraction 
of Total Mas s  
Included.
0.403
TABLE 3.24 THE RELEASE OF PILOCARPINE NITRATE FRCM 
POLYPHTHALAMIDE MICROCAPSULES CONTAINING 
BOVINE SERLM ALBUMIN INTO pH 7.4 BUFFER 
A T  32°C.
194
Release of Pilocarpine Nitrate: Figure 3.20 and Table 3.24 show
the release of pilocarpine nitrate from bovine serum albumin 
containing microcapsules which was found to be rapid.
Approximately 95% of the total amount of pilocarpine nitrate 
released was lost in the first minute.
3.6.3 Polyphthalamide Microcapsules prepared using Short Chain 
Crosslinking Molecules
Preparation; Polyphthalamide microcapsules with crosslinked 
walls prepared using the short chain crosslinking molecules 
diethylenetriamine and 1,3,5 benzentricarboxylic acid chloride 
were prepared as follows. 'Solutions 1' and '3* were the same 
as described for polyphthalamide microcapsule preparation 
(see Section 3.2) except that the Span 85 concentration was 
0.13% v/v, and polyethyleneimine was not included. The buffer 
concentration was 0.45M. 'Solution 2* consisted of 0.4M 
diethylenetriamine in distilled water and 'Solution 4' was 
composed of 0.044M phthaloyl chloride and 0.044M 1,3,5 
benzenetricarboxylic acid chloride in chloroform: cyclohexane
1 part to 5 parts by volume containing 0.13% Span 85. The 
method of preparation was as for polyphthalamide microcapsules 
except that after the addition of 'Solution 4' the suspension was 
stirred for 30 minutes before pouring into cyclohexane.
Properties : Figure 3.21 shows the appearance of polyphthalamide
microcapsules prepared using short chain crosslinking molecules.
As can be seen the majority of the microcapsules are spherical but 
there are a large proportion of aggregates present. The size 
distributions of two typical batches of these microcapsules 
are illustrated in Figure 3.22. The median volume diameters
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FIGURE 3.21 POLYPHTHALAMIDE M I C R O C A P S U L E S  PREPARED














a. Batch 1, median volume diameter 34jim
b. Batch 2, median volume diameter 38;um
FIGURE 3.22 SIZE DISTRIBUTION OF TWO BATCHES OF
POLYPHTHALAMIDE MICROCAPSULES PREPARED
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FIGURE 3.23 THE RELEASE OF PILOCARPINE NITRATE FROM 
POLYPHTHALAMIDE MICROCAPSULES PREPARED 
USING SHORT CHAIN CROSSLINKING 
MOLECULES INTO pH 7.4 BUFFER AT 32^0.
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Initial Pilocarpine 
Nitrate Concentration. 1 . 8 6  X lO-^M
Mass of Pilocarpine 
Nitrate in Initial 
Aqueous Phase.
1.395 X  10“^moles






















1 0 1.323 96.8
2 0 1.354 99.1
30 1.363 99.8
60 1.331 97.4
90 1 .363 99.8
1 2 0 1.366 1 0 0 . 0
Mass of Pilocarpine 
Nitrate Released 
Expressed as Fraction 
of Total Mass 
Included.
0.584
TABLE 3.25 THE RELEASE OF PILOCARPINE NITRATE FRCM 
POLYPHTHALAMIDE MICROCAPSULES PREPARED 
USING SHORT CHAIN CROSSLINKING MOLECULES 
INTO pH 7.4 BUFFER AT 32QC.
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of the two batches are 34pm and 38pm and there is a 
relatively high percentage of particles with diameters in the 
40pm to 60pm size range. Figure 3.23 and Table 3.25 show the 
release of pilocarpine nitrate from the microcapsules. The 
release was rapid, approximately 90% of the total drug recovered 
being released in the first five minutes.
3.6.4 Polyphthalamide Microcapsules prepared by a Double Polymc.r\’s<xbjiorv 
Technique
Preparation; Polyphthalamide microcapsules were prepared by a 
double polymerisation technique using two methods. These are 
referred to as double walled microcapsules.
Double Walled Microcapsules Method A : Microcapsules were
prepared as described for polyphthalamide microcapsules in 
Section 3.2, After the addition of 75ml 'Solution 4' and 
stirring for 3 minutes the suspension was poured into 100ml 
cyclohexane and centrifuged. The supernatant was removed 
and the microcapsules resuspended in 75ml 1% Span 85 in 
cyclohexane. Whilst stirring at 2,000 rpm 10ml of a solution 
consisting of 0.33M phthaloyl chloride in chloroform:cyclohexane 
1 part to 5 parts by volume containing 1% v/v Span 85 was added. 
Stirring was continued for 3 minutes after which the suspension 
was centrifuged, the supernatant discarded and the microcapsules 
washed using 50ml cyclohexane.
20 0
Double Walled Microcapsules Method B : Microcapsules were
prepared as described for polyphthalamide microcapsules in 
Section 3.2. After the addition of 75ml 'Solution 4* and 
stirring for 3 minutes the suspension was poured into 50ml 
cyclohexane and centrifuged. The microcapsules were harvested, 
freeze dried for 5 hours and immersed in 6ml equivolume 
aqueous 0.4M piperazine solution and 0.45M carbonate-bicarbonate 
buffer containing 10% w/v polyethyleneimine. Following 
centrifugation the supernatant was removed, the microcapsules 
were resuspended in 75ml 'Solution 3' and the suspension was 
stirred at 2,000 rpm in a 250ml conical flask for 1 minute.
75ml 'Solution 4' was added and stirring continued for 3 minutes. 
The suspension was poured into 100ml cyclohexane and the 
microcapsules again centrifuged. The supernatant was removed 
and the microcapsules dispersed in 50ml cyclohexane. This 
suspension was then centrifuged and the supernatant discarded.
Properties; Figure 3.24 shows the appearance of double walled 
polyphthalamide microcapsules. The interiors are clear and 
the majority of type A microcapsules are spherical. A large 
number of aggregates are present in the microcapsules prepared 
using Method B. There are also a large proportion of what 
appear to be small lumps of polymer present and the 
microcapsules are generally crenated. The size distributions 
of the two types of microcapsule are given in Figure 3.25 
which shows that in both cases the median volume diameter 
is approximately 25pm. The double walled microcapsule suspensions 
prepared by Method B however consist of a larger proportion 
of particles in the 40pm to 60pm size range. The release
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of pilocarp, ine nitrate from the two types of double walled 
microcapsules is given in Figure 3.26 and Table 3.26. It may 
be seen from Figure 3.26 that the pilocarpine nitrate was 
released rapidly. In the case of the microcapsules prepared 
using Method A 90% of the mass of pilocarpine nitrate released 
in 120 minutes was released within the first minute. A 
similar value was obtained for microcapsules prepared using 
Method B although from the release profile it appears that 
the remaining pilocarpine nitrate was released more slowly.
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FIGURE 3.24 DOUBLE WAL LE D POL YFH THAL.4M I DE M I CROC Al 8ULE S 
FREFARHD USING a) METHOD A AND b) METHOD 
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FIGURE 3,25 SIZE DISTRIBUTION OF TWO BATCHES OF
DOUBLE WALLED POLYPHTHALAMIDE MICROCAPSULES 
PREPARED USING a) METHOD A AND b V  METHOD B.
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1.6_
Initial Pilocarpine Nitrate 
Concentration
• Method A 1.86 x 10~^l
O Method B 1.82 x 1 0 " %
P  w i  * 0 „
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FIGURE 3.26 THE RELEASE OF PILOCARPINE NITRATE FRCM 
DOUBLE WALLED POLYPHTHALAMIDE M I C R O CAPSULES 
PREPARED BY M E T H O D  A AND ME T H O D  B INTO







Nitrate Concentration. 1.86 X 10-% 1.82 >: 1 0 - %
M a s s  of Pilocarpine 
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Aqueous Phase.
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(minutes) ^ 0.616 92.1 1.419 93.5
3 0.624 93.3 1.452 95.7
5 0.642 96.0 1.433 94.4
10 0.644 96.3 1.435 94.5
20 / 0.645 96.4 1.424 93.8
30 0.658 98.4 1.459 96.1
60 0.673 100.5 1.548 102.0
90 0.666 99.6 1.550 102.1
120 0.669 100.0 1.518 100.0
24
hours
0.683 102.1 1.612 106.2
M a s s  of Pilocarpine 
Nitrate Released 
Expressed as Fraction 
of Total Mass 
Included.
0.277 0.208
TABLE 3.26 THE RELEASE O F  PILOCARPINE NITRATE FROM 
DOUBLE WALLED POLYPHTHALAMIDE MICROCAPSULES 
PREPARED BY M E T H O D  A  AND ME T H O D  B INTO pH 7.4 
BUFFER A T  32^0.
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3.7 Electron. Microscopy of Microcapsule Walls
Detail of the microcapsule walls was investigated using electron 
microscopy. The method used for scanning electron microscopy of 
samples prepared by a critical point drying technique is outlined 
in Section 3.3.1. For transmission electron microscopy microcapsule 
suspensions were prepared in acetone. The samples together with an 
aqueous solution of ruthenium red were placed in a plastic vial and 
rotated. Rotation was then continued for 12 hours after which the 
acetone water mixture was replaced by an epoxy resin. The resin was 
hardened by heating in an oven for 12 hours and sectioned using a 
microtome. Following sectioning, the layers were mounted on copper 
grids and stained with lead citrate and uranyl acetate.
Scanning electron micrographs of the surface of a polyphthalamide 
microcapsule are shown in Figure 3.27. The microcapsule surface 
is seen to be extremely uneven with large indentations, possibly 
pores or voids of approximately 0.1pm diameter. Figure 3.28 shows 
transmission electron micrographs of sectioned polyphthalamide 
microcapsule walls illustrating the appearance of a transverse section 
of the walls. The wall is estimated to be 0.6 to O.Bp in thickness 
and there are three clearly distinct regions within it.
From the core outwards;
1. a dense discontinuous hodular layer
2. a narrow dense continuous layer and
3. a relatively thick loosely attached, less dense layer
To ensure that the nodular layer was part of the wall and not due
to the resin or the ruthenium red its composition was analysed 
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to the transmission electron microscope. This technique allows 
the distribution of certain elements within a sample to be 
identified and analysed semi-quantitatively. Analysis of a point 
in a nodule present in the section of wall shown in Figure 3.30a 
resulted in the spectrum given in Figure 3.29. The large peak 
at 8 eV corresponds to copper which was the material used to form 
the mounting. A peak is also seen at 3.2 eV which is the M peak 
for uranium. The entire specimen shown in Figure 3.30a was then 
scanned for emissions corresponding to 3.2 eV and the picture in 
Figure 3.30b constructed. The image of the microcapsule wall 
and the image of the emissions correpsonding to 3.2eV coincide 
indicating that the uranium acetate stain was present in the 
nodules and in the bulk of the wall. Since neither the resin nor 
the ruthenium red will stain with uranyl acetate (137) the 
observed inner layer must be part of the wall.
The appearance of the microcapsule walls prepared using the short 
chain crosslinking molecules is represented in Figure 3.31 from 
which no obvious difference between these microcapsule walls and 
those of polyphthalamide microcapsules is apparent. Again the surface 
is seen to be rough with discontinuities or pores present, the 
majority or which are less than 0.5]im diameter. The transmission 
electron micrographs (Figure 3.32) however do indicate a difference 
between the two types of capsule. The microcapsule section in 
Figure 3,32b which is estimated to be approximately 0.2 to 0.3^m 
in thickness consists of only two layers.
1, a dense discontinuous outer layer
2. a thin less dense continuous inner layer
2 ; 2
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FIGURE 3,31 SCANNING ELECTRON MICROGRAPH OF THE 
SURFACE OF POLYPHTHALAMIDE MICROCAFSULES 
PREPARED USING SHORT CHAIN CROSSLINKING
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Figures 3.33, 3.34 and 3.35 are the scanning electron and transmission 
electron micrographs respectively of microcapsules prepared with double 
layer walls. The appearance of the outer surface of the walls 
(Figure 3.33) is the same as that for polyphthalamide microcapsules.
The transmission electron micrographs however do show differences.
The section from the microcapsules prepared by method A (Figure 3.34) 
consists of two regions, a nodular inner layer and a relatively dense 
outer layer. There is also some less dense material present 
on the surface. The wall thickness is estimated to be 0.4 to O.S^m. 
The section from Type B double walled microcapsules clearly shows the 
presence of two distinct walls. Figure 3.35b shows the whole 
microcapsule from which the specimen in Figure 3.35a was taken.
The microcapsule is collapsed to an extent where in parts the walls 
are touching and it is evident from Figure 3.35a that the wall is 
composed of two bands. The inner band is consistent with the 
structure found in polyphthalamide microcapsule walls. The outer 
band comprises an inner diffuse layer which in places appears 
hollow and an outer thin dense layer. This double wall is 
estimated to be approximately 0.3 to 0.4ym in thickness.
Gelatin microcapsules collapsed during the preparative technique 
for electron microscopy and therefore the structure of these 
microcapsules was not investigated using this method.
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3.8 Permeability of Polyamide Films
The diffusion and permeability of solutes through a polymer may be 
determined from film permeability measurements and construction 
of a Barrer Plot (138), a method which has been used extensively 
elsewhere (68, 73). In order to assess the permeability 
characteristics of polyphthalamide membranes, the permeability of 
pilocarpine nitrate through films prepared by interfacial 
polymerisation was determined. The permeability of ethyl-4- 
aminobenzoate through such films was also investigated as an 
example of a solute whose interaction with polyamides is well 
characterised (67, 68, 73). For comparative purposes the 
permeability of both pilocarpine nitrate and ethyl-4-aminobenzoate 
through a commercially available non-oriented nylon 6 film was also 
determined.
3.8.1 Preparation of Polyphthalamide Films
Polyphthalamide films were prepared by an interfacial 
polycondensation technique. 60ml cyclohexane containing 
0.01 moles phthaloyl chloride was placed in a 23cm diameter 
watch glass. 60ml of aqueous 0.4M piperazine containing 20ml 
0.45M carbonate-bicarbonate buffer was introduced through a funnel 
under the cyclohexane layer. The film formed at the interface 
was of insufficient strength to support its own weight when 
removed from the reaction solutions. Consequently, after 
removing the polymer film formed initially a metal grid was placed 
in the aqueous solution and after approximately 30 seconds 
'lifted' through the aqueous/organic interface, thus coating 
the grid with the freshly formed polymer.
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3.8.2 Estimation of Polyphthalamide Film Thickness
Due to the fragility of the polyphthalamide films formed and 
their water swollen nature it was not possible to determine 
film thickness using conventional methods such as a 
micrometer. The approximate thickness of polyphthalamide 
films mounted on a metal grid was therefore determined using 
a vernier microscope. Five measurements were made on each of 
five samples which gave values ranging between 20jam and 140^m.
The mean values for each sample were 75pm, 90pm, 50pm, 75pm 
and 80pm which gave an overall mean of approximately 75pm and 
a sample standard deviation of 40pm. The large variation in 
film thickness was attributed to difficulty in coating the 
grid with a uniform layer of polymer and also in focussing 
the vernier microscope on the edge of the film. The values 
of film thickness can therefore be considered to be only 
approximate.
3.8.3 Estimation of Non-Oriented Nylon 6 Film Thickness
The thickness of non-oriented nylon 6 film (Carron Grade 77c) 
was estimated using a micrometer. Five measurements were made 
on each of five samples of dry film and the mean thickness estimated 
to be 21.8pm (S.D. = 2.6pm). It has been shown previously 
that wet and dry film thicknesses are not significantly 
different for nylon 6 membranes (68).
22 0
3.8.4 Measurement of Permeability 
General Method
Permeability cells of an all glass construction were used, 
which consisted of a donor and receptor compartment separated 
by a polyamide film as shown in Figure 3.36. Each compartment 
had a capacity of 50ml and the aperture diameter was 3.5cm.
The two compartments were tightly clamped together and in the 
case of the polyphthalamide film, the film supported by the 
metal grid was clamped between the two compartments. The 
donor and receptor solutions and the assembled apparatus were 
equilibrated to 32°C in a water bath. Immediately before 
the start of an experiment the permeability cell was quickly 
dismantled and a freshly prepared polyphthalamide film 
or a nylon 6 film clamped between the cells and reimmersed 
in the water bath. The solutions were added simultaneously 
into their respective compartments at the same rate to avoid 
undue distension of the membrane. This was achieved by 
adding the solutions via burettes positioned above the donor 
and receptor compartments. The solutions in each compartment 
were stirred by an all glass paddle stirrer at 200 rpm shaft 
speed. It was not possible to use a faster stirring speed due 
to the fragility of the membrane. The donor solution
consisted of a solution of the appropriate solute in buffer, 
and the receptor solution was the buffer solution without 
solute. Samples were removed from the receptor solution at 
timed intervals for assay. The sample volume for the assay 
of pilocarpine nitrate by liquid scintillation counting was 
1.5ml, and 1.0ml for the assay of ethyl-4-aminobenzoate.
The mass of solute removed in each sample was corrected for 



























Permeability of Polyphthalamide Film
The permeability of pilocarpine nitrate through
polyphthalamide film is illustrated in Figure 3.37 and the
data are given in Table 3.27. The donor solution used was 
-21.85 X 10 M pilocarpine nitrate in pH7.4 isotonic phosphate 
buffer also containing tritiated pilocarpine. It can be 
seen from Figure 3.37 that the permeation of the pilocarpine 
nitrate was rapid, the donor and receptor solutions reaching 
equilibrium in approximately 120 minutes. Comparison of the 
data for two separate determinations shows good reproducibility.
The permeation of ethyl-4-aminobenzoate through polyphthalamide 
film is represented in Figure 3.38. The two donor solutions 
investigated were (a) 3.0 2 x 10~^M ethyl-4-aminobenzoate in 
pH 1.0 Clark Lub's buffer and (b) 3.01 x 10 M ethyl-4-aminobenzoate 
in pH 7.4 Sorensens phosphate buffer. Using a pKa value of 
2.57 (67) the solute would be approximately 97% and 1,5 x 10 
in the ionised form at the two respective pHs. It has been 
reported that ethyl-4-aminobenzoate degrades rapidly at high 
temperatures and low pH (139). However, at the temperature and 
pH of this experiment the degradation of the solute over the 
time period studied was considered negligible. Examination of 
Figure 3.38 and Table 3.27 show that there is no apparent 
difference in the permeation of ionised and unionised 
ethyl-4-aminobenzoate through the polyphthalamide film.
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Permeability of Non-Oriented Nylon 6 Film
The data presented in Figure 3.39 illustrate the permeation 
of pilocarpine nitrate and ionised and unionised 
ethyl-4-aminobenzoate through non-oriented nylon 6 film.
The donor and receptor solutions were as described for the 
permeability of polyphthalamide film. As can be seen from 
Figure 3.39 and Table 3.28 the pilocarpine nitrate and ionised 
ethyl-4-aminobenzoate did not permeate the nylon 6 film within 
5 hours. The observed lag time for the permeation of unionised 
ethyl-4-aminobenzoate was approximately 40 minutes. The 
permeability coefficient of unionised ethyl-4-aminobenzoate . - 
through non-oriented nylon 6 film was calculated using 
Equation 3.4.
dC, PAC.
dt IV. (equation 3.4)
where is the receptor solution concentration
is the donor solution concentration
is the volume of the receptor compartment
A is the cross sectional surface area
1 is the film thickness
P is the permeability coefficient
Using the slope of the Barrer plot dC‘
( ' dt ')
the value of the
permeability coefficient was calculated to the 1.06 x 10-12
2 -1 M sec
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•  Determination 1 






FIGURE 3.39 THE PERMEATION OF PILOCARPINE NITRATE IN pH
7.4 BUFFER (A), ETHYL-4-AMINOBENZOAIE IN pH
7.4 BUFFER (#0) AND ETHYL-4-AMINOBENZOAIE IN 
pH 1.0 BUFFER (■). THROUGH NON-ORIENTED 
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3.9 Polyphthalamide Microcapsules - In Vivo Studies
The effect of microencapsulated pilocarpine nitrate on the pupil 
diameter of the rabbit was investigated. A suspension of 
polyphthalamide microcapsules for instillation into the eye was 
prepared as follows. Polyphthalamide microcapsules were
frozen in liquid nitrogen and freeze dried for a period of five 
hours. These were then immersed in an aqueous solution of
7.38 X 10 pilocarpine nitrate to give a concentration of 
microcapsules of approximately 25% v/v. The suspension was 
allowed to equilibrate for 12 hours after which time 0.05ml of
this suspension was placed in the conjunctival cul-de-sac of the left 
eye of each of two rabbits using a replicating pipette. Determination 
of the miosis induced by the pilocarpine nitrate was made by 
measuring the pupil diameter of the left eye using a plastic rule 
prior to and at timed intervals after dosing. The rabbits were 
maintained under constant lighting conditions.
After a rest period of one week this was repeated using a
7.38 X 10”^M aqueous solution of pilocarpine nitrate. The left 
eye of the same rabbits was again used. Figure 3.40 shows the 
effect of both preparations on the pupil diameter of both rabbits.
In the case of both the pilocarpine nitrate solution and the 
microcapsule suspension in rabbit A and rabbit B the diameter reached 
a minimum at approximately 30 minutes post instillation. The pupils 
returned to their original diameter within the accuracy of measurement 
after approximately 180 minutes.
The dwell time of polyphthalamide microcapsules in the left eye of 
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99MPolyphthalamide microcapsules containing Te labelled albumin, 
a gamma ray emitter, were prepared as in Section 3.2. The labelled 
albumin was dissolved in the aqueous phase prior to encapsulation to 
give a concentration of 2mg per ml and an activity of approximately 
20 mCi per ml. After preparation the suspension was frozen in 
liquid nitrogen and freeze dried. Sufficient water was then 
added to the dried microcapsules to form a suspension of approximate 
concentration 5% v/w (determined by Coulter Counter). 0.05ml of 
the suspension was instilled into the left eye of the rabbit and the 
animal located such that the eye was positioned for observation by 
the Maxi Camera 11 which was fitted with a medium pin hole collimator 
and spacer. Images of total gamma emission over 15 second periods 
were recorded continuously for 15 minutes and discontinuously for 
up to approximately 90 minutes. Experiments with fluoresceinated 
albumin showed that the albumin remains inside the microcapsules 
(see Section 4.3).
As a comparison an estimation of the rate of clearance of labelled
albumin in aqueous solutions was also made. 0.05ml of aqueous 
99MTc labelled albumin solution of concentration lOmg per ml and an 
activity of ImCi per ml was instilled into the left eye of the 
rabbits used above 24 hours prior to dosing with the microcapsules. 
The rabbit was located such that the left eye was positioned for 
observation by the Maxi Camera 11 and images of gamma emission over 
a 15 second period were recorded continuously for 15 minutes.
From the images obtained regions of interest were drawn around the 
orbit of the eye and the tear duct. The activity remaining in 
these areas at given times was calculated. Corrections were made
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for background count and for technetium decay using Equation 3.5,
(equation 3.5)
0.693 where X = ' -
o • U
t = time in hours
6.0 is the half life of technetium in hours.
Figure 3.41 represents the difference in dwell time in the rabbit
99Meye between polyphthalamide microcapsules containing Tc labelled 
albumin and an aqueous solution of ^^^Tc labelled albumin. The 
aqueous albumin solution was cleared rapidly from the eye, reaching 
approximately 10% of the instilled mass within 15 to 20 minutes. 
Approximately 60% of the instilled mass of microcapsules however 
was still present in the eye after 90 minutes. Photographs of 
selected gamma camera images are shown in Figures 3.42 to 3.44.
Figure 3.42 shows the distribution of labelled albumin solution 
in the eye of rabbit A as a function of time whereas Figure 3.43 
shows the distribution of polyphthalamide microcapsules 
containing labelled albumin also in the eye of rabbit A as a 
function of time. In both Figures, Plates 1, 2 and 3 are the 
distribution at times 0,15 seconds and 45 seconds respectively.
In Figure 3.42 Plate 4 gives the distribution at 7 minutes 45 seconds 
and in Figure 3.43 Plate 4 gives the distribution at 6 minutes 
45 seconds. The shade of colour is a function of the intensity 
of activity, white being the greatest concentration of activity 
and blue the least. It may be seen from Figure 3.42 that after 
15 seconds the albumin solution is beginning to drain through 





















FIGURE 3.41 THE DIVELL TIME QF ALBUMIN AND 
POLYPHTHALAMIDE MICROENCAPSULATEC
ALBUMIN IN THE RABBIT EYE.
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almost complete. In contrast the series of images in Figure 3.43 
showing the distribution of polyphthalamide microcapsules containing 
albumin indicate that the microcapsules collect over the inner 
portion of the eye and form a 'horse-shoe'. They are not evenly 
dispersed over the surface and there are no signs of drainage occurring. 
Figure 3.44 shows the distribution of polyphthalamide microcapsules 
containing labelled albumin at longer time periods. Plates 1, 2 and 
3 are the left eye of rabbits A, B and C at 45 minutes, 30 minutes 
and 20 minutes respectively. In all cases drainage into the 
lachrymal duct has started to occur although a large proportion of 
microcapsules are still present on the surface of the eye.
235
It) in
■a V m mc c 01 ■O0 0 4-> Cu V 3 0




< < < <
f- H h f-l
M 03 CQ cc
DC 23 CQ 00
< < < <DC •• DC •• % •• DC
F lG U R l- 3 .4 2  THH CLKA^ANCH. OF Tc LABF.I.LKD A l.R LM lN  S(->LUTK>N 
F v'(M n iF  WABBl r  KYF..
236
! I i r i / t  Î .4  i 'HI c;n AFA.v,.r. (u  i c i  vt nn :A L/V : iu k  ^,ICHC^CAI'sn-ES c o N r A ix ix u  
rc  1 A B I.l.I  .»•.!> AI.HI.M IN  c I 1 K ’N F l«  f :  11 IF F ABM I  f  F.YT'.
237
FIGURK 3 .4 4  rHK CI.KARANCR OF FOLYI H m A l.^V IIlJF. N: ICROCAPSIHES C O N TA IM N G  
rc  LABFLLF.D A LW IM IN  SOLUTION FRCM fHI-l R ABBI F EYF. AT 
LONG rU iF : I ’K R IO D S.
DISCUSSION
238
4.1 Preparation and Properties of Nylon 6.10 and Polyphthalamide Microcapsules 
Previous attempts to prolong the actions of drugs in the treatment 
of glaucoma have involved the use of viscolysers or large reservoir 
devices such as the Ocusert (see Section 1.1.3.4). An alternative 
approach to controlling the release of drugs to the eye is to prepare 
a suspension of drug containing microcapsules which, on ophthalmic 
administration, will slowly release their contents. This concept 
is based on literature reports concerning the preparation and properties 
of microcapsules which show that:
1) Microcapsules containing a variety of drug substances can be 
readily prepared using a number of techniques (46-50, 90, 99,
106, 107, 140).
2) The release of drugs from microcapsules can be controlled 
(99, 122, 141, 142).
3) Microcapsules can be prepared having a mean diameter of less 
than 20ym, a size which is considered suitable for the 
administration of particles to the eye (29, 87, 143, 144, 145),
4) Microcapsules prepared by some techniques are flexible (29),
a property which may reduce irritations caused by particles when 
administered to the eye.
Of the many methods available for the preparation of microcapsules 
(Section 1.2.2) few are designed to encapsulate drugs dissolved or 
dispersed in an aqueous core. Coacervation for example is used 
solely for the encapsulation of lipophilic molecules whereas 
physical methods of microencapsulation such as the Wurster Process 
generally result in the encapsulation of solid particles. Of the 
methods used for preparing microcapsules containing an aqueous core, 
there have been several reports concerning the interfacial polymerisation
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technique. Using this technique, some of the more frequently reported 
polymers utilised as wall materials are the polyamides (87-90, 92-112, 
118-120, 126-129). Other examples include polyurethane and 
polyphenolester (146, 147). From the literature it appears that 
polyamide microcapsules can be readily prepared and therefore this 
type of microcapsule was selected for study in this investigation.
The majority of reports concerning the preparation of this type 
of microcapsule are based on the original method described by Chang 
and others (29) for the preparation of nylon 6.10 microcapsules.
An outline of this method is given in Section 1.5.2,1. Attempts to 
prepare microcapsules in this study using this method were however 
unsuccessful and resulted only in the formation of what appeared to be 
small particles of polymer and emulsion droplets. In the successful 
preparation of polyamide microcapsules, other workers have previously 
modified the technique of Chang and others. Such modifications 
include the microcapsule harvesting technique, the method of 
emulsion formation, the composition of the reactant solutions and the 
reaction conditions (87, 89, 92, 93, 95, 98, 99, 100, 110). These 
are described fully in Section 1.5.2. Attempts to modify the initial 
method of preparation based on these reports were unsuccessful in 
this investigation in producing microcapsules.
It was noted that in Chang's original method of preparing nylon 6.10 
microcapsules the aim was to encapsulate haemoglobin (29). Haemoglobin 
contains amino groups which during polymerisation react with the linear 
polymer chains thereby crosslinking the polymer and becoming incorporated 
into the microcapsule membrane (94). This may result in the formation 
of a more stable membrane giving rise to the successful formation 
of microcapsules. Other reports have indicated that proteins such
as albumin are also incorporated into the microcapsule walls by 
reaction of their amino groups with the acid chloride molecules in 
the polymer chains (120). It was suggested by Aisina and others 
(94) that polyethyleneimine could similarly be used to crosslink 
the linear chains of polymer forming a network as shown in Figure 4,1. 
It is expected that the microcapsule membranes with such a crosslinked
Figure 4.1
Schematic Representation of the Structure of Microcapsule 
Membranes prepared containing Polyethyleneimine
AQUEOUS
PHASE






O  Represents polyethyleneimine 
m o l e c u l e s .
 --- Represents polyamide chains.
structure will be stronger than those prepared in the absence of 
crosslinking agents and therefore the inclusion of crosslinking 
agents such as haemoglobin or polyethyleneimine will result in an 
increased microcapsule yield. In this study the incorporation of 
10% w/v polyethyleneimine in the aqueous phase used in the hitherto 
unsuccessful methods of microencapsulation, resulted in the 
successful formation of nylon 6.10 microcapsules (Section 3.IT).
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This contrasts to the work of Koishi and others (87) and Shigeri and 
others (89) who successfully prepared microcapsules using an interfacial 
polymerisation technique in the absence of any crosslinking agents.
The methods used however resulted in the preparation of relatively 
small microcapsules of approximately 2ym diameter, and no indication 
of the yield obtained was given.
In order to instill solid particles in the eye without irritation 
it has been suggested that their diameter should be less than 
20]im (135). Conventionally microcapsules are considered to be of 
a size ranging from a few micrometers in diameter to a few millimeters 
(31) although the diameters of those prepared by interfacial 
polymerisation techniques are usually in the range 2.0pm (89) to 
80pm (29). The microcapsules initially prepared in this study 
had diameters of approximately 200pm, There are a number of 
parameters which are known to influence the size of microcapsules 
prepared by interfacial polymerisation. These are primarily 
factors which affect emulsion droplet size and emulsion stability.
With regard to emulsion droplet size, it is expected that an increase 
in the total shear in an emulsion system brought about by an increase 
in stirring speed, a change in the shape of container or a change 
in the type of stirrer, will result in a decrease in the size of the 
emulsion droplets formed (14 8). In a microencapsulation system, 
this will in turn result in a reduction in microcapsule size.
For example, Koishi and others (87) reported that in the preparation 
of polyphthalamide microcapsules, increasing the stirring speed from 
237 rpm to 1,100 rpm reduced the microcapsule size from 8.55pm to 
2.45pm. Chang and others (29) also reported that for an increase in 
stirring speed from '1' to '5* there was a reduction in microcapsule
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size from 80pm to 30pm. A similar effect was found in this 
investigation in which the diameters of nylon 6.10 microcapsules 
decreased from approximately 200pm to 20pm with a corresponding 
increase in stirring speed from approximately 500 rpm to 2,000 rpm 
(Section 3.1.1.2). There have been no reports in the literature 
concerning the effect of container shape on microcapsule size.
However, several authors have reported the effect of mechanism of 
emulsion formation. Chang and others (29) for example found that 
the minimum diameter of microcapsules which could be prepared using 
a magnetic stirrer was approximately 20pm, whereas smaller 
microcapsules of about 2pm diameter could be prepared using an 
homogeniser. Of the methods of émulsification investigated in this 
study, only an overhead stirrer motor connected to a paddle stirrer 
was found to produce satisfactory microcapsules. This conflicts 
with the use of a magnetic stirrer and homogeniser in the successful 
preparation of microcapsules reported by Chang and others (29) and 
may arise due to differences in stirring speed. The magnetic stirrer 
used in this investigation may have been of insufficient speed to 
form a stable emulsion, or alternatively any microcapsules formed 
may have been too large to maintain their integrity. Conversely 
the emulsions formed by the ultrasonic probe and homogeniser 
may have been of too small a droplet size for microcapsule
formation or perhaps the extreme shear in the system caused the
disintegration of already formed microcapsules.
The effect of surfactant concentration on microcapsule size has
been shown by Koishi and co-workers (87) in the preparation of
polyphthalamide microcapsules. It was reported that with an 
increase in surfactant (Span 85) concentration from 5 to 15% v/v.
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the mean volume diameter of the microcapsules formed decreased from 
3.34pm to 3.16pm. Similarly, in the preparation of nylon 6.10 
microcapsules Chang and others (29) found that on increasing the 
Span 85 concentration from 1 to 5% v/v the mean microcapsule 
diameter decreased from approximately 80pm to 40pm. Above 5% v/v 
however increasing the surfactant concentration had no appreciable 
effect on microcapsule size. In this study, no effect of 
surfactant concentration on microcapsule size was observed. However, 
during the initial studies, observations of microcapsule size were 
made using an eye piece micrometer with which only gross changes 
in size could be detected. Also the effect of surfactant 
concentration may not have been observed since a limited range of 
concentrations were investigated. Similarly, no effect of 
temperature on microcapsule size was observed although it has been 
reported previously that an increase in temperature results in a 
reduction in microcapsule size (89).
Development of the preparation of nylon 6.10 microcapsules 
containing polyethyleneimine based on the factors affecting 
microcapsule size discussed above resulted in the successful 
preparation of nylon 6.10 microcapsules of approximately 20pm 
diameter. In agreement with the work of Chang and others (29) 
who concluded that it was not possible to prepare microcapsules 
with diameters below 20pm using a magnetic stirrer, attempts to 
prepare microcapsules below 20pm using the Overhead stirrer in this 
investigation were unsuccessful.
From the various techniques published in the literature concerning 
the preparation and recovery of polyamide microcapsules prepared by
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the interfacial polymerisation method, it is apparent that each 
technique has yielded microcapsules with differing properties.
It is suggested therefore that properties such as yield, size, 
size distribution and appearance are characteristic only for a 
given microencapsulation system and will vary widely between 
experimental workers. In order to study the properties of 
microcapsules prepared by interfacial polymerisation, Chang and 
others (29) reported a method by which the formed microcapsules 
were transferred from the organic reaction mixture to an aqueous 
phase. This involved quenching polymerisation by pouring the 
reaction mixture into the mixed solvent system which was followed 
by centrifugation, washing in cyclohexane and transference to an 
aqueous Tween 20 solution prior to dispersion in saline. Other 
workers have used similar methods involving quenching in the 
appropriate solvent system followed by washing with various 
concentrations and volumes of Tween 20 solution and resuspending in 
sodium chloride (92), phosphate buffer solution (103), Tween 20 
solution (87) and Polysorbate 20 solution (100). Tween 20 and 
Polysorbate 20 are believed to aid dispersion and prevent the 
microcapsules aggregating. Alternatively Mori and colleagues (110) 
collected microcapsules either by filtration or centrifugation 
followed by washing in ethanol prior to washing with water, whereas 
Luzzi and others (99) recovered their microcapsules either by a 
spray drying process or by flash evaporation. The reasons for the 
use of these different methods were not however given. In the 
preparation of nylon 6.10 microcapsules in this study it was found 
that quenching in cyclohexane in place of the mixed solvent system 
aided centrifugation due to the increased density difference between 
the microcapsules and the suspending medium. Furthermore, washing
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in acetone prior to the aqueous Tween 20 solution used by Chang 
and others (29) removed the bulk of the hydrophobic cyclohexane 
from the surface of the microcapsules and therefore aided dispersion 
in the aqueous medium. Recovery of the microcapsules from the 
aqueous Tween 20 solution by centrifugation as described by 
Chang and others however, was variable and full recovery was not 
achieved. This is thought to be due to the viscosity of the 
Tween 20 solution, its similarity in density to that of the 
microcapsules and the presence of trace amounts of cyclohexane. 
Separation from the medium by filtration, as suggested by Mori 
and others (110) was similarly unsuccessful. Although filtration 
through sintered glass and membrane filters removed some excess 
liquid from the microcapsule suspensions, it was observed that 
the filters readily blocked and the remaining microcapsule slurry 
contained a large proportion of extracapsular water (approximately 
70-80%v/v as determined by Coulter Counter). This high volume of 
extracapsular water is thought to arise due to blockage of the 
filter by the microcapsules or to the formation of a packed bed of 
microcapsules on the surface of the filter which prevents the passage 
of liquid. Similar handling difficulties were encountered in an 
attempt to prepare a column of microcapsules through which buffer 
solution could be passed in order to simulate the release of drug 
in the eye. Another possible explanation for the presence of the 
high water content following filtration is obtained from a 
consideration of the packing of spheres and the volume of voids 
between them. For example, the porosity of orthorhombic packed 
monodisperse spheres has been calculated to be 40% (149) where 
porosity is defined as the ratio of the open space volume to the 
combined open space and solid material volumes, expressed as a
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percentage. For cubic packed spheres this value was reported to 
be 47%. Consequently, if during filtration, the microcapsules in the 
bulk of the suspension remained as spheres, it is unlikely that all 
the extracapsular water would be removed.
Rotary evaporation, drying over phosphorous pentoxide and evaporation 
to the atmosphere were similarly unsuccessful in removing the 
extracapsular water without destroying the integrity of the 
microcapsules. Based on the method described by Mori and others (110) 
however, it was considered that washing the microcapsules in acetone, 
a solvent miscible with both cyclohexane and water, might yield a 
product suitable for direct dispersion into water. Microcapsules 
recovered by this method were readily redispersed in water to yield 
unflocculated suspensions. Concentration of these aqueous 
suspensions could be achieved either by rotary evaporation or by 
freeze drying. Freeze drying and rotary evaporation were also 
carried out on the acetone and cyclohexane washed microcapsules 
following centrifugation. The latter technique was used in the 
measurement of release from polyphthalamide microcapsules and is 
discussed in Section 4.2.2. In order to maintain the integrity 
of their nylon 6.10 microcapsules on storage Chang and co-workers (29) 
dispersed the microcapsules in isotonic saline. Shiba and others (92) 
similarly used 0.9% sodium chloride solution, whereas Grunwald and 
Chang (103) reported O.IM phosphate buffer as a suitable suspending 
solution. In this investigation however, water was found to be 
a suitable medium in which to maintain the microcapsules. No 
osmosis such as that described by Chang and others (29) was observed to 
occur on dispersion of the microcapsules in hypertonic and hypotonic 
solutions. This difference is possibly due to the absence of a large
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percentage of high molecular weight material (such as haemoglobin), 
from the core of the microcapsules prepared in this work.
Polyamide microcapsule walls are thought to be impermeable to
high molecular weight solutes but permeable to those of low molecular
weight (119). Microcapsules containing a large
proportion of haemoglobin might therefore be expected to exhibit
similar osmotic properties to those found in cells with a
semi-permeable membrane such as red blood cells. The absence
of high molecular weight solutes or a considerable reduction in
their concentration in the microcapsules could therefore account
for the lack of osmotic effect observed.
One property of microcapsule suspensions which has been studied by 
a number of workers is their size distribution. Various techniques 
have been used to assess this property for example, Takenaka and 
others (143) used a particle size analyser to determine the size of 
gelatin acacia microcapsules. The most frequently reported technique 
however, involves linear measurement of the diameter of microscope 
images of aqueous microcapsule suspensions. This technique was used 
by Nixon and Hassan (150) for determining the size of gelatin acacia 
microcapsules containing thiabendazole and by Takenaka and others 
(151) for determining the size of enteric coated microcapsules 
prepared by spray drying. This technique was also used by Shigeri 
and others (89), Jenkins and Florence (106) and by Koishi and 
colleagues (87) for determining the size distributions of nylon 6.10 
and polyphthalamide microcapsules prepared by the interfacial 
polymerisation technique. An alternative method for determining 
the size and size distribution of microcapsules is the Coulter 
Counter technique. This method was previously reported by Luzzi and
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co-workers (99) for sizing polyamide microcapsules and Morris and 
Warburton (53) for determining the size and size distribution of 
three ply walled water/oil/water microcapsules. In this 
investigation the Coulter Counter gave reproducible results for 
the determination of nylon 6.10 and polyphthalamide microcapsule 
diameters as shown in Table 3.14. Values of the median volume 
diameter of four batches of polyphthalamide microcapsules calculated 
using this method were 27,0, 26.0, 23.0 and 28.0ym (Table 3.6). 
Results obtained were confirmed by microscope observations using the 
Fleming Particle Size Analyser (Figures 3.5 and 3.6).
The factors which have been shown to affect the size distribution of 
microcapsules prepared by the interfacial polymerisation technique 
are the same as those affecting microcapsule size discussed above. 
The size distribution of the microcapsules will therefore be 
dependent upon émulsification and microencapsulation conditions and 
would be expected to vary considerably between authors. Koishi and 
others (87) reported their polyamide microcapsules to have diameters 
ranging from less than 1 to approximately 8ym, whereas the spray 
dried nylon 6.10 microcapsules prepared by Luzzi and colleagues had 
a size distribution of approximately 6 to 30pm. Using the 
Coulter Counter technique the median volume diameter of both the 
nylon 6.10 and polyphthalamide microcapsules formed in this study 
ranged between approximtely 5pm and 60pm. Within this range 
however the values were not distributed normally. This is similar 
to size distributions for 3 ply walled and gelatin coacervate 
microcapsules determined by other workers (144, 150). Chang and 
others (29) reported that the nylon 6.10 microcapsules prepared 
using an homogeniser in their investigation did not exhibit a normal
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size distribution. The distribution obtained showed a skew 
towards the lower capsule sizes. In contrast, Takenaka and 
others (143) and Luzzi and others (99) reported that the size 
distributions of their microcapsules did obey the log normal 
distribution law. In the latter example however, the lower 30% 
of the population was not included in the analysis. The size 
distributions of the polyamide microcapsules prepared in this 
study were again found to be skewed toward the lower capsule sizes. 
This is thought to have arisen as a result of rupture of the larger 
microcapsules during preparation and recovery or possibly as a 
result of instability or incomplete encapsulation of the larger 
emulsion droplets.
It has been reported by Koishi and others (89) that microcapsule 
size is dependent upon the type of polymer formed at the interface 
and the concentration of the monomers used to form the polymer.
That is, it is thought to be a function of the strength of the 
microcapsule membranes. For example, it was reported that the 
mean diameter of microcapsules prepared from 1,6 hexamethylenediamine 
and sebacoyl chloride was 5.90pm whereas the diameters of those 
prepared from piperazine and phthaloyl chloride under the same 
polymerisation conditions was 3.37pm. This is consistent with 
the findings in this study which showed that altering the nature 
and concentration of the monomers used in the interfacial 
polyermisation affected the microcapsule size, Polyphthalamide 
microcapsules prepared using 0.044M phthaloyl chloride and 0.4M 
piperazine were found to have a median volume diameter of 26.0pm, 
in comparison with 16.0pm for nylon 6.10 microcapsules prepared using 
0.015M sebacoyl chloride and 0.4M 1,6 hexamethylenediamine.
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The method of determination of size distribution used also enabled 
estimation of the yield of microcapsules obtained. At present there 
is a paucity of information in the literature regarding the yield 
of microcapsules prepared by interfacial polymerisation and other 
techniques. In the preparation of nylon 6.10 and polyphthalamide 
microcapsules studied in this investigation it is expected that if 
all the aqueous phase is encapsulated, allowing for the relatively 
thin microcapsule walls, the yield of microcapsules should be 
approximately 7.5ml, The data in Table 3.8 (Section 3.3.3) shows 
that the estimated capsular volume for two batches of nylon 6.10 
microcapsules following rotary evaporation was 0.23ml and 0.34ml.
This is considerably lower than would be expected and may be due to 
incomplete encapsulation and/or rupture of the walls caused by 
centrifugation. Polyphthalamide microcapsules are believed to have 
stronger walls than nylon 6.10 (92) which may make them more 
resistant to centrifugation. However, batches of polyphthalamide 
microcapsules prepared using 0.015M phthaloyl chloride were found to 
have yields of only 0.53ml and 0.32ml, very little greater than that 
for nylon 6.10 microcapsules. In an attempt to increase microcapsule 
yield, the concentration of diacid chloride present was increased 
3-fold. This resulted in a yield of approximately 5ml (Table 3.8). 
For four batches the yields ranged from 3.57ml to 5.85ml. This 
increase in yield may be due to an increase in the mass of polymer 
formed enabling more complete encapsulation to be achieved. A 
similar effect however, was not observed in the nylon 6.10 system 
when the concentration of sebacoyl chloride was increased 3-fold.
This resulted only in the formation of what appeared to be an 
amorphous mass of polymer extending from the microcapsule surface 
into the organic phase. This is thought to be due to excess 
polymerisation in the bulk of the organic phase. The disparity
25 1
between the two systems is believed to arise as a result of 
differences in the partition coefficients of the two diamines for 
the organic phase, 1,6 hexamethylenediamine is reported to have a 
greater affinity for the organic phase than has piperazine (87). 
Alternatively, the disparity may be due to differences in the optimal 
polymerisation conditions for the two combinations of monomers,
(see Section 1.5.1.2).
Differences between the nylon 6.10 and polyphthalamide microcapsule 
systems are also seen in the appearance of the microcapsules 
(Figures 3.1-3.4). The appearance of polyamide microcapsules 
prepared by interfacial polymerisation techniques has been the 
subject of several reports in the literature (29, 87, 92, 90).
It has been reported that, in general, such microcapsules are 
mainly spherical with clear interiors. Exceptions to this are the 
spray dried polyamide microcapsules prepared by Luzzi and others (99) 
and the microcapsule suspensions prepared by Chang and others (29) 
using an homogeniser, which were found to contain a significant 
number of irregularly shaped capsules. Photographs and 
photomicrographs of the nylon 6.10 microcapsules prepared in this 
investigation (Figures 3.1, 3.2) are very similar to those shown 
by other workers (29, 90, 92, 87). The microcapsules formed were 
again found to be mainly spherical with clear interiors. In 
contrast, however, the polyphthalamide microcapsules were more 
irregular in shape although the interiors were clear (Figures 3.3, 3.4) 
Observations of the shapes obtained from the deformation of emulsion 
droplets in plane hyperbolic and shear flow have been reported by 
Rumscheidt and Mason (115) and are illustrated in Figure 4.2.
Figure 4.2
The Deformation and Burst of Emulsion Droplets in Plane 
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These shapes are typical of those found in the polyphthalamide 
microcapsule suspensions which are therefore thought to arise as 
a result of coalescence or deformation of emulsion droplets as 
polymerisation occurs. Similarly shaped microcapsules may also 
be formed in the nylon 6.10 system. Due to the weaker membrane 
of the nylon 6.10 capsules however (92) these may subsequently 
rupture to form new spherical emulsion droplets. In the presence 
of continuing polymerisation these may then form new spherical 
microcapsules. In the absence of polymerisation however, the 
emuls ion droplets will remain as unencapsulated aqueous phase, 
and this may be responsible for the low yield of nylon 6.10 
microcapsules obtained. It was also observed that what appeared
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to be small particles of polymer were present in the polyphthalamide 
microcapsule suspensions. These were not found in the suspensions 
of nylon 6.10 microcapsules and are thought to have arisen as a 
result of polymerisation in the bulk organic phase caused by the 
increase in diacid chloride concentration. This is similar to the 
formation of the amorphous mass formed in the nylon 6.10 system in 
the presence of increased sebacoyl chloride. Alternatively, these 
particles may arise due to the break up of distorted emulsion droplets 
as illustrated in Figure 4.2 (A3, C5 and D5.) . If sufficient diamine 
is contained within these small droplets, it is expected that 
polymerisation would occur. It might also be expected however, 
that such particles would form in the nylon 6.10 system. In addition, 
these particles may arise as a result of impurities present in the 
phthaloyl chloride which unlike sebacoyl chloride does not require 
frequent purification to effect microcapsule formation. This 
difference between the two microencapsulation systems may be due to 
an increased tolerance toward the hydrolysis products of phthaloyl 
chloride as compared with those of sebacoyl chloride. Alternatively, 
it may be due to a difference in the concentration of hydrolysis 
products. Impurities present in the phthaloyl chloride which do 
not appear to affect the formation of microcapsules may nevertheless 
promote polymerisation in the organic phase resulting in the 
formation of particles. Such particles however, were not observed 
in nylon 6.10 microcapsule suspensions prepared using impure 
sebacoyl chloride of sufficient purity to effect capsule formation.
There have been few reports in the literature concerning the 
structure of polyamide microcapsules although it is usually assumed 
that they consist of a hollow core surrounded by a thin wall of polymer
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Exceptions to this are the microcapsules prepared by Jenkins and 
Florence (106) which had the appearance of solid particles.
Similarly nylon microcapsules containing a solid core were prepared 
by McGinity and others (90). The hollow nature of both the nylon
6.10 and polyphthalamide microcapsules prepared in this study was 
clearly demonstrated using scanning electron microscopy techniques. 
Figures 3,2 and 3.4 for example show micrographs of suspensions of 
freeze fractured microcapsules in which the interiors of the 
microcapsules are visible and which suggest that the microcapsule 
walls are thin relative to the diameter. Several authors have 
estimated the thickness of microcapsule membranes prepared by 
interfacial polymerisation. The thicknesses reported have varied 
widely according to the polymerisation conditions used. On the 
basis of electron microscope observations, for example, Chang and 
others (29) reported that the membranes of their nylon 6.10 
haemoglobin containing microcapsules were about 0.02]im in thickness. 
Lim and Moss (111) however, estimated the membrane thickness of 
polyamide microcapsules prepared by their method to be approximately 
0.08pm. Transmission electron micrographs of the microcapsules 
prepared in this study showed that the walls of both the nylon 6.10 
and polyphthalamide microcapsules were approximately 0.7pm in 
thickness. This is considerably greater than the values reported 
by other workers (29, 95, 100, 111). This disparity is believed 
to be due to differences in the methods of microcapsule preparation, 
in particular the presence of crosslinking agents. The use of 
different crosslinking agents in the preparation of microcapsules 
with modified walls in this study however, resulted in little 
difference in microcapsule wall thickness (Section 3.7).
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In conclusion, microcapsule properties vary widely according to the 
microencapsulation conditions used. Important parameters in 
determining the properties of microcapsules prepared by the 
interfacial polymerisation technique appear to be stirring speed, 
surfactant concentration, the presence of crosslinking agents, 
monomer type and monomer concentration. The microcapsules formed 
by the methods developed in this investigation were found to be 
hollow mainly spherical particles with diameters in the 5 to 60pm 
size range. The mean volume diameters of nylon 6.10 and polyphthalamide 
microcapsules were 16.0pm and 26.0pm respectively. The wall thickness 
in both cases was estimated to be 0.7pm.
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4.2 Microencapsulation of Pilocarpine Nitrate
The preparation of microcapsules containing drug molecules generally 
involves incorporation of the drug into the microcapsule core 
material prior to formation of the microcapsule wall. Alternatively, 
the drug substance may be the total microcapsule core about which the 
wall is formed. For example, in the preparation of sulphamethoxazole 
microcapsules by the gelatin-acacia coacervation technique, the 
polymeric wall forms around micronised crystals of sulphamethoxazole 
(143). Similarly, the physical methods of microencapsulation 
generally involve deposition of the wall material about solid 
particles (151) (Section 1.2.2), In the preparation of microcapsules 
by the interfacial polymerisation technique and some microencapsulation 
methods involving non-aqueous phase separation techniques, the 
drug to be encapsulated is initially dissolved or dispersed in a 
liquid core material which is then emulsified. The wall of the 
microcapsules is formed around the individual emulsion droplets.
For example, in the formation of polyamide microcapsuleicontaining 
sodium pentobarbital in an aqueous core, a water in oil emulsion 
was formed prior to the polymerisation of two monomers at the 
water/oil interface, resulting in the formation of nylon 
microcapsules containing the drug (99) . In the preparation of 
such emulsions it is predicted that, dependent upon the lipophilicities 
of the drugs to be encapsulated, the nature of the organic phase and 
the relative phase volumes present, a given fraction of the drug 
included in the initial phase will partition to the organic phase.
The high surface area of the dispersed phase together with the high 
agitation rate will contribute to the speed at which this 
partitioning occurs. The fraction of drug present in the organic 
phase will remain unencapsulated. In the microencapsulation of
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drugs in polyamide microcapsules containing various matrices,
McGinity and others (90) reported that approximately 50% of the 
diphenhydramine hydrochloride to be encapsulated was lost to the 
organic phase during the microencapsulation process. The partition 
of sulphathiazole sodium, sodium salicylate, phenytoin,diazepam 
and theobromine during the preparation of these microcapsules was 
however considerably less. Similarly, Naik (123) reported that 
during the encapsulation of a number of sulphonamide derivatives in 
polyamide microcapsules, 88 to 96% of the solute included was 
encapsulated. In this investigation the nitrate salt of pilocarpine 
was selected for study as this is the least lipophilic of the 
pilocarpine salts (152) and is therefore expected to yield the 
highest concentration of pilocarpine in the encapsulated phase.
In the absence of polymerisation however, approximately 50% of 
the pilocarpine nitrate initially included in the microencapsulation 
system partitioned into the organic phase (Table 3.12). This loss 
is considered to arise as a result of the relatively large volume 
of organic phase used in the microencapsulation system and the 
presence of chloroform in which pilocarpine nitrate is slightly 
soluble. A similar percentage was lost to the organic phase when 
polymerisation was allowed to occur and this fraction was found to 
be independent of concentration (Tables 3.10 to 3.12). The 50% 
initial pilocarpine nitrate mass remaining in the aqueous microcapsule 
core was found to be readily removed by the acetone and Tween 20
solutions used to wash and resuspend the formed drug containing
microcapsules (Tables 3.10 and 3.11). This further loss of 
pilocarpine nitrate from the microcapsules was prevented by harvesting 
the microcapsules directly from the cyclohexane wash in which the drug
is poorly soluble (152). In this way approximately half the initial
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mass of drug included in the preparation remained associated with 
the microcapsules. This value, which was again found to be 
independent of concentration, is consistent with the total mass of 
pilocarpine nitrate recovered from microcapsule suspensions during 
release studies (Tables 3.17 - 3.21).
Another factor which may influence the incorporation of a drug
into microcapsules prepared by an interfacial polymerisation method
is the interference of the drug with the polymerisation reaction.
This phenomenon has been reported in the encapsulation of aniline (54)
and of the quarternary ammonium compounds methantheline bromide and
benzalkonium chloride (90). Reaction is thought to occur between
nitrogen containing groups present in the drug molecules and the acid
chloride functions thereby terminating polymerisation. It is possible
that this may also occur in the encapsulation of pilocarpine nitrate
as no microcapsules were formed when the drug was included in the
internal aque ous phase of the microcapsule system at a
- 2concentration of 18.5 x 10 M and above (Table 3.13). -
Pilocarpine nitrate may also interfere with the formation 
of the polymer at lower concentrations as microcapsule suspensions 
prepared containing 14.78 x 10”^M pilocarpine nitrate contained a 
large number of agglomerates. Supportive evidence of this 
interaction however, was not found from scanning electron 
micrographs of the surface of the microcapsules prepared in the 
presence of 1.85 x 10 pilocarpine nitrate (Figure 4.3). The 
upper micrograph shows what appear to be star shaped crystals 
present in surface discontinuities. These crystals are thought to 
be pilocarpine nitrate, buffer salts or unreacted monomer which has 
migrated to the surface during drying. However, the surface
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appearance of the same sample of microcapsules after washing with 
water prior to preparation for electron microscopy (Figure 4.3b) is 
similar to that of microcapsules formed in the absence of pilocarpine 
nitrate (Figure 3.27), HPLC analysis of pilocarpine nitrate released 
from the microcapsules failed to detect the presence of any degradation 
products (Figure 3.15) which indicates that the microencapsulation 
technique had no adverse affect on the stability of the pilocarpine 
nitrate molecule.
An alternative method by which drugs might be incorporated into the 
core of microcapsules with permeable walls involves immersing 
formed microcapsules, prepared in the absence of the drug, in a 
solution of the drug until equilibrium between the microcapsule 
core and the solution is reached. By this method there can be no 
interference of the drug with the polymerisation reaction. In the 
preparation of polyphthalamide microcapsules containing pilocarpine 
nitrate this was achieved by immersing freeze dried polyphthalamide 
microcapsules prepared in the absence of pilocarpine nitrate, in an 
aqueous solution of the drug for 12 hours. Determination of 
pilocarpine nitrate uptake onto the whole and broken freeze dried 
microcapsule walls (Table 3.16) together with observations of wall 
water permeability suggest that the microcapsule walls were 
permeable to pilocarpine nitrate and that equilibration between 
the microcapsule core and the solution occurred rapI (Lly.
Thus there are two methods by which drugs may be included in the 
aqueous core of microcapsules prepared by the interfacial polymerisation 
technique. Inclusion of compounds containing nitrogen prior to 
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4.3 Release Characteristics of Polyphthalamide Microcapsules
Two possible mechanisms have been proposed for the release of drugs 
from microcapsules; disintegration of the capsule or diffusion of 
the drug through the microcapsule wall. In most cases with the 
exception of biodegradable microcapsules, drug is released via 
diffusion through the wall which remains intact. The rate of 
release of drugs from microcapsules and microcapsule formulations 
has been the subject of several investigations. For example, 
materials whose release from coacervate walled microcapsules has 
been studied include thiabendazole, various barbiturates and 
sulphamethoxazole (145, 153, 154). Similarly the release of 
isoniazid, phenobarbitone sodium and salicylaraide from cellulose 
walled microcapsules has been investigated (50, 142, 155).
In particular, the rate of release of drugs from polyamide 
microcapsules prepared by the interfacial polymerisation technique 
has been studied by several workers (99, 118, 119, 122) and the 
reported methods for determining the release profiles have varied 
widely. Prior to release determination McGinity (107) 
air dried sulphathiazole sodium and gelatin containing polyamide 
microcapsules to remove formalin, organic solvents and water.
The release of the drug into O.IM HCl and O.IM acetate buffer in a 
round bottom flask maintained at 37°C was then studied. The 
dissolution medium was stirred at 100rpm and the release of the 
drug was followed spectrophotometrically. In contrast, Luzzi
and others (99) , either spray dried or flash evaporated microcapsule 
suspensions containing sodium pentobarbital prior to release 
measurements. The release was again determined at 37°C, but the 
dissolution media in this case were O.IM HCl, O.IM KH^PO^ - KOH buffer 
pH 6.75 or distilled water and the stirring speed was only 6 rpm.
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Alternatively, the method used by Florence and Jenkins (122) for 
the determination of release of trifluoperazine embonate from nylon 
6.10 microcapsules involved placing a quantity of microcapsule 
suspension in a Visking bag. In this case the release into 
pH 7.4 buffer was determined. The buffer was stirred at 60rpm.
From these investigations it is apparent that the rate of release of 
drugs from microcapsules is a function not only of the method used 
to prepare the microcapsules and the nature of the encapsulated 
solute, but also of the method by which release is determined.
In particular, it is dependent upon the nature of the dissolution 
medium and it is expected that it will also be dependent upon 
agitation rate. In this study, four in vitro methods for the 
determination of the release of pilocarpine nitrate from 
polyphthalamide microcapsules were developed. Firstly, following 
polymerisation, pilocarpine nitrate containing microcapsules were 
removed from the cyclohexane wash and rotary evaporated to remove 
the residual organic solvent prior to immersion in the release 
medium. Secondly, polyphthalamide microcapsules prepared in the 
absence of pilocarpine nitrate were freeze dried. The microcapsules 
were then immersed in a solution of pilocarpine nitrate until 
equilibrium was reached, following which the release from the 
suspension was determined. The third method used involved freeze 
drying of suspensions of microcapsules prepared in the presence of 
pilocarpine nitrate prior to the determination of release, and the 
fourth method consisted of partial freeze drying of microcapsule 
suspensions. This was achieved by drying for a period of only 
30 minutes. In all cases the powder or suspension obtained was 
dispersed in 50ml isotonic phosphate buffer, pH 7.4 at 32°C; 
these values are approximately the pH of tear fluid and the
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temperature of the cornea respectively. Analysis of pilocarpine
nitrate was carried out using liquid scintillation counting
techniques with one exception where HPLC was used. This was
undertaken to ensure that the release profiles obtained were those
of pilocarpine nitrate and not of either a labelled degradation
product or a tritium exchange product (Figure 3.14). Furthermore,
observations of microcapsule appearance (Figure 3.9) and size
distribution (Figure 3.10) following freeze drying of microcapsule
suspensions indicate that this method of harvesting has no
detrimental effect on the microcapsules which were found to collapse
on drying and to reconstitute well on dispersion in water. It was
observed however, that the powder was very hygroscopic, absorbing
moisture from the atmosphere immediately after removal from the freeze
drier. This is thought to give rise to the large variation in
concentration observed in samples removed from different batches of
freeze dried material which may be seen in Table 3.15. The release
profiles obtained using each of the four methods of release described
above are given in Figures 3.11 to 3.14. Inspection of the data
(Tables 3.17 to 3.21) indicates that in all cases the release of
pilocarpine nitrate was rapid. There are however, differences
between the profiles obtained for the release from the microcapsules
determined by the different methods containing the same initial
pilocarpine nitrate concentration. For example, the release
-2profiles from microcapsules initially containing 1.9 x 10 M 
pilocarpine nitrate in Figures 3.11 and 3.12 suggest that the 
initial release from the microcapsules is faster when determined 
by Method 2 as compared with Method 1. Using Method 1, after 5 
minutes approximately 78% of the total mass of pilocarpine nitrate 
released at equilibrium was lost whereas for Method 2 the value was 97%.
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Similarly the initial release rate is higher in Method 2 than in 
Methods 3 and 4. There are a number of factors which may be 
responsible for these differences such as the presence of trace 
amounts of solvent or the presence of unencapsulated drug.
Using Methods 1 and 4, following rotary evaporation or partial freeze 
drying, trace amounts of cyclohexane may remain associated with the 
microcapsule walls which will prevent the aqueous medium from 
wetting the microcapsule surface. Conversely, over drying the 
microcapsule surface during freeze drying may result in an apparent 
delay in the release due to a finite time requirement to re-wet the 
surface. Differences between the profiles obtained using Method 2 
and Methods 1, 3 and 4 however, may simply be due to masking of the 
initial true release rate in Method 2 brought about by the rapid 
dilution of the extra capsular pilocarpine nitrate present in 
solution. Similarly, adsorption of moisture from the freeze dried 
microcapsules may produce an initially elevated release rate due to 
the adsorbed water prematurely leaching drug from the core.
Elevated release rates will also be observed if solute migration, 
such as that which takes place during the drying of granules (156), 
occurs during drying of microcapsules. That is, as the surface 
liquid evaporates, so it is replenished with water from the core 
carrying with it dissolved solute; this water then evaporates 
leaving the solute on the surface of the microcapsules. This 
phenomenon may also occur during flash evaporation, spray drying and 
air drying (99, 107). Artificially high release rates will also be 
observed if, as is indicated by the yields obtained (Table 3.8) 
incomplete encapsulation of the aqueous phase takes place during 
polymerisation. The unencapsulated pilocarpine nitrate solution 
in this case is thought to collect at the microcapsule surface
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during centrifugation. It is apparent therefore that, due to the 
physical nature of the polyamide microcapsules and the methods by 
which they are prepared for release studies, comparison of release 
data obtained using different methods of release determination 
cannot be made. Of the methods described above partial freeze 
drying was considered to be the method of choice as this was the only 
method by which gelatin containing microcapsules could be successfully 
dried and reconstituted (Section 3,6.1).
Some variation in the release profiles obtained from two batches of
microcapsules containing the same initial drug concentrations in which
the release is determined by the same method may also be observed in
Figures 3.11, 3.12 and 3.14. In the release from
_2microcapsules prepared containing 3.61 x 10 M pilocarpine nitrate
—3determined by Method 1 (Figure 3.11), after 120 minutes 3.017 x 10
moles of drug had been released per gram of microcapsule slurry for
xio‘5
determination 1, which compares with a value of 2.532^moles in the case
of determination 2, Similarly in the release of drug from microcapsules
initially containing 1.9 x 10 ^M pilocarpine nitrate determined by 
Method 4 after 120 minutes the total mass released per gram of 
microcapsule slurry was found to be 1.678 x 10 ^ moles (determination 1)
-5and 1.534 x 10 moles (determination 2). This is to be expected 
however due to the batch to batch variation in the 'concentration' 
of microcapsules in the slurry produced after rotary evaporation 
and freeze drying (Tables 3.8 and 3.15) together with the variation 
in the distribution of pilocarpine nitrate during the microencapsulation 
process (Table 3.11). It is also not surprising that the greatest 
differences are seen in the release profiles obtained for freeze dried 
material (Figure 3.13) as this product yields the greatest variation
in concentration (Table 3.15).
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The effect of pilocarpine nitrate concentration on the release rate 
from polyphthalamide microcapsules is also illustrated in 
Figures 3.11 to 3.13. There have been few reports in the 
literature concerning the effect of encapsulated solute 
concentration on the permeability of microcapsule walls and 
microcapsule release characteristics, although it was noted by 
Naik (123) that high solute concentrations interfered with the 
microencapsulation process and influenced the rate of release.
The drug release profiles of microcapsules prepared containing
1.85 X 10“^M, 3.61 X 10“^M, 7.36 x 10"^M and 14.78 x 10~^M 
pilocarpine nitrate in Figure 3.11 (Tables 3.17 and 3.18) show
that at all concentrations the initial release of pilocarpine nitrate
was rapid. At initial pilocarpine nitrate concentrations of
-2 -21.85 X 10 M and 3.61 x 10 M however, a plateau in the release
profile was reached within 60 minutes and no further release of the
drug was observed up to 120 minutes. At the higher concentrations
some reduction in the release rate occurred following the initial
rapid release although a plateau was not attained. Consideration
of the distribution of the drug during preparation however, (Table 3.18),
suggests that at these higher drug concentrations no appreciable
amount of pilocarpine nitrate remained associated with the
microcapsules after 120 minutes. For example, from one batch of
_2microcapsules prepared containing 14.78 x 10 M pilocarpine nitrate,
-55.65 X 10 moles were released within the first 5 minutes and
-5following this a further 3.357 x 10 moles were released over a
—5115 minute period. In total therefore, 9.007 x 10 moles were 
released representing 55.6% of the amount included, 48.3% already 
being lost to the organic phase during preparation. Similarly, the
drug release profiles of microcapsules prepared containing approximately
-2 -2 1.8 X 10 M and 14.8 x 10 M pilocarpine nitrate given in Figure 3.13
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and Table 3.20 show that at both concentrations the initial release
of drug was rapid. At the lower pilocarpine nitrate concentration
a plateau in the release profile was reached within approximately
10 minutes, after which time no more pilocarpine nitrate was
-5released. A plateau which corresponds to about 20 x 10 moles 
pilocarpine nitrate was not reached in the release from the 
microcapsules containing the higher concentration of drug until 
approximately 30 minutes. In contrast however. Figure 3.12
(Method 2) indicates that for initial pilocarpine nitrate
-2 -2 concentrations of 1.8 x 10 M and 14.8 x 10 M a  plateau in the
release profile was reached in both cases in 5 minutes. The
-5plateaux corresponded to approximately 6 x 10 moles per gram 
-5and 50 x 10 moles per gram for the lower and higher concentrations 
respectively. This suggests that the concentration of encapsulated 
drug does not affect the release from the microcapsules. Rather, 
it is the concentration of solute present during polymerisation 
which affects the permeability of the microcapsule walls and therefore 
their release properties. This is further evidence that pilocarpine 
nitrate interferes in the polymerisation reaction (see Section 4.2) 
and is in agreement with the work described by Naik (123).
As discussed in the preceding paragraphs under all conditions studied
the release of pilocarpine nitrate from polyphthalamide microcapsules 
was extremely rapid. From several reports in the literature on the 
permeability of microcapsules to electrolytes and other 'small' 
molecules (95, 98, 100, 111, 118, 119) this type of release is to be 
expected. Chang and Poznansky for example (119) reported the 
equilibration time for sucrose permeating into polyamide microcapsules 
as 35.5 seconds and for urea the value was 4.3 seconds.
Similar values were reported for the permeation of glycerol, glucose
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and sucrose through the walls of poly (hexanediamine terephthaloyl
chloride) microcapsules (111). In terms of release profiles
Luzzi and others (99) found that the time taken for the release
of 50% of the sodium pentobarbital content of nylon 6.10 microcapsules
was in the order of 10 to 15 minutes whereas Degennaro (108)
reported that 80 to 90% of the total solute content of polyamide
microcapsules prepared by their method was released within the
first 5 minutes in most cases. This contrasts to the findings of
Florence and Jenkins (122) who reported release of trifluoperazine
embonate from nylon 6.10 microcapsules over periods of up to 64 hours.
In this study 50% of the total mass of pilocarpine nitrate released
from the polyphthalamide microcapsules at equilibrium was lost within
2 minutes independent of the method of release measurement used.
With the exception of the studies by Degennaro (108) this is
considerably faster than the release rates reported by other authors
and may be due to the methods of preparation and release determination
used. For comparison of the release data obtained Table 4.1 gives
the t^Qg, tgQ^ and values for each of the systems investigated,
(Where t and t are the times taken to release 50% and 90% b? u %
of the total mass of pilocarpine nitrate released at equilibrium
and is the mass released in 10 minutes expressed as a percentage
of the total mass released at equilibrium.^ In all cases 90% of
the total amount released was lost within 20 minutes and 50% within
one minute for an initial pilocarpine nitrate concentration of 
-21.85 X 10 M. The values are in the range 82 to 100%. For
an initial pilocarpine nitrate concentration of approximately 
_214.7 X 10 M, 50% of the total mass of pilocarpine nitrate released 
was lost within 2 minutes and the values range between 66% and 
100%. These findings suggest that the microcapsule walls are
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Solute Pilocarpine Nitrate. Prednisolone
Sodium
Phosphate.
Release Method 1 2 3 4 4
Concen tration
of Solute in




(minutes) 1 1 1 2 1 1 1 1 1 1
tgo%
(minutes) 20 20 65 60 1 1 4 15 1 20
^10
(%) 82 76 71 64 100 100 99 88 96 86
TABLE 4.1 RELEASE OF: PILOCARPINE NI TRAIE AND PKEDNISOLONE 
SODIUM PHOSPHATE FROM POLYPHTHALAMIDE 
MICROCAPSULES.
Where; ^50% and t g o %  are the appr oximate times taken 
in minutes to release 50% and 90% respectively 
of the total solute content released at 
equilibrium.
MjLO is the mass of solute released in 10 
minutes expressed as a percentage of the mass 
released at equilibrium.
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ineffective in significantly controlling the release of pilocarpine 
nitrate and indicate that the walls are freely permeable to the drug.
In order to ensure that this rapid release rate is not peculiar to 
the pilocarpine nitrate molecule, the release from microcapsules 
prepared containing prednisolone sodium phosphate was investigated. 
This compound was selected as it is of a similar size to pilocarpine 
nitrate, is readily assayed and contains no reactive nitrogen groups. 
The release of the prednisolone sodium phosphate was again rapid 
(Figure 3.16). The t^^^, t^^^ and values are given in Table 4.1 
from which it may be seen that the release was only slightly slower 
than that obtained for pilocarpine nitrate using the same method of 
release measurement. It has been suggested that the permeability 
of polyamide microcapsule membranes to various solutes is a function 
of their molecular weight (111, 119); for example, Lim and Moss 
reported the half equilibration times for the permeation of glycerol 
(moleculon weight 92) glucose (molecular weight 180) and sucrose 
(molecular weight 342) through the walls of polyamide microcapsules 
as 1.8, 4.9 and 10.6 seconds respectively. The difference in release 
rates observed for prednisolone sodium phosphate and pilocarpine 
nitrate may therefore be a function of the molecular size of the 
two solutes. (The molecular weight of prednisolone sodium phosphate 
is 484 and that of pilocarpine nitrate is 271). This dependency 
of release rate upon molecular size may also give rise to the widely 
different release rates reported by authors working with different 
solutes.
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It is considered that the rapid release of both pilocarpine nitrate
and prednisolone sodium phosphate from the polyamide microcapsules
may also be a function of the large surface area to volume ratio of the
microcapsules together with the relatively large volume of release
medium resulting in sink conditions. That is the surface area
of 4.0ml microcapsules with a mean volume diameter of 26pm is
2calculated to be approximately 9,200 cm , In vitro release from 
these 4.0ml microcapsules was determined by dispersion into 50ml 
buffer solution. These conditions are considerably different 
from the in vivo situation in the eye in which it was considered 
the microcapsules may exhibit some sustained release effect. The 
in vivo data, however, similarly suggest that the release of 
pilocarpine nitrate from the polyphthalamide microcapsules is rapid. 
That is, there was no difference in the miotic response induced by 
encapsulated pilocarpine nitrate as compared with pilocarpine nitrate 
solution following instillation into the rabbit eye (Figure 3.40).
In both cases the pupil diameter reached a minimum at 30 minutes post 
instillation and returned to its initial size after approximately 
180 minutes. Miosis was used as an indication of pilocarpine 
kinetics (17, 157, 158) as it was found that there is no intraocular 
pressure response to pilocarpine in the rabbit eye. The in vivo 
release data given in Figure 3.40 may indicate either that the 
microcapsules have no significant effect in controlling the release 
of pilocarpine nitrate or that the microcapsules are washed immediately 
from the eye and therefore do not prolong the contact time of the 
drug. This second hypothesis is not consistent with the study of 
microcapsule dwell time in the eye. The dwell time of microcapsules 
containing gamma labelled albumin which is known to remain associated 
with the microcapsules (Section 4.4) was investigated using a gamma
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camera technique. 88% of the activity associated with the 
microcapsules instilled in the rabbit eye remained in the eye 
after one minute and after twenty minutes this valve had decreased 
by only a further 3% (Figure 3.41). In comparison, on instillation 
of a gamma labelled albumin solution the activity decreased to 39% 
within only one minute. From this, it may be concluded that the 
microcapsules are effective in significantly increasing dwell time 
in the eye when compared with the albumin solution and also with 
viscous eye drops (15). The microcapsules however, do not appear 
to control the in vitro or in vivo release of encapsulated pilocarpine 
nitrate or the in vitro release of prednisolone sodium phosphate.
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4.4 Mechanism of Release of Pilocarpine Nitrate from Polyphthalamide 
Microcapsules
The rapid release of both pilocarpine nitrate and prednisolone 
sodium phosphate from polyphthalamide microcapsules discussed above, 
suggests that the polyamide microcapsule walls are freely permeable 
to small solutes. The nature of the interaction mechanism between 
small solutes, in particular weak organic acids and bases, and 
polyamides has been the subject of several reports in the literature. 
Richardson (67) showed that the sorption of a weak base, ethyl-4- 
aminobenzoate, by nylon 6 powder involves penetration of the drug 
into the polymer matrix. The mechanism of the interaction is unclear 
but is believed to involve hydrogen bond formation between the drug 
and the amide groups in the polymer chain. The bonds may then be 
stabilised by Van der Waals' forces. Similarly Kapadia and colleagues 
(72) investigated the interaction of a number of 4-hydroxybenzoate 
derivatives with polyamides and proposed that these solutes formed 
very weak hydrogen bonds with the amido groups in the polymer which 
were then stabilised by Van der Waals' forces. In contrast, other 
workers have suggested that the interaction between polyamides and 
organic acids or chlorbutol involves forces only of the Van der Waals' 
type (70). A close correlation between the extent of the interaction 
and the percentage of solute in the unionised form has been found 
by several workers. Richardson (67) reported on the sorption of 
ethyl-4-aminobenzoate by nylon 6 powder and concluded that when the 
drug was present in the ionised form there was no detectable sorption. 
Similar findings were reported by Ho (68) for the sorption of 
ethyl-4-aminobenzoate by nylon 6 films and by Kapadia and others (72) 
for the sorption of salicylic acid by nylon 6.6. The state of 
ionisation of weak aromatic acids and bases has also been shown to 
influence their permeation through polyamide films. For ethyl-4-
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aininobenzoate permeation in which determinations were made using a 
simple permeation cell, Ho (68) observed that in the completely 
ionised state the drug did not permeate commercially prepared nylon 6 
films. In the unionised form however, permeation did occur.
It is unlikely therefore that a charged molecule which is not capable 
of forming a specific interaction with polyamides would permeate through 
nylon films. Figure 3.39 shows that pilocarpine nitrate in pH 7.4 
buffer and ionised ethyl-4-aminobenzoate do not permeate commercially 
prepared nylon 6 films which is in agreement with these findings. 
Similarly, ethyl-4-aminobenzoate in the unionised form was found to 
permeate the nylon 6 film (Figure 3.39). The permeability coefficient 
of unionised ethyl-4-aminobenzoate through the nylon 6 film was 
calculated to be approximately 1.1 x 10 s«c  ̂with a lag time
of about 40 minutes, which is in good agreement with values reported 
by other workers (68, 73). This lag time is believed to be due to 
the time taken for the drug to penetrate the polymer matrix at the 
donor side and diffuse to the receptor side. The permeability data 
for pilocarpine nitrate and ionised and unionised ethyl-4-aminobenzoate 
through polyphthalamide films prepared by interfacial polymerisation 
(Figures 3.37 x 3.38) however, is inconsistent with accepted drug-nylon 
interaction theory. In all cases, equilibrium between the receptor 
and donor solutions in the permeability cells was achieved within 
120 minutes and no measurable lag time was observed. The absence 
of a lag time suggests that the solutes are not diffusing through 
the polymer matrix solely at a molecular level and may indicate the 
presence of water filled pores or channels in the film. Figure 3.38 
also shows that there was no apparent difference in the permeation 
rate of ionised and unionised ethyl-4-amino-benzoate again suggesting 
that the polyphthalamide films are different in nature from commercially
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prepared nylon 6 films. The absence of a linear portion of the 
permeability profiles together with the variability in film thickness 
make calculations of permeability coefficients through the 
polyphthalamide films difficult. Estimations of the permeability
over the time period 5 to 30 minutes however, give values of
-11 -10 - 10^ ^4 . 7 x 1 0  , 7.1 X  10 , 6 . 3 x 1 0  /for pilocarpine nitrate,
ionised and unionised ethyl-4-aminobenzoate respectively. These
are approximately 500 times greater than that for unionised
ethyl-4-aminobenzoate through the commercially prepared nylon 6
film (Figure 3.39), and are consistent with permeation occurring
not by diffusion through the polymer matrix but by another mechanism
such as via water filled channels.
Extrapolation of the data obtained for the polyphthalamide films 
to the microcapsule walls must however be treated with caution. 
Although the films used were prepared by an interfacial polymerisation 
method based on that used in the preparation of microcapsules, 
modifications to this method were necessary. In particular, changes 
to the monomer concentration and solvent composition were made in 
order to produce films of sufficient strength to be drawn from the 
interface. Also, the support of a grid was necessary to maintain 
the integrity of the film in the diffusion cell (Section 3.8.4).
In addition, it was not possible to prepare films of large diameter 
and this therefore necessitated using small aperture diffusion cells. 
As a result of corresponding small volume of the receptor compartment 
in these diffusion cells, volumes of solution removed for assay were 
significant and removal of samples resulted in a differential 
hydrostatic pressure across the film. Furthermore, the fragility of 
the films prevented the donor and receptor solutions being stirred at
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speeds greater than 300 rpm. In contrast to the microcapsule
system however, the films were able to limit the permeation of
the pilocarpine nitrate. This may be due to the relative film/wall
thicknesses and the surface area. Film thicknesses were estimated
2to be in the order of 70ym with a surface area of 9.62 cm and a
donor compartment volume of 50ml. The microcapsules, in comparison,
had a wall thickness of about 0.7ym and for a capsule volume of 4ml the
2calculated surface area is over 9,000 cm .
It is apparent from the above discussion that a mechanism other than 
that involving diffusion of solute through the polymer matrix governs 
the release of drugs from polyphthalamide microcapsules. The release 
mechanism is thought to be determined by the structure and physical 
properties of the microcapsule walls. The appearance of polyamide 
membranes prepared by interfacial polymerisation has been described 
by both Morgan and Kwolek (81) and Enkelmann and Wagner (79).
The surface of the film adjacent to the aqueous phase was found to 
be smooth, whereas that adjacent to the organic phase was rough.
This type of structure is also observed in the scanning electron 
micrographs of freeze fractured nylon 6.10 and polyphthalamide 
microcapsules (Figures 3.3, 3.4 and 3.9). The inside of the walls 
are smooth whereas the outer surface of the walls are rough and 
suggest the presence of pores or surface discontinuities. The 
surface of the microcapsules prepared by McGinity and others (90) 
were also found to be rough and those prepared containing a gelatin 
matrix were reported to have a rough and porous surface with a 
plate-like structure. In contrast, the outer walls of some 
pesticide containing microcapsules appear smooth (34). Again 
this is in agreement with the findings of Enkelmann and Wegner (79)
27 7
and Morgan and Kwolek (81) as in this case the polymer is formed 
in an emulsion where the continuous phase is aqueous and the 
dispersed phase is an oil. The surface appearance of microcapsules 
prepared by interfacial polymerisation was also reported by Jenkins 
and Florence (106) who concluded that the walls were highly porous 
in nature. The pores were considered to be of a filamentous 
structure and those seen in films prepared by interfacial polymerisation 
ran from one surface of the film to the other which, it was concluded, 
agreed with the radiating structure of polymer strands in the capsules. 
It is also consistent with the findings of Enkelmann and Wegner (79) 
who suggest that in interfacial polymerisation the polymer chains form 
perpendicular to the surface. These structures in all cases differ 
from the nylon 6 powder described by Wicks (73)
which was considered to be highly crystalline in nature and non-porous, 
although the surface was highly convoluted. This suggests that the 
properties of polyamides prepared by interfacial polymerisation may 
generally be expected to differ from those prepared by more 
conventional techniques, which is consistent with the permeability 
data discussed above.
Using transmission electron microscopy, investigation of the pores 
present in the microcapsule walls prepared in this study again 
indicated that the surface was porous in nature but did not confirm 
that any of these pores penetrated to the centre of the core. The 
micrographs in Figure 3.28 show that the walls are composed of 3 
distinct layers which are shown diagrammatically in Figure 4.4.





Middle Layer Outer Layer
EXTERIOR
The three layers from the core outwards are:
1. A dense discontinuous nodular layer. This is thought to be 
formed due to the presence of polyethyleneimine which would 
initially form a dense crosslinked polymer network at the 
interface as discussed in Section 4.1. As polymerisation 
proceeds the diffusion of the polyethyleneimine will be 
limited preventing further crosslinking in the outer layers 
of the wall (see Figure 4.1).
2. A narrow dense continuous layer. This layer is probably the 
site of maximum polymerisation between the diamine and the 
diacid chloride
A relatively thick loosely attached less dense layer.
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This type of structure is consistent with the report that as the 
membrane thickness increases the structure of the membrane becomes 
more and more disordered and the outer layers are composed of 
relatively low molecular weight polymer (79). As polymerisation 
reaches completion several factors may give rise to the formation 
of this lower molecular weight polymer. These include hydrolysis 
of the diacid chloride and depletion of the diamine in the 
polymerisation zone brought about by its reduced rate of diffusion 
through the already formed membrane. Such low molecular weight 
material may result in the loose 'amorphous' layer observed in the 
microcapsule walls. It is this outer layer which is considered 
responsible for the surface appearance of the microcapsules 
suggesting the presence of pores or discontinuities.
Pores and voids may arise as a result of the method by which the 
microcapsules are prepared. As polymer is formed on the organic 
side of the interface solvent may be trapped during polymerisation. 
Polyamides have a low affinity for organic solvents and on drying it 
might be expected that this will be removed resulting in pores and 
channels. Other workers have previously reported the presence of 
pores in microcapsule wall materials. Okohata and others (159) 
clearly showed the presence of pores of approximately lym diameter 
in the surface of polyamide microcapsules of approximately 2.5mm 
diameter. Transmission electron micrographs indicated that these 
pores penetrated the wall. Using measurements of the effective 
osmotic pressure of a number of electrolytes across the membranes 
of their nylon 6.10 microcapsules (of approximately 270pm diameter), 
Chang and others (29) estimated the size of pores present to be 
about 1.6nm. By increasing the reaction time during preparation
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from 3 to 15 minutes this pore size could be reduced to 0.5nm (30).
This reduction in pore size may be due to more extensive polymerisation 
within the microcapsule membrane giving rise to a more dense polymer 
matrix. A conflicting finding was reported by Ndong-Nkoume and 
others (160) who found no pores present in the walls of polyamide 
microcapsules prepared in the presence of L-lysine. This 
discrepancy is thought to be due to either the presence of the 
L-lysine or the increased concentration of diacid chloride present, 
0.063M in comparison with 0.018M reported by Chang and others.
The increased monomer concentration may again lead to the formation 
of a more dense membrane. Alternatively, the discrepancy may be 
due to the difference in microcapsule diameter (15pm as compared with 
270pm) which it has been reported gives rise to microcapsules with 
a reduced porosity and hence permeability (161). Pores have also been 
observed in the walls of microcapsules prepared by other techniques, 
such as phase separation (162, 163) where it has been suggested that 
these pores play an important role in determining the release of 
drugs from the core.
The hypothesis that pores or channels are present in the walls of 
microcapsules prepared by interfacial polymerisation techniques 
is further supported by determinations of the molecular weight cut 
off of the membranes. Miyawaki and colleagues (118) determined the 
molecular weight cut off of haemoglobin containing nylon microcapsules 
using a permeability measurement technique. Formed microcapsules 
were immersed in a solution of tracer (for example salmine, or 
brilliant blue) until equilibrium was reached. The external 
solution was then discarded and the release from the microcapsules 
determined. From this it was found that dextran blue and salmine
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were unable to penetrate the capsule wall whereas brilliant blue 
and phenylalanine permeated the membrane. The molecular weight 
cut off was therefore reported to lie between 1,000 and 10,000.
In contrast, the molecular weight cut off of the membranes of 
microcapsules prepared in this investigation was found to lie 
between approximately 20,000 and 40,000. Microcapsules were 
prepared containing (a) albumin fluorescein isothiocyanate of 
molecular weight 68,000; (b) fluorescein isothiocyanate dextran
of molecular weight 39,000 and (c)fluorescein isothiocyanate dextran 
of molecular weight 17,500. Following preparation the microcapsules 
were washed repeatedly with 10ml pH 7.4 isotonic phosphate buffer 
and the supernatant examined for colour. The supernatant from the 
microcapsules prepared containing fluorescein isothiocyanate dextran 
of molecular weight 17,500 was found to be coloured, the remaining 
two being colourless. Thus it was concluded that the microcapsule 
walls were permeable to the lower molecular weight dextran but not 
the remaining two solutes giving rise to the reported value for 
the molecular weight cut off.
The effect of molecular volume on the diffusion and permeation of
solutes through a polyamide film was investigated by Rodell and
colleagues (164). It was reported that as the molecular size of
a series of 4-hydroxybenzoates (namely p hydroxy, methyl p hydroxy,
propyl p hydroxy and butyl p hydroxy benzoates) increased the rate
of diffusion and permeation in nylon decreased. For a given set
of conditions the permeability coefficient increased from 0.93 to 
7 2 - 12.66 X  10 cm sec . It is unlikely therefore that molecules 
having a molecular weight of 17,500 will permeate a polyamide matrix 
within a few minutes which again suggests the presence of water filled 
channels or pores in the capsule walls.
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Attempts to determine pore size using nitrogen adsorption techniques 
were unsuccessful. Using this method it was calculated that the 
pore size varied between 1.5 and 15nm and the mean pore radius was 
estimated to be approximately 4nm (see Appendix A.2). Consideration 
of the molecular weight of dextran unable to permeate the microcapsule 
walls (that is, molecular weight 39,000) together with measurements 
of the pore radius of haemoglobin (molecular weight 68,000, mean pore 
radius 3.3nm (119)) suggests that this value is an overestimate. 
Similarly, estimation of the molecular size of the fluorescein 
isothiocyanate dextran molecules using a photon correlation 
spectrometer, in order to predict pore size, were unsuccessful.
However, it is expected that the presence of pores in the microcapsule 
walls, sufficiently large to allow the permeation of molecules of 
molecular weight 17,500, will readily allow the permeation of 'smaller' 
molecules such as pilocarpine nitrate. The rapid rate of release 
from the polyphthal amide microcapsules seen in the release profiles 
(Figures 3.11 to 3.14) is therefore considered to be a function 
of the presence of pores in the microcapsule membranes.
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4.5 Modifications to the Release Characteristics and Permeability of 
Polyphthalamide Microcapsules
There have been several recent reports in the literature concerning 
modifications to polyamide microcapsule preparation conditions in 
an attempt to alter the permeability and release characteristics of 
the microcapsules. The methods used may be broadly classified 
into two types. (1) the inclusion of a matrix material in the 
core, present so as to limit the diffusion of the encapsulated drug 
to the wall prior to release and (2) modifications to the wall 
structure such as an increase in the density of the polymer or an 
increase in the wall thickness in order to decrease microcapsule 
membrane permeability (161) and therefore limit the diffusion of the 
drug through the microcapsule membrane. For example, McGinity (107) 
reported the inclusion of formalised gelatin in the preparation of 
polyamide microcapsules in an attempt to control the release of 
sulphathiazole sodium from the core. The release from both the 
nylon microcapsules and the formalin treated nylon gelatin 
formulation into O.IN HCl and O.IM acetate buffer was found to be 
rapid however and there was little difference in release rate for 
the two microcapsule types. A later report investigated the use of 
other matrix materials such as calcium alginate and calcium 
sulphate (90). Data concerning the release of drugs from these 
microcapsules was not given. An example of the second type of
modification, that is a change in wall structure was reported by 
Lim and Moss (111). Following preparation polyamide microcapsules 
were harvested and redispersed in cyclohexane prior to the addition 
of a further volume of diacid chloride. On immersing the formed 
capsules in the cyclohexane any diamine remaining in the microcapsule 
partitions into the cyclohexane. Due to the poor affinity
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of the diamine for the cyclohexane however, the partitioning is 
reduced relative to that seen in the primary polymerisation in 
which the organic phase consisted of 1 part chloroform and 4 parts 
cyclohexane. Addition of a further volume of diacid chloride 
therefore results in polymerisation with any unreacted diamine 
within the voids of the already formed network giving rise to a 
denser membrane. Alternatively, increasing the affinity of the 
diamine for the second organic phase results in the secondary 
polymerisation occuring on the organic side of the original 
membrane producing thicker walls (112). In both cases it was 
purported that these methods could be used to control the upper 
limit of permeability of the microcapsules and thereby reduce the 
diffusion of solutes of given molecular weights through the 
membranes.
In this investigation attempts to alter the release characteristics 
of polyphthalamide microcapsules (Figures 3.11 to 3.15) involved both 
techniques. These included the addition of gelatin or albumin to 
the microcapsule core prior to polymerisation. Gelatin has 
previously been used to control the release rate of sulphathiazole 
sodium as described above whereas the albumin is known to be 
incorporated into the microcapsule walls and it was considered 
the pilocarpine nitrate may bind to the albumin thereby reducing the 
rate of release of the drug.
Other techniques which were developed to control the release of 
pilocarpine nitrate were the use of short chain crosslinking molecules 
in place of polyethyleneimine and the preparation of double walled 
microcapsules based on the two methods reported by Lim and Moss (111,112)
3 8 5
Naik (123) reported that the presence of crosslinking agents in 
interfacial polymerisation, in particular diethylenetriamine and 
triethylenetetramine, gives rise to microcapsules with membranes 
of increased porosity. The pores present in the polyphthalamide 
microcapsule walls may be due to the molecular size of the 
polyethyleneimine used in the original preparation. The 
polyethyleneimine may hold apart the polyphthalamide chains and 
give rise to an open porous network. The use of short chain 
crosslinking molecules in the preparation of microcapsules was 
first described by Vandegaer and Wayne (104). It is thought 
that these give rise to a more closely crosslinked polymer network 
than that obtained using polyethyleneimine thus resulting in a denser 
membrane. Transmission electron microscopy however did not confirm 
that a denser membrane was formed using either the short chain 
crosslinking molecules or the double polymerisation technique 
Method A (Section 3.6.4). In the case of the double walled 
microcapsules prepared by Method B, electron microscopy indicated 
that a double wall was formed around the aqueous core (Figure 3.35). 
The inner wall was a trilaminate structure similar in appearance to 
the membrane observed in the original polyphthalamide microcapsules, 
whereas the outer layer was a single dense band. As shown in 
Figures 3.19, 3.20, 3.23 and 3.26 these modifications were 
unsuccessful in controlling the release of pilocarpine nitrate.
Data obtained from these release profiles is given in Table 4.2 
from which it is apparent that in all cases 50% of the total mass 
of pilocarpine nitrate released at equilibrium was lost in the first 
minute and 90% in the first four minutes. Some deviation is seen 
in the release from the microcapsules prepared containing gelatin 
and those prepared using the short chain crosslinking molecules, 
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MlO 94 100 100 97 96 95 96
(%)
TABLE 4.2 RELEASE OF PILOCARPINE NITRATE FROM 
POLYPHTHALAMIDE MICROCAPSULES WITH 
MODIFIED CORE AND WALLS.
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the diffusion rate of the pilocarpine nitrate. The deviation is 
however small and in contrast the effect of the modifications on 
the appearance of the microcapsules is marked. For example, the 
reduced Span 85 concentration required to form the microcapsules in 
the absence of polyethyleneimine is thought to be responsible for 
the increase in the median volume diameter observed for the gelatin 
containing microcapsules and those prepared using the short chain 
crosslinking molecules. These had values of 35pm and 36pm respectively 
(Figures 3.18, 3.22). Similarly the absence of polyethyleneimine 
from the microcapsules prepared using the short chain crosslinking 
molecules is believed to give rise to the agglomerates observed in 
these microcapsule suspensions together with their irregularity in 
shape (Figure 3.21). This is consistent with the work of Aisina and 
others (94) who indicated the need for the presence of a polymeric 
filler material in the aqueous core of the microcapsules in order 
to maintain their integrity. In contrast, the collapsed microcapsules 
and aggregates seen in the suspensions of double walled microcapsules 
prepared by Method B (Figure 3.24) are thought to arise due to the 
effect of redispersion in the hypertonic solution of polyethyleneimine 
followed by the secondary polymerisation occuring between individual 
microcapsules causing them to adhere. The opaque interior of the 
microcapsules prepared containing gelatin (Figure 3.17) is probably 
due to the presence of the gelatin in the microcapsule core.
The modifications to the preparative technique described appear to 
have had no effect on the surface structure of the microcapsules 
when examined by scanning electron microscopy (Figures 3.31 and 3.33), 
This technique could not however be used to study the structure of 
gelatin containing microcapsules as they collapsed and aggregated
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during processing. Similarly the modifications to the methods of 
preparation had little effect on wall thickness which was estimated 
to be approximately 0.8|jm (Figures 3 , 3 2 , 3.34, 3.35). Using 
transmission electron microscopy however it was found that the 
structure of the walls was dependent upon the method of preparation.
The walls of the microcapsules prepared using the 
short chain crosslinking molecules consisted of only two layers 
(Figure 3.32) (1) a dense discontinuous outer layer and (2) a thin
less dense continuous inner layer. This contrasts with the walls of 
the polyphthalamide microcapsules which were of a trilaminate structure 
(see Figure 4.4) and may suggest that the inner dense nodular layer 
present in the polyphthalamide microcapsules is due to the presence 
of polyethyleneimine. Similarly, the site of maximum crosslinkage 
of the polyamide chains and hence maximum membrane density may be a 
function of the affinity of the crosslinking agents for the different 
phases. In the case of the short chain crosslinking molecules this 
may give rise to the formation of the more dense portion of the 
membrane in the outer layer. The walls of the microcapsules 
prepared by the double polymerisation Method B were also of a 
different structure, as discussed above (Figure 3.35). These 
walls were composed of an inner trilaminate structure comprising 
the wall of the original polyphthalamide microcapsule and an outer 
single band formed by the second polymerisation. That this outer 
layer consists of only a single dense band is thought to be a 
function of the diffusion rate of the diamine through the already 
formed microcapsule wall.
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It is apparent therefore that it is possible to alter the structure 
and appearance of polyamide microcapsules considerably by changing 
the polymerisation conditions. Such modifications as described 
however, appear to have little effect on the rate of release of 
small solutes which, under the conditions described was found to 
be very rapid. Without further modifications the polyphthalamide 
microcapsules prepared in this investigation are of little benefit 
in controlling the release of drugs in the eye.
CONCLUSIONS AND SUGGESTIONS 
FOR FURTHER WORK
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This study indicates that in the presence of a crosslinking agent, 
polyethyleneimine, nylon 6.10 and polyphthalamide microcapsules with an 
aqueous core may be readily prepared by an interfacial polymerisation 
technique. Electron microscopy revealed that the microcapsules 
formed using this technique are hollow spheres and have thin walls 
relative to their diameter. Optimisation of the preparation conditions
confirmed reports in the literature that microcapsule size is largely
dependent upon émulsification conditions, in particular stirring speed. 
Microcapsule yield is strongly affected by the concentration and nature 
of the monomers used.
Small solutes may be incorported in the aqueous core of the microcapsules 
by two methods; immersion of formed microcapsules in an aqueous solution 
of the solute or dissolution of the solute in the aqueous phase prior to
polymerisation. In the latter method the solute partitions into the
organic phase during microcapsule formation and as a result complete 
encapsulation is not achieved. Furthermore, any reactive nitrogen 
groups present in the solute may interfere with the polymerisation 
reaction and prevent microcapsule formation.
Electron microscopy, permeability measurements and molecular weight 
cut off determinations suggested that the walls of the polyphthalamide 
microcapsules were morphologically complex and indicated the presence of 
pores in the membranes as previously reported by Chang and others (29). 
Studies on the in vitro release of low molecular weight solutes 
(molecular weight 200 to 500) from the microcapsules suggested that 
these solutes readily permeated the microcapsule walls and it is 
considered that the solutes diffused through the membranes via the pores. 
In vivo investigations also indicated that the microcapsules did not
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significantly control the release of pilocarpine nitrate although the 
dwell time of the microcapsules in the eye was considerably greater than 
that obtained using aqueous solutions.
Attempts to modify or reduce the in vitro release rate characteristics 
of the microcapsules by modifications to the microcapsule core and wall 
were unsuccessful. Further investigation of the properties of these 
modified microcapsules is necessary in order to characterise them and 
to determine the effect of the modifications on pore size. Comparative 
determinations of pore size may be achieved by molecular weight cut off 
studies or by investigation of the relationship between molecular volume 
and rate of release of various solutes from different microcapsule 
preparations. In addition, film permeability measurements or the 
development of an in vitro model to simulate drug release in the eye 
would assist in predicting in vivo release profiles. Selection of 
the optimal method by which to reduce pore size and control release 
in vivo as a basis for further modifications may then be possible.
Such modifications may include the preparation of multiple walled 
microcapsules, the use of different crosslinking agents or the 
preparation of microcapsules with walls formed by different polymers.
An alternative approach to preparing polyamide microcapsules with an 
aqueous core and different release characteristics may be to freeze dry 
microcapsules containing an organic phase. This organic phase would then 
be replaced by an aqueous core by immersion of the dried capsules in water. 
Development of a system in which measurable sustained release is observed 
would then enable factors affecting the release from the microcapsules 
to be studied.
This project has served to indicate the feasibility of using polyphthalamide 
microcapsules for the sustained release of such drugs as pilocarpine nitrate 
to the eye. It has been shown that the dwell time of the microcapsules
in the eye is significantly greater than that obtained using aqueous 
solutions although the microcapsule walls are freely permeable to 
pilocarpine nitrate and do not control its release. Considerable 
further work is necessary in order to modify the microcapsule preparation 
conditions to produce microcapsules with walls of a less porous nature 
which are effective in controlling the release of small solutes.
APPENDIX
A.1.1 Least Squares Linear Regression Analysis
When a linear relationship is assumed to exist between two 
variables, it is usual to fit a straight line by least-squares 
regression analysis. The simplest statistical model for this 
type of analysis assumes that the independent variable X is known 
without error of measurement, and that the corresponding measured 
values of the dependent variable Y are scattered normally about 
their true values. Hence each value of the dependent variable 
is normally distributed about a mean.
The method of least squares regression analysis obtains estimates 
of the intercept a, and the slope b, in the linear equation 
Y = a + bx such that the sum of the squares of the deviations of 
the observation Y^ from their mean values a + # X^ is a minimum.
These values are
a = ZY^ - bZX^ (equation A.l)
= Y - bx (equation A.2)
b = n ZX^Y^ - ZX^ZY^ (equation A.3)
n ZX.2 _ (ZX )2
= Z(X^ - X) (Y^ - Y) (equation A.4)
Z(X. - X)2
where n is the number of points on the line
A.1.2 Correlation Coefficient
The correlation coefficient (r) is defined as:
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r = Z(X. - X) (Y. - Y)
/  - 2 -  2 (X. - X) (Y. - Y)
(equation A.5)
To represent a linear relationship between two variables X and Y, 
r must be ± unity. The calculated value of r is compared with the 
tabulated value at the 5% probability level for n-2 degrees of 
freedom, and if found to be greater than the tabulated value, the 
observations are considered to be linearly related.
A.1.3 Variance of the Slope





2where ae is the residual variance of the dependent variable Y 
and is obtained from:
2 2 ere = Z D
n-2
(equation A.7)
where ZD is the residual sum of squares 
which is obtained from the equation:
ZD^ = (Y. - Y)2 _ b^Z(X. - X)2 (equation A.8)
The standard deviation of the slope is given by the square root 
of the variance.
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A.1.4 Variance of the Intercept
2The variance of the intercept (a) is termed and is given by the
equation :
2 2 2 = Z - ae
----------- —  (equation A.9)
n Z (X. - X '
2 2 where ae = ZD
n - 2
The standard deviation of the intercept is given by the square root 
of the variance.
A.1,5 To Determine the Equality of Two Estimates of a Parameter
This test is generally termed the Student 't' test. The equality
2 2of estimates and with variance and respectively of 
a parameter P is assessed by means of the following statistic:
t = P^ - Pg (equation A.10)
V  + =2'
The value of 't' is compared with tabulated values with n^ + n^ - 4 
degrees of freedom where n^ and n^ are the number of observations 
used in the estimation of P^ and P^ respectively. If the calculated 
value of *t' exceeds the tabulated value at the 5% probability level, 
the parameters are considered to be significantly different at that 
level.
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A.2 Determination of Pore Size Distribution from Nitrogen Adsorption 
Techniques
The pore size distribution from which the mean pore radius reported 
in Section 4,4 was calculated is given in Table A.L This was calculated 
according to the work sheet in Table A.2. An explanation of this 
work sheet is given below.
Columns 1 and 2 in Table A.2 represent the data obtained directly 
from the desorption isotherm. The adsorbed volumes are normalised 
for one gram of adsorbent.
Table A.2
Work Sheet for Calculation of Pore Size Distribution
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Column 3 - the Kelvin radius (rk) is calculated from the Kelvin equation




where P is the equilibrium vapour pressure of the liquid contained 
in a narrow pore of radius rk
Po is the equilibrium pressure of the same liquid exhibiting a 
plane surface
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If nitrogen is the adsorbate at its boiling point of 77°K, the 
working equation becomes
(equation A. 12)
Column 4 - the film depth t is calculated using the Halsey equation.
For nitrogen this is written as
t = 3.54 r_______ 5______ 11/3 (equation A, 13)
4.303 log Po/p-*
where 3.54 is the estimated diameter in Angstroms of a nitrogen 
molecule in a close hexagonal packed liquid structure.
Column 5 is the pore radius (rp) calculated from
rp = rk + t (equation A.14)
Columns 6 and 7 rk and rp are prepared by calculating the mean value in each 
decrement from successive entries.
Column 8 the change in film depth At is calculated by taking the difference 
between successive values of it.
Column 9 AVgas is the change in adsorbed volume between successive P/Po 
values and is determined by subtracting successive values from 
column 2.
Column 10 AVliq is the volume of liquid corresponding to AVgas, The
most direct way to convert AVgas to AVliq is to calculate the 
moles of gas and to multiply by the liquid molar volume. For 
nitrogen at standard temperature and pressure this is given by
- X 34,6 (equation A. 15)
22.4 X 10
o 9 9
Column 11 represents the volume change of the adsorbed film remaining on
the walls of the pores from which the centre core has previously 
evaporated. This volume is the product of the film area and the 
decrease in the film depth. It is necessary to assume no pores 
are larger than 950 A° (P/Po = 0.99) and therefore the first 
entry in column 11 is zero. Subsequent entries are calculated 
as the product of At for a decrement and ZS from the row above.
Column 12 the actual pore volume is calculated from the volume of liquid 
given in column 10. This volume is composed of the volume 
evaporated out of the centre cores plus the volume desorbed from 
the film left on the pore walls. Therefore since
AVliq = nr^L + AtZS (equation A.16)
where L is the pore length 
-2and Vp = TTr̂ L
by combining the two previous equations the actual pore volume
Vp = 2 p -  ̂ [AVliq - (AtZS) (10 ^)]cm^ (equation A.17) 
r ^
Column 13 is the surface area of the pore walls calculated from the pore 
volume by
2Vd - 4 2S = ______ X 10 (m ) (equation A. 18)
rp
3 - . owhere Vp is given in cm and rp in A .
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Column 14 is the summation of the value S multiplied by At from the
following decrement to calculate the film volume decrease in 
column 11.
Summation of the values in column 12 leads to an estimation of 
the total volume of the pores ZVp.
On the assumption that pores are cylindrical the average pore
radius r is calculated using the equation av
^av ^ (equation A. 19)
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